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Chapter 1 
General introduction 
This thesis discusses metabolism and functional effects of purine nucleosides 
and oxypurines in the heart. The study is mainly limited to the nucleosides 
adenosine and inosine and the oxypurines: hypoxanthine, xanthine and urate, all 
adenine-nucleotide catabolites. It is confined to effects in mammals, especially rats, 
pigs, and humans. 
Within certain disciplines, various aspects of the purines have been explored 
extensively. Neuropharmacologists have researched the adenosine receptors. Purine 
analogues have been synthesized for the treatment of neoplasms and virus 
infections. The erythrocyte membrane has been used to evaluate the transport 
across membranes. The study of some metabolic diseases and renal calculus 
formation provided knowledge of normal purine metabolism. 
There are several reasons why an important part of this thesis is devoted to 
adenosine. The knowledge of adenosine-induced effects is the most detailed. 
Adenosine has stronger effects than, for example, inosine. There are indications for 
the involvement of adenosine in the effects of other nucleosides. 
Purines are important in cardiac research. Ischemia rapidly elevates purine 
concentrations. This elevation may serve as a diagnostic tool for the quantification 
of ischemia. The difference in enzyme activities between various species causes 
concentration differences. Both endogenous and exogenous nucleosides affect 
hemodynamics and metabolism. Several drugs modify purine metabolism or purine 
induced effects. Purinergic receptors mediate effects of the nucleosides. The effects 
in vivo and in isolated organs are different, as nucleosides have both direct effects 
on cardiac cells, and indirect through the autonomic system. 
The objective of this thesis is the evaluation of purine function and metabolism 
in the heart, in the hope that this knowledge is useful for extended basic research 
and for the treatment of the cardiological patient. Transport and metabolism are 
discussed to demonstrate what concentrations may be expected and which 
conditions alter purine levels. The functional effects of the nucleosides in the heart 
are shown and their modification by the autonomic system. 
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Finally, effects in pathological hearts, interaction with drugs, and some clinical 
applications are presented. 
Organization of this thesis 
Chapter 2 discusses the concentrations of purines in several species, their 
localization, with emphasis on the role of vascular endothelium. Furthermore, it 
shows the effect of some metabolic diseases on the purine concentrations. 
Chapters 3 and 4 give a description of the metabolism of adenine nucleotides and 
purines: chapter 3 describes the catabolic pathways and the rate of nucleotide 
depletion during ischemia; chapter 4 shows the anabolic pathways and the 
(im)possibilities for rapid adenine-nucleotide level repletion after ischemia. Chapter 
5 discusses nucleoside transport across the cell membrane. Chapter 6 and 7 
evaluate the functional effects: chapter 6 focusses on the effects in isolated heart, 
the direct hemodynamic effects, and the adenosine receptors; chapter 7 
concentrates on the effects in vivo and discusses the modifying effects of the other 
systems, like the autonomic system. Chapter 8 assesses the potential clinical 
applications of purine administration, effects of purines on diseased tissue and the 
modification by several drugs of purine metabolism and functional effects. 
Chapter 9 summarizes the thesis. 
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Chapter 2 
Purine concentrations 
Intravascular concentrations 
Purine concentration depends on species and localization. Humans have a 
high plasma urate concentration, and 100 times lower precursor concentrations. 
The variation in adenosine concentrations is primarily due to the differences 
between individuals; the concentration for a given individual is relatively 
constant48• The half-life of adenosine in blood is only a few seconds due to a rapid 
uptake in erythrocytes71• Nevertheless, there is a more or less stable concentration 
of about 0.1 JLM adenosine in blood. In an isolated heart, there is no arterial supply 
of adenosine. The administration of exogenous adenosine in this concentration 
markedly influences the effects of inosine infusion [appendix 2]. It may also alter 
nucleoside incorporation in isolated heart (see chapter 4). 
Pigs have high plasma inosine and hypoxanthine concentrations, but urate 
levels are low [appendix 3]. 
Adenosine, inosine, hypoxanthine and xanthine are usually assessed in 
deproteinized blood plasma by high pressure liquid chromatography (HPLC). Urate 
is usually measured enzymatically in serum, but HPLC also provides very accurate 
measurements63• 
The role of endothelium 
Vascular endothelium forms an active metabolic barrier for a number of 
purines. It incorporates or catabolizes adenosine and inosine; in the heart it is the 
most important localization of the enzymes which catabolize inosine and 
hypoxanthine9,46. There are often large differences between the interstitial and the 
plasma concentrations. Several authors measured differences in adenosine 
concentration between the venous effluent and the interstitium of the heart. The 
interstitial adenosine concentration is 0.8 JLM in rat hearf1 and 0.18 JLM in isolated 
rat or guinea-pig heartv. In the dog heart the interstitial adenosine concentration 
amounts to about 0.1 J,£M49• All authors find a higher concentration in interstitium 
than in the effluent or in the veins. Infusion of adenosine increases the 
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concentration in the veins, but only marginally or not at all in the interstitium. 
Exogenous adenosine in concentrations below 1 JLM does not reach the interstitium. 
Therefore its effects must be mediated by the endotheliunf1.88. The interstitial 
inosine concentration is about 0.6 JL~. 
Detection of nucleotide breakdown 
Purine levels increase by ATP-breakdown. The adenosine levels rise, but as 
a consequence of the short half-life never reach high levels. Inosine and even better 
hypoxanthine are useful indices of A TP breakdown. We measure differences 
between aorta and coronary sinus/ great cardiac vein concentration of hypoxanthine 
to evaluate possible protection of drugs during procedures like coronary 
angioplascyt15 or atrial pacing stress test53• Hypoxanthine has also been used to 
assess the severity of birth asphyxia in neonates64'm or to follow the condition of 
critically ill patients109• 
Metabolic disease 
Metabolic diseases may influence purine levels@. Gout is a disorder of urate 
metabolism, restricted to humans. It is characterized by hyperuricemia and 
recurrent attacks of acute arthritis. Its usual cause is a reduced excretion of urate 
by the kidney. It may also be secondary to conditions with increased urate 
production. The basis of the Lesch-Nyhan syndrome is a deficiency of the enzyme 
hypo~anthine-guanine phosphoribosyltransferase. The blockade of hypoxanthine 
salvage induces an increased rate of de novo purine synthesis52• The levels of urate 
in blood, urine and cerebro-spinal fluid are increased. Urate deposits are found in 
kidneys and joints, leading to nephropathy and gout. The neurological symptoms 
include severe mental retardation, spasticity and choreoathetosis. Patients with 
adenine phosphoribosyltransferase deficiency often present with 2,8-dioxyadenine 
stones@. Adenosine deaminase and purine nucleoside phosphorylase deficiency 
cause a severe combined immunodeficiency by an accumulation of deoxyadenosine 
triphosphate. Xanthinuria, urinary xanthine stones and myopathy are features of 
xanthine oxidase deficiency. 
Patients with Duchenne muscular dystrophy have lower adenine, but higher 
adenosine and xanthine levels than normal controls14• 
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Drugs may alter the concentration of purines. Patients treated with cytostatics 
have often very high urate levels due to cell necrosis. Diuretics, like the thiazide 
derivatives, increase urate levels by decreased kidney excretion'25• Some anti-
epileptics decrease urate levels by an unknown mechanism 72• Dipyridamole 
increases adenosine concentration by an inhibition of cellular uptake. Mioflazine, 
which acts by a similar mechanism, is being tested as hypnotic. Allopurinol 
decreases urate production by inhibiting the enzyme xanthine oxidoreductase. Some 
of these drugs will be discussed in chapter 8. 
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Chapter 3 
Adenine nucleotide catabolism 
The energy for cardiac contraction is derived from breakdown of ATP to ADP. 
The available ATP within a myocyte is only sufficient for a few beats65• Under 
normal (normoxic) conditions, ADP is rapidly rephosphorylated by oxidative 
phosphorylation. Measurements with nuclear magnetic resonance spectroscopy 
indicate that the creatine kinase reaction: 
ATP + Cr + H+ ~ ADP + CrP 
is in equilibrium (Cr = creatine, CrP = creatine phosphate). The ADP 
concentration measured in homogenized tissue is higher than the free concentration 
by binding of ADP to contractile proteins. 
An imbalance between oxygen demand and supply reduces oxidative 
phosphorylation. ATP levels fall and ADP levels rise. AMP levels rise by the 
adenylate kinase reaction: 
ATP +AMP ~ 2ADP 
AMP is catabolized by 5' -nucleotidase with formation of adenosine, or to IMP by 
AMP-deaminase. IMP is rapidly converted to AMP in skeletal muscle. In heart, 
however, this conversion is very slow'24• 5'-Nucleotidase also catalyzes the 
breakdown of IMP to inosine. During normoxia hydrolysis of S-
adenosylhomocysteine contributes significantly to adenosine production, but during 
ischemia most adenosine is produced by AMP1• 
Even when oxygen supply to a myocardial cell has completely stopped, 
depletion of ATP will take more than a few seconds. Creatine phosphate may act 
as an energy buffer for seconds. Its function is probably the transport of high-
energy phosphate bonds from mitochondria to contractile proteins. 
Nucleoside breakdown 
Adenosine and inosine pass the cell membrane through the nucleoside 
transporter (see chapter 5). Adenosine is rapidly taken up into the cell and 
phosphorylated by adenosine kinase or deaminated to inosine by adenosine 
deaminase. Nucleoside phosphorylase breaks down inosine to hypoxanthine and 
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ribose-1-phosphate. The activity of this enzyme is almost absent in cardiac 
myocytes, but high in the endothelium'08• Breakdown of hypoxanthine to xanthine 
and of xanthine to urate is catalyzed by an endothelial enzyme, xanthine 
oxidoreductase. In some species, but not in primates, uricase catabolizes urate to 
allantoin. 
Rate of catabolism 
In the isolated rat heart, net ATP breakdown occurs even if it is perfused with 
a well-oxygenated buffer. Shortly after preparation of the heart, the efflux of 
purines is high due to the inevitable period of ischemia. In the experiments 
described in appendix 6, we found a purine concentration of 0.57 ~M in the 
effluent after equilibration. Consequently the decrease in adenine nucleotide levels 
is about 25 nmoljmin per g dry weight (dwt). We found similar values in other 
experiments. There are several explanations for the purine loss. It could be the 
normal turnover rate of adenine nucleotides. The rate of nucleotide formation in 
vivo is equal to the rate of breakdown. In the isolated preparation, no substrates 
are provided for generation, and consequently, there is net breakdown. Another 
explanation is an increased rate of catabolism in isolated heart. The absence of 
erythrocytes in the perfusion buffer may limit the oxygenation in this model. 
After 15 min stop-flow ischemia, the purine release is about 6 ~moljg dwt in 
the first five minutes reperfusion [appendix 6]. Van Bilsen et al. found that, ATP 
levels decreased from 18.9 to 9.3 ~moljg dwt by 30 minutes stop-flow ischemia, and 
to 5.7 ~molfg dwt by 90 minutes ischemia128• The rate of nucleotide breakdown 
depends on the model and the method of simulating ischemia. Pacing the heart 
during a period of hypoperfusion increases damage, as it elevates the oxygen 
demand. The purine efflux is higher, if the oxygen is removed from the buffer 
(anoxia), than if flow to the heart is stopped. A high flow causes washout of 
purines. Heart function just before ischemia may affect the severity of the ischemic 
injury. In isolated rat heart, time to onset of contracture is inversely related to pre-
ischemic function [appendix 5]. Reduction of pre-ischemic function may be the 
mechanism by which some drugs provide protection against ischemia in various 
models and the clinical situation29• 
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In several models purine production is a good quantitative measure of 
ischemia. The production of nucleosides depends on the AMP level. Addition of 
pyruvate reduces the AMP level in a normoxic glucose-perfused isolated heart 
preparation4S. Pyruvate increases the CrP concentration and reduces the level of 
inorganic phosphate. Bunger et al. found a lowering of adenosine and inosine 
production by pyruvate in isolated guinea-pig heart13• Our results do not suggest 
such an effect in isolated rat heart [appendix 6]. 
To protect a heart against ischemic damage during heart surgery, it is arrested 
by high potassium and cooled. We evaluated adenosine as a possible adjunct to 
potassium cardioplegia. Before a 20-minute stop-flow period, isolated rat hearts 
were arrested with a three-minute high-potassium infusion [appendix 4]. Adenosine 
addition to this high-potassium cardioplegic solution accelerated cardiac arrest and 
improved post-ischemic function recovery. Addition of the adenosine deaminase 
inhibitor erythro-6-amino-9-(hydroxy-3-nonyl)purine (EHNA) buffer did not reduce 
the post-ischemic purine production. EHNA did increase the adenosine/inosine 
ratio after reperfusion. Therefore, the adenosine deaminase activity is presumably 
not important for the rate of purine production after ischemia. Zoref-Shani et al. 
concluded the same from experiments in cardiomyocytes149• 
Xanthine oxidoreductase 
Xanthine oxidoreductase (XOD) activity is localized in the endothelium. 
Reports on the activity of this enzyme in homogenates of hearts of various species 
(especially man) are conflicting. We compared the apparent XOD-activity in 
isolated hearts from four rodent species [appendix 7]. In rat and mouse heart XOD 
activity was highest, in rabbit heart it was low, while guinea-pig heart showed 
intermediate activity. In the rabbit heart, increasing hypoxanthine concentrations 
caused increased production of xanthine, without altering the production of urate. 
The urate production in guinea-pig heart is comparable to that in rat and mouse, 
but xanthine production is low. We conclude that there are not only differences in 
XOD-activity between species but also in the ratio of the products. This difference 
in ratio contradicts the argumentation of Smolenski et al., who maintain that the 
absence of xanthine production in human heart provides evidence that it has no 
XOD activit)119• 
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Inosine infusion in isolated rat heart increases the hypoxanthine, xanthine and 
urate concentration. Elevation of the inosine infusion rate, increases in the xanthine 
and hypoxanthine concentrations, but reduces the urate concentration [appendix 2]. 
An explanation for this phenomenon is a competition between hypoxanthine and 
xanthine for XOD. 
During coronary angioplasty, there is a difference between the urate levels of 
aorta and coronary sinus/ great cardiac vein63• This finding suggests urate production 
and therefore XOD activity in the human heart. The activities in homogenates of 
human heart vary from less than 0.1 mU/g wet weight (wwt)38,119 to more than 50 
mU / g wwt73, 130. In perfused human hearts, we found a low but detectable urate 
production (XOD = 0.31 ± 0.12 mU/g wwt) [appendix 7]. 
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Chapter 4 
Synthesis of adenine nucleotides 
Pathways for adenine nucleotide synthesis 
After reduction of the adenine nucleotide levels, repletion to normal 
concentrations is slow. Appendix 1 reviews the pathways for generation of these 
nucleotides. Briefly, there are four pathways: 
1. phosphorylation of adenosine to AMP. 
2. ribophosphorylation of adenine to AMP. 
3. ribophosphorylation of hypoxanthine to IMP, followed by conversion to AMP. 
4. de novo synthesis of IMP followed by conversion to AMP. 
Many authors have investigated enhanced nucleotide regeneration by providing 
substrates for these pathways. 
Adenosine phosphorylation 
The incorporation of adenosine is faster than the other pathways11'148• The 
transport through the cell membrane limits the incorporation rate, not the 
adenosine kinase activiif,36. Reibel and Rovetto showed that hours of adenosine 
treatment restored post-ischemic ATP levels in isolated rat head05• In an earlier 
study, they found no increase after 30 minutes treatmenti04• The elevation of 
adenosine concentration to augment nucleotide regeneration provides practical 
problems. The adenosine half-life in blood is only seconds71• The nucleoside affects 
hemodynamics at low concentrations (see chapter 6). Furthermore, the endothelium 
has an active adenosine metabolism and therefore acts as a barrier between the 
capillary lumen and the interstitium. 
Adenine ribophosphocylation 
The maximum rate of adenine incorporation into cardiac myocytes is about 
50% of that of adenosine11'148• There are few reports on enhanced nucleotide 
regeneration by adenine in the in vivo/ex vivo heart. Ward et al. described 
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increased myocardial ATP levels by 24 hours adenine/ribose administration in the 
post-ischemic open-thorax dog132• In an earlier (preliminary) report, they found no 
effect on nucleotide levels after 90 minutes treatment131• We found no significant 
improvement after 45 minutes treatment in isolated rat heart [appendix 6]. The 
difference in species and model may explain why we did not find elevations in 
adenine nucleotide levels. Possibly the severity of ischemia and the length of 
treatment were not enough to find a marked improvement. Blood banks use 
adenine for the preservation of erythrocytes. Toxic effects on kidney after chronic 
adenine feeding have been described, but adenine/ribose preservation is in use for 
transplantation kidneys. 
Hypoxanthine/inosine salvage 
The incorporation of hypoxanthine is 10 times slower than adenosine 
incorporation in cardiomyocyteS11'148• Inosine is only useful for regeneration after 
breakdown to hypoxanthine36,87. There is a considerable difference in nucleotide 
levels between isolated hearts treated with inosine during reperfusion and untreated 
hearts54'144• This difference is larger than can be explained from measurements of 14C 
inosine incorporation54• The incorporation rates of inosine vary from 0.4 to 40 
nmol/min per g dwt2,36,54,14S. We were unable to find increases of nucleotides by 
inosine treatment in post-ischemic rat heart [appendix 6]. A 6-minute infusion of 
inosine in the pig did not increase cardiac nucleotide levels, but altered the 
ATP/ADP ratio [appendix 3]. The maximum conversion rate of IMP to AMP 
measured in cardiomyocytes is about 15 nmolfmin per g dwt11.36. 
Infused inosine may affect adenine nucleotide levels in the post-ischemic 
myocyte in several ways: 
1. Exogenous inosine enters an endothelial cell through the nucleoside 
transporter. Subsequently the nucleoside is broken down to hypoxanthine, 
which leaves the cell through a nucleobase transporter (see chapter 5). The 
hypoxanthine diffuses to a similar transporter of a myocyte and enters into 
the cell. Then hypoxanthine is incorporated into IMP and converted to AMP. 
2. Infused inosine passes unaltered either through the endothelium or through 
clefts between the cells. It enters the myocyte through the nucleoside 
transporter. Then inosine competes with adenosine for transport both into 
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and out of the cell (see chapter 5). Adenosine kinase rapidly rephosphorylates 
the increased amount of intracellular adenosine. 
3. Inosine affects both hemodynamics and metabolism, and may thereby alter 
nucleotide levels. 
De novo synthesis 
The production of IMP from precursors is very slow. Swain et al. reported 
that aminoimidazole carboxamide riboside (AICAriboside ), which is converted in 
two steps to IMP by enzymes of the de novo pathway, may enhance nucleotide 
regeneration1:1D. Other authors were unable to reproduce the improvement in ATP 
levels60,83. The agent increases left ventricular compliance in the post-ischemic 
isolated cat heart84• It also causes a progressive deterioration of function in the 
post-ischemic region in the open-chest dog60• 
Ribose 
The incorporation rate of hypoxanthine into IMP, and adenine into AMP, and 
the de novo pathway are dependent on the availability of phosphoribosyl 
pyrophosphate (PRPP). The synthesis rate of PRPP of rat-heart myocytes with 
ribose as substrate is 50 nmoljmin per g dwf6. Harmsen showed that hypoxanthine 
incorporation was faster when ribose was added54• We added ribose in our inosine 
and adenine incorporation study for a maximal incorporation rate [appendix 6]. 
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Chapter 5 
Transport of nucleosides and nucleobases across the cell membrane 
There are four ways for purines to cross the cell membrane99: 
1. facilitated transport of nucleosides 
2. active nucleoside transport 
3. nucleobase transport 
4. non-mediated transport 
Facilitated transport 
Almost all cells possess a low affinity, high capacity, non-concentrative 
(passive) nucleoside transporter. There are, however, large differences in properties 
and numbers of transporters between species and cell types. Transporters of freshly 
isolated human, pig and guinea-pig erythrocytes exhibit directional symmetry (no 
difference between influx and efflux kinetics), but differential mobility of empty and 
loaded carriers. For instance the uridine-loaded carrier moves on the average 6 
times faster than the empty carrier. The transporter of human erythrocytes stored 
for 1 or 2 weeks under blood bank conditions becomes asymmetrical. In isolated 
rat heart, adenosine transport ( < 50 JLM) follows Michaelis-Menten kinetics with 
a Km of 5 JLM and a Vmax of 10 nmoljmin per g tissue62• At concentrations above 
50 JLM non-saturable transport becomes important43• Rat-heart cells have a common 
transporter for adenosine, inosine and guanosine47• Geisbuhler et al. measured a 
Km value for adenosine of 6 JLM, guanosine 18 JLM, and an intermediate value for 
inosine47• Other authors find similar values for the affinity of adenosine9• Heaton 
and Clanachan argue that a Km of 10 JLM represents an underestimation, which is 
caused by long incubation and interference of intracellular adenosine metabolism56• 
These authors measured a value of 146 JLM in guinea-pig cardiomyocytes. The 
Vmax for adenosine transport in these cells is about 3 nmoljs per g protein43,47• 
Transporters can be blocked by inhibitors. Cell-types can be characterized by 
the percentage nucleoside transporters blocked by a nanomolar concentration of 
nitrobenzylthioinosine (NBTI) or by the inhibition of dipyridamole. In contrast to 
its effect in guinea-pig heart, dipyridamole does not inhibit transport in rat heart62• 
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Inhibitors of the nucleoside transporter include many, mainly hydrophobic, 
substances with various structures like nimodipine, diltiazem, verapamil, lidoflazine 
and diazepam. Nucleoside transport inhibition of calcium channel antagonists 
occurs at concentrations far above those necessary for their effects on calcium 
channels. In cultured endothelial cells from calf aorta, 10 J,£M dipyridamole causes 
a 96% transport inhibition, while the inhibition by papaverine, prazosine and 
nifedipine is only 30-60W2• 
Inhibition of nucleoside uptake may decrease the intracellular adenosine 
concentration, and therefore the incorporation of adenosine. As the affinity for 
adenosine of adenosine kinase is higher than that of adenosine deaminase, 
inhibitors affect incorporation less than deamination. Dipyridamole shifts the 
balance between adenosine phosphorylation and deamination in human blood26• 
In case of high adenosine concentrations, transport inhibition may reduce substrate 
inhibition of adenosine kinase, and thus increase adenosine incorporation. 
Dipyridamole also inhibits the activity of purified adenosine kinase at low 
adenosine concentrations, and stimulates the activity under optimal conditions28• 
In dogs dipyridamole and mioflazine inlnbit both adenosine uptake and 
release1 .. 74• Therefore dipyridamole may limit nucleotide depletion during 
ischemia59• Uptake inhibition occurs, however, at lower inhibitor concentrations 
than release. This is an argument for an asymmetric transporter. 
The nucleoside transporter bears similarities to the glucose transporter. 
Isolation of the nucleoside transporter is complex due to copurification with the 
glucose transporter, which is in about 20-fold excess142• 
Inosine infusion in isolated rat heart increases the concentration of adenosine 
in the effluent [appendices 2,6]. Combined infusion of inosine and adenosine results 
in a much higher effluent adenosine concentration than infusion of only adenosine. 
As inosine does not affect adenosine metabolism36, inosine probably competes with 
adenosine for the nucleoside transporter. Geisbuhler et al. described competitive 
inhibition of adenosine transport by inosine in cardiomyocytes with an apparent Ki 
of 112 J,£M47• Our findings suggest that inosine in a nearly physiological 
concentration modifies adenosine transport, and therefore both intracellular and 
extracellular adenosine concentrations. 
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Active nucleoside transport 
Active sodium-dependent nucleoside transport has only been described in a 
few specialized cell types, such as intestinal epithelium. Inhibitors of facilitated 
nucleoside transport may increase the nucleoside concentration in these cells, as 
they inhibit the efflux of the nucleosides. 
Nucleobase transport 
Cell types differ in the way they transport hypoxanthine. In some, hypoxanthine 
is transported by the same carrier as the nucleosides. In these cells dipyridamole 
inhibits hypoxanthine transport. In others there is a special nucleobase transporter 
for hypoxanthine. Human erythrocytes are equipped with a specific transporter with 
a Km of 200 ~M'". This transporter exhibits directional symmetry. Its mobility is 
not influenced by hypoxanthine loading. NBTI, dipyridamole or nucleosides don't 
inhibit hypoxanthine transport in rat-heart cells11• Therefore, there is a separate 
hypoxanthine transporter. 
little is known about adenine transport. In human erythrocytes, there is a 
specialized transporter for adenine, distinct from the hypoxanthine transporter. 
This transporter is symmetrical and adenine loading does not alter its mobility. 
However, its affinity for adenine is so low (Km > 5 mM) that its measurement is 
hindered by the solubility of adenine98• Brown et al. report a high affinity (Km 1.6 
~M) transporter for adenine in rat cardiomyocytes11• 
Non-mediated transport 
Transport not mediated by a carrier has been described both for nucleosides 
and nucleobases. The rate is at least 20 times slower than carrier-mediated 
transport. It only becomes important with extremely high purine concentrations or 
when inhibitors are used. 
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Chapter 6 
Hemodynamic effects of purines in isolated heart 
Adenosine receptors 
The action of adenosine in several cell systems involves external cell membrane 
receptors. The receptors are classified by an activation or inhibition of adenylate 
cyclase and the rank order of potency of adenosine analogues40• Adenosine 
analogues that are often used for receptor discrimination are N-phenylisopropyl-
adenosine (PIA) and 5'-N-(ethyl-carboxamide)adenosine (NECA). The presence of 
Al and A2 receptors in heart has been confirmed, an A3 receptor is under debate. 
The Al receptor is characterized by: 
* an inhibition of adenylate cyclase 
* a rank order of potency of PIA > adenosine > NECA 
The A2 receptor is characterized by: 
* a stimulation of adenylate cyclase 
* a rank order of potency of NECA > adenosine > PIA 
An A3 receptor, without effect on c-AMP, but acting directly on calcium channels 
has been postulated in rat brain and pig ventricle107• 
In broken cell preparations, apart from extracellular adenosine receptors, there 
is a further class of sites which are especially sensitive for the purine domain of the 
adenosine molecule (P-sites). Presumably, the P-site is intimately associated with 
the adenylate cyclase catalytic subunit Activation of this site by adenosine 
invariably inhibits enzyme activity. Cardiomyocytes possess Al receptors58, A2 
receptors are only found in coronary arteries20 (on the smooth muscle cells), and 
on the endothelium113• 
In isolated hearts infusion of adenosine causes vasodilation, in addition to negative 
chronotropy, dromotropy and inotropy. Adenosine is a potent vasodilator. Berne 
hypothesized that adenosine was the mediator of coronary autoregulation, reactive 
hyperemia and metabolic vasodilation5'6• There is a good correlation between 
coronary flow and the interstitial adenosine concentration during intra-coronary 
infusion of various amounts catecholamines49• Infusion of adenosine deaminase 
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(ADA) attenuates reactive hyperemia, but has no influence on autoregulation35• 
Decking et al. found no direct relationship between coronary conductance and 
interstitial adenosine concentration, while the adenosine levels were modified by 
hypoxia and infusion of ADA or coformycin27• The role of adenosine in coronary 
vasoregulation is not completely unravelled41• The increase of the coronary artery 
concentration of adenosine to a physiological level (0.1 J.LM) in isolated rat heart 
causes a small vasodilation [appendix 2]. The very slow rate of this increase in flow 
is surprising. 
Endothelial receptors probably mediate the vasodilation induced by exogenous 
adenosine, because exogenous adenosine ( < 1 JLM) does not reach the interstitium 
(see chapter 2). Adenosine-analogues increase the level of c-AMP in isolated 
endothelial cells, with a potency corresponding to their affinity for the A2 receptor. 
However, the concentrations to exert this effect are 10 times higher than the levels 
which affect coronary flow1• A concentration of 1 mM has less effect than 0.1 mM, 
but this may be a P-site effect. Although adenosine-induced vasodilation parallels 
the increase in endothelial c-AMP, inhibition of adenylate cyclase does not alter 
vasoregulation89• Adenosine relaxes coronary artery rings better after contraction 
by prostaglandin F2a than by high potassium103• This observation may be important 
to unravel adenosine's mechanism of vasodilation. 
Adenosine has a negative chronotropic and dromotropic effect on isolated 
preparations. Some authors suggest that adenosine mediates the bradycardia early 
during ischemia139• We showed that a high adenosine concentration added to 
potassium cardioplegia decreased arrest time [appendix 4]. Adenosine causes a 
hyperpolarization of the sinoatrial node cells by an activation of potassium 
channels4 [appendix 4]. Acetylcholine has a similar effect, but in contrast to 
adenosine it is inhibited by atropine'4'. Adenosine potentiates the negative effects 
of the vagus on heart rate95• Besides an effect on potassium channels, there is also 
a reduction of calcium currents, and slow-time and voltage-dependent inward 
currents, but only after stimulation by isoproterenol•. 
Adenosine reduces the contractility of isolated atria, but only in very high 
concentrations. This effect probably depends on the level of cyclic-AMP (see 
chapter 7). Cerbai et al. state that the potassium agonist but not calcium antagonist 
effect of adenosine cause the hyperpolarization, shortening of action potentials and 
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negative inotropi5• 
Inosine and other purines 
Inosine causes coronary vasodilation [appendix 2]. It is, however, 200-300 times 
less potent than adenosine68• Infusion of 30 to 400 JLM inosine increased coronary 
flow dose dependently in an isolated rat-heart preparation. However, inosine 
transiently decreased flow half a minute after starting the infusion [appendix 2]. 
Inosine and adenosine were also infused together. Inosine (10 JLM) alone did not 
cause vasodilation, and adenosine (0.1 JLM) induced only a partial and slowly 
developing vasodilation. The combination, however, decreased flow within 30 
seconds. This was followed by a rapid and (almost) complete vasodilation. Infusion 
of inosine together with ADA or the adenosine-receptor antagonist 8-
phenyltheophylline induced a lower coronary flow than without these substances 
[appendix 2]. 
While adenosine lowers contractility, inosine may increase cardiac function. 
In isolated rabbit heart inosine increases dP / dt32,75• The influence of inosine on 
function and heart rate is negligible in isolated rat heart [appendix 2]. 
Some of the effects induced by inosine are similar to the effects of adenosine, 
while others are the opposite. We speculate that in the case of the former, they are 
mediated by increased adenosine. Inosine infusion increases the concentration of 
adenosine (see chapter 5). The effects of inosine, which differ from those induced 
by adenosine, may be caused by a number of speculative mechanisms. There may 
be a special receptor for inosine. Inosine may compete with adenosine for binding 
with a receptor, and thereby antagonize the effects of adenosine. However, inosine 
also reduced coronary flow when the adenosine receptors were blocked by 8-
phenyltheophylline [appendix 2]. Which effect of inosine prevails depends on the 
local adenosine concentration, adenosine transport and number and type of 
receptors. In contrast to adenosine, inosine may reach considerable intracellular 
concentrations. Therefore it may exert its effect also inside the cell. 
Adenine, hypoxanthine, xanthine and urate have no effect on heart function. 
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Chapter 7 
In vivo effects 
The purine effects in vivo are more complex than those described in the previous 
chapter. In vivo the purines interact with other systems such as the adrenergic 
system. 
Effects of adenosine on autonomic nerves 
Autonomic nerves have purinergic receptors. In the isolated rabbit heart, 1-
100 J.'M adenosine reduces noradrenaline release after sympathetic stimulation via 
an effect on presynaptic receptors137• However, adenosine infusion does not alter 
the effects of sympathetic nerve stimulation in an open-thorax dog model112• In 
awake human volunteers, adenosine increases the levels of both adrenaline and 
noradrenaline118• The dissimilarity in model and species may cause the difference 
between these observations. 
Depression of contractility by adenosine 
A1-receptor activation inhibits the adenylate cyclase activity in the heart. Most 
authors find an inhibition of the catecholamine-induced rise in c-AMP by 
adenosine33,34. Adenosine itself, in contrast to its A1 selective analogues, consistently 
inhibits c-AMP generation in heart cells114• A P-site rather than a receptor-mediated 
effect of the nucleoside may be assumed. However, adenosine inhibits the effects 
of forskolin, a receptor-independent activator of adenylate cyclase140• Dipyridamole 
increases and theophylline decreases this effect, indicating that it is adenosine-
receptor mediated. Removal of adenosine by ADA, or receptor inhibition by 8-
phenyltheophylline, augments the effects of catecholamines in isolated rat hearfS. 
However, the removal reduces the efficiency of the heart, possibly secondary to a 
metabolic effect. Adenosine does not inhibit the effects of the stabile c-AMP 
analogue dibutyryl-c-AMP140• It does reduce the positive inotropic effect of the 
phosphodiesterase inhibitor 3-iso-butyl-1-methylxanthine, without an effect on c-
AMP or c-GMP levels8• 
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In summary: 
1. Adenosine reduces adenylate-cyclase activity via the extracellular Al-
receptor or the P-site, and thus lowers the level of c-AMP. 
2. The nucleoside decreases the effects of phosphodiesterase inhibitors without 
changing the concentration of cyclic AMP or cyclic GMP, and therefore alters the 
effects of these cyclic nucleotides. 
3. However, adenosine does not inhibit the effects of a stabile c-AMP 
analogue. 
We conclude that the mechanism is not fully clarified. 
Effects of adenosine on heart rate 
Although adenosine has negative chronotropic properties in isolated rat heart, 
it increases heart rate in conscious man17'18'136• Propranolol does not reduce this 
effect, but a combination of propranolol plus atropine does18• 
Effects of adenosine on blood pressure 
In patients under anesthesia adenosine is being tested to accomplish controlled 
hypotension (see chapter 8). Recently Biaggioni et al. compared the effects in 
healthy volunteers and patients with autonomic failure7• In healthy volunteers a 
bolus injection of adenosine caused an early (30 s) increase in both systolic and 
diastolic blood pressure. A drop in systolic and diastolic blood pressure and 
bradycardia followed. These hemodynamic changes coincided with a deepening of 
thorax excursions. A continuous infusion increased systolic and decreased diastolic 
pressure and heart rate. There was an elevation of noradrenaline and adrenaline 
levels. Patients with autonomic failure were much more sensitive to adenosine. 
They reacted with a decrease in systolic and diastolic blood pressure, and a 
decrease in heart rate. The deepening of thorax excursions was less clear than in 
the healthy volunteers. The authors explain these effects by an activation of carotid 
chemoreceptors. This activation increases heart rate, systolic blood pressure and 
respiration. The respiratory effect stimulates the pulmonary stretch receptors, 
causing tachycardia 
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Effects of inosine on heart function 
Inosine increases contractility under several experimental 
conditions24.30'67'117'127'143• In the open-thorax rat preparation, inosine reduces dP /dt.,.., 
heart rate and mean arterial pressure6'. Inosine increases the potency of 
noradrenaline, while decreasing its maximal effect in rat atria"". The nucleoside has 
no effects in the open-thorax guinea pit'. 
We hypothesized that the positive inotropy induced by inosine would be 
mediated by c-AMP. Therefore, we infused inosine intravenously into an open-
chest pig model [appendix 3]. We found an increase in dP/dt.... and a reduction 
of mean arterial pressure. There was no effect on left ventricular end diastolic 
pressure or heart rate. We found no increase in the cyclic AMP levels, and could, 
therefore, not confirm our theory. 
Effects of adenosine in the kidney 
One of the (side) effects of a low adenosine concentration is renal 
vasoconstriction. High adenosine concentrations induce vasodilation. An afferent-
arteriolar Al-receptor mediates vasoconstriction and A2-receptors on both afferent 
and efferent arterioles mediate vasodilation86• Occupation of Al-and A2-receptors 
inhibits and stimulates renin secretion in the kidney'6• 
Purine effects on glucose metabolism 
Adenosine alters the insulin responsiveness in adipose tissue, skeletal muscle 
and heart. In adipocytes adenosine enhances glucose transport and oxidation, and 
inhibits lipolysis. In skeletal muscle adenosine reduces the effects of insulin. 
Adenosine increases glucose uptake in isolated rat heart79• In dogs the effect is 
similar, with a concomitant reduction of lactate uptake66• Adenosine potentiates the 
increase of glucose uptake by insulin78• Addition of ADA to adenosine annihilates 
this potentiation. The potentiation is independent of changes in blood flow, as 
nitroprusside is ineffective. Inhibition of the adenosine receptors annihilates the 
effects of insulin on glucose uptake. 
As adult-pig erythrocytes lack a functional glucose transporter, the high 
inosine concentration in pigs may serve as energy source'42.145'146• In dogs inosine 
shifts myocardial metabolism towards increased uptake of carbohydrates and away 
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from free fatty acid utilization116• The nucleoside increases the insulin levels117• In 
isolated mouse pancreas B-cells, inosine stimulates insulin production. Nucleoside 
phosphorylase inhibitors attenuate the inosine-induced hormone production, but a 
combination of hypoxanthine and nbose is ineffective10• 
Adenosine and the immune system 
Adenosine modulates the function of several inflammatory cells. Human B-
and T-lymphocytes, polymorphonuclear leucocytes, monocytes, basophils and 
platelets possess an A2-receptor. Lymphocytes and neutrophils also have anAl-
receptot". Adenosine reduces the superoxide production of human neutrophils, 
stimulated with N-formylmethionylleucylphenylalanine (FMLP), but not all other 
stimulants133• Occupation of the A2-receptor of neutrophils both prevents adhesion 
and injury to endothelial cells21• 
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Chapter 8 
Influence of drugs on purine-induced effects 
and potential clinical applications 
Modification of adenosine-induced effects 
It is possible to administer purines to exert certain effects directly. 
Alternatively, transport inhibitors can increase the effects of endogenous purines. 
Adenosine analogues can selectively stimulate or inhibit purine receptors. 
Dipyridamole enhances the adenosine concentrations by inhibiting nucleoside 
transport across the cell membrane. Through this mechanism dipyridamole 
potentiates the effects of adenosine19• It inhibits platelet aggregation and induces 
vasodilation (e.g., for thallium-201 scintigraphy). 
The methylxantbines theophylline and caffeine block purinergic receptors. 
Only concentrations that are far above the normal (therapeutical) concentrations 
inhibit phosphodiesterase44'102• Caffeine antagonizes the effects of a continuous 
adenosine infusion118• Heart rate increases less and diastolic blood pressure 
decreases less. The effects of caffeine on blood pressure and, hypothetically, 
vasoconstriction may be the cause of the association between coffee consumption 
and cardiovascular morbidity and mortality. 
Adenosine-provoked pain 
Healthy human volunteers tolerate only limited doses of adenosine. High 
concentrations cause discomfort or pain in thorax, neck and jaws, sometimes 
mimicking angina pectoris, palpitations, colicky pains in the stomach, dry mouth, 
stuffed nose and restlessness17'1 ... 1'118• Patients report that the pain provoked by 
adenosine is similar to the pain from angina pectoris or myocardial infarction122• 
Adenosine-provoked pain is reduced by theophylline and aggravated by 
dipyridamole121• Therefore Sylven et al. suspect adenosine to play a role in the pain 
due to ischemic heart disease121• The mechanism of angina-like pain and 
vasodilation are different. There are differences in the dose-response relation and 
the time of onset of the effects123• The lowest pain-producing dose induces maximal 
vasodilation. Patients with duodenal ulcer state that the epigastric pain induced by 
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adenosine is equivalent to their ulcer pain'35• In asthmatic patients inhalation but 
not intravenous infusion of adenosine provokes bronchospasm76• 
Adenosine and arrhythmias 
In patients with spontaneous supraventricular arrhythmias, adenosine is able 
to slow heart rate or terminate the arrhythmias134• In a small number of patients, 
the nucleoside terminated the tachycardia except in the patients with an atrium 
flutter134• Addition of dipyridamole reduced the effective dose tenfold134• The ability 
of adenosine to block atrioventricular conduction allows diagnosis and treatment 
for most supraventricular tachycardias. The short half-life and the absence of 
negative inotropic effects make it moderately safe if administered during ventricular 
tachycardia 51. 
In a dog model with a total occlusion of the left anterior descending coronary 
artery (LAD), intraventricular administration of adenosine or dipyridamole reduces 
the number of arrhythmias. There is also a reduced number of arrhythmias, 
including ventricular fibrillations, after release of the occlusion. Adenosine may 
serve as a natural anti-arrhythmic agent in vivo"'". 
Adenosine-induced controlled hypotension 
Adenosine is a potent vasodilator. This property has brought some investigators 
to test adenosine for the induction of controlled hypotension during surgery. 
Controlled hypotension reduces blood loss and facilitates surgery. Owall et al. 
reported on successful adenosine-induced hypotension in five relatively young 
patients without reported lung or heart disease during neurolept anesthesia93• A 30 
% reduction in systolic tension was associated with a 42% reduction of myocardial 
oxygen consumption. In another series, adenosine induced hypotension in six 
patients without alterations of heart rate, myocardial oxygen consumption, 
catecholamine levels or lactate extraction. Two patients had marginal ST -segment 
changes. However, in a third, there was a severeST-segment depression possibly 
caused by coronary steal92• The myocardial effects of adenosine-induced hypotension 
were therefore tested in dogs with an 80% reduction of the left anterior descending 
coronary artery"'. The aggravation of ischemia by coronary steal and reduced 
perfusion pressure balanced the protection by a decrease in heart rate and left-
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ventricular pressure, which led to a reduction of oxygen consumption. 
Subendocardial ECG and lactate extraction, indices of ischemia, were not affected. 
To assess the influence of adenosine on coronary steal, patients with stabile angina 
pectoris received theophylline during exercise testing. Theophylline reduced both 
pain and ST-segment depression during submaximal workload, and increased the 
maximal work load39• This indicates that adenosine possibly induces coronary steal 
in cardiac patients. In the anesthetized pig adenosine was compared to sodium 
nitroprusside and nitroglycerine for the induction of controlled hypotension90• In 
contrast to the other substances, adenosine caused a stable reduction of systolic 
pressure, without effect on heart rate. Perfusion, measured with microspheres, of 
cerebrum, cerebellum, the spinal area, muscles, heart and the splanchnic area was 
unaltered or increased. Adenosine did not reduce the renal perfusion, but there was 
a dramatic reduction in urine production. 
Cardiac protection 
In several models purine derivatives have been shown to protect against the 
effects of myocardial oxygen shortage. We showed the benefits of the addition of 
adenosine to potassium cardioplegia in the isolated rat heart [appendix 4]. Inosine 
prevents the slow post-ischemic deterioration of function in isolated guinea pig 
heart144• Takeo et al. showed protection by adenosine, inosine and hypoxanthine in 
isolated rabbit heart126• The mechanism of protection by inosine remains unclear. 
Inosine protects against myocardial damage by adrenaline administration=. 
A potential mechanism is the increase in adenosine levels, causing a reduced 
increase in c-AMP levels by the catecholamines. 
Administration of large quantities of purines may provoke attacks of gout or 
induce stone formation. Urate levels should therefore be monitored carefully. 
Xanthine oxidase (XO) is one of the possible mediators of reperfusion damage 
by free radicals. Ischemia may partially convert xanthine dehydrogenase (XD) to 
XO. During reperfusion, there is the combination of a high hypoxanthine 
concentration with the reintroduction of molecular oxygen. This situation can cause 
a high XO activity and thereby production of superoxide radicals. 
Allopurinol, a drug employed in the treatment of gout, is both substrate and 
inhibitor of XOD. The inhibition is competitive with low allopurinol concentrations, 
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and non-competitive with high concentrations42• Oxypurinol, the product of 
allopurinol breakdown by XOD, is an even stronger non-competitive inhibitor of 
XOD. 
A number of studies evaluated allopurinol or oxypurinol for protection against 
ischemia or reperfusion induced damage. Damage can be measured as infarct size, 
number of arrhythmias, loss of cardiac function. Several studies in various models 
showed protection•.z.so.77.96.101'138• However, in comparable studies these drugs were 
ineffective37'70,94,10l,l06. There are several explanations for the differences. Allopurinol 
may delay cell death, but does not limit infarct size after a longer reperfusion 
period85• There may be a critical length of ischemia, during which allopurinol 
protects, while it is ineffective against longer or shorter ischemic periods. 
Allopurinol works better, if given hours before the ischemic period. This time may 
be necessary to allow breakdown of allopurinol to oxypurinol. However, oxypurinol 
has little effect, just as allopurino~ if given shortly before reperfusion70• An 
alternative explanation is that an unknown product of allopurinol metabolism is 
able to protect the heart. This would explain, why allopurinol has the best effects 
when given about 18 hours before ischemia. By facilitating electron transport, 
allopurinol could also enhance the reduction of triphenyl tetrazolium chloride, one 
of the dyes most commonly used for the detection of vital tissue97• 
Protection may be independent of the XOD activity. In rat heart, protection 
by allopurinol is similar to that by hypoxanthine, which is a substrate for X077• 
Even in species in which XOD is hardly detectable, like man, pig or rabbit25,37'100 
[appendix 7], allopurinol may exert a protective effect. There are, however, 
mechanisms of protection by allopurinol different from XO inhibition. Allopurinol 
has weak scavenger activity. It scavenges 002 and HOCl, but not superoxide or 
hydroxyl radicals25• Allopurinol may also act as an electron transfer agent from 
ferrous iron to ferric cytochrome c!'. Allopurinol does not modify antioxidant 
properties of extracellular fluid, because the scavenging potential of normal 
biological fluids is tremendous147• 
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Chapter 9 
Summary 
There are several reasons why purines are important in the heart. Under 
normal, physiological, conditions these substances may exert several effects. During 
oxygen shortage, purines rapidly leak out of the cells. Under these conditions the 
nucleosides probably cause vasodilation and bradycardia. Purines are potentially 
useful both for diagnostics and for therapy in patients. 
In many species the normal plasma concentration of the nucleosides adenosine 
and inosine is below 1 J.LM. Concentration differences may exist between the 
compartments of the heart. The endothelium is a metabolically active barrier 
between the capillary lumen and the interstitium. Enzymes in the endothelium 
break down adenosine and inosine, which are produced by adenine nucleotide 
degradation. Xanthine oxidoreductase catabolizes hypoxanthine further to xanthine 
and urate in some species, but not in man. 
The ischemic purine production of a heart gives a good indication of the 
amount of adenine nucleotide breakdown, and therefore of the severity of oxygen 
shortage. Both activity and the properties of xanthine oxidoreductase are species-
dependent. During ischemia xanthine dehydrogenase may be converted to xanthine 
oxidase. The oxidase form may induce free radical formation. 
The ischemic purine release depletes the adenine nucleotide content. Without 
treatment nucleotide levels remain depressed for days. Administration of purines 
may accelerate the nucleotide regeneration. Adenosine has the highest 
incorporation rate in isolated cells. In vivo treatment with adenosine is useless. The 
half-life of adenosine in blood is only a few seconds. Adenosine in a low 
concentration does not reach the interstitium, high concentrations of the nucleoside 
affect hemodynamics. Incorporation of inosine (via hypoxanthine) is much slower. 
Inosine competitively inhibits adenosine transport through the cell membrane, as 
both nucleoside use the same transporter. In theory inosine may reduce adenosine 
transport both into the cell as well as out of the cell. 
Al and A2 receptors mediate the hemodynamic effects of adenosine. 
Activation of the A2 receptor induces vasodilation. The Al receptor mediates 
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negative inotropy, chronotropy and dromotropy. Adenosine derived from cardiac 
cells acts directly on smooth muscle cells, while exogenous adenosine probably 
activates receptors on the endothelium. Inosine also causes vasodilation, but only 
at a concentration, which is 200-300 times higher than the active adenosine 
concentration. Part of the effects of inosine may be attributed to an increase of 
the adenosine concentration. Other effects of inosine include a transient 
vasoconstriction and an increase in heart function. 
The effects of adenosine in vivo are markedly different from the effects in an 
isolated organ. Adenosine modulates sympathetic effects. The nucleoside reduces 
noradrenaline release after sympathetic nerve stimulation. Activation of the Al 
receptor inhibits adenylate cyclase. Furthermore, adenosine may also antagonize the 
intracellular effects of cyclic-AMP. Adenosine also acts on the renin system and on 
glucose metabolism. 
Healthy volunteers react with an increase in heart rate and blood pressure to 
adenosine administration. High doses of adenosine may provoke an angina pectoris 
like pain. Another potential application of adenosine is the induction of controlled 
hypotension during anesthesia. However, maximal coronary vasodilation can cause 
a steal phenomenon. Adenosine may improve the protection by potassium 
cardioplegia, by accelerating the time to arrest. Its ability to block atrioventricular 
conduction may be of help in the diagnosis of arrhythmias. 
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Samenvatting 
Er zijn verschillende redenen waarom purines belangrijk zijn in bet hart. Onder 
normale, fysiologische, omstandigheden oefenen deze stoffen diverse effecten uit. 
Tijdens zuurstoftekort lekken purines snel uit de eel. Nucleosiden kunnen dan o.a. 
vaatverwijding en bradycardie veroorzaken. Purines zijn mogelijk bruikbaar zowel 
voor diagnostiek als bij behandeling van patienten. 
Onder normale omstandigheden zijn de intra- en extracellulaire concentraties 
van de nucleosiden adenosine en inosine laag. Tussen de compartimenten van het 
hart kunnen er concentratie verschillen bestaan. Het endotheel vormt een metabool 
actieve barriere tussen het capillaire lumen en het interstitium. Adenosine en 
inosine, gevormd bij adenine nucleotide afbraak, worden in het endotheel verder 
gecatabolizeerd tot hypoxanthine. In sommige species breekt xanthine 
dehydrogenase hypoxanthine verder af tot xanthine en vervolgens uraat. De 
activiteit van dit enzym bij de mens is echter laag. 
De ischemische purine productie geeft een goede indicatie van de hoeveelheid 
afgebroken nucleotiden, en vormt daarom een maat voor de ernst van het zuurstof 
tekort. De activiteit en de eigenschappen van xanthine dehydrogenase verschillen 
per species. Tijdens ischemie kan dit enzym omgezet worden tot xanthine oxydase, 
wat tijdens reperfusie vrije radicalen kan produceren. 
Door het weglekken van purines tijdens en na ischemie ontstaat er een 
verlaagd adenine nucleotide gehalte in de hartspiercel. Zonder behandeling duurt 
het dagen voordat dit tekort is opgeheven. Versneld herstel van de nucleotide 
gehalten is in principe mogelijk door het aanbieden van purines die ingebouwd 
kunnen worden. Adenosine heeft de hoogste inbouwsnelheid in geisoleerde cellen, 
doch in het bloed wordt het binnen seconden afgebroken. Bovendien passeren lage 
concentraties de endotheel barriere niet en hebben hoge concentraties 
hemodynamische effecten. Inbouw van inosine (via hypoxanthine) verloopt vele 
malen trager. Inosine remt competitief het adenosine transport over de 
celmembraan, daar beide nucleosiden van een gemeenschappelijk transporteiwit 
gebruik maken. Theoretisch kan inosine daarom zowel de uitwas, als ook de 
(her )opname van adenosine verminderen. 
De hemodynamische effecten van adenosine verlopen via Al- en A2-
41 
receptoren. Activatie van A2-receptoren veroorzaakt vaatverwijding, Al-receptor 
activatie heeft negatieve inotropie, chronotropie en dromotropie tot gevolg. De 
vaatverwijding bij intracoronaire toediening van adenosine komt mogelijk tot stand 
via endotheliale A2-receptoren. Inosine veroorzaakt eveneens vaatverwijding, doch 
bij een 200-300 maal hogere concentratie dan adenosine. Een belangrijk deel van 
de effecten van inosine is te verklaren uit een door inosine veroorzaakte verhoging 
van de adenosine concentratie. Bij sommige effecten. wals contractiliteitsverhoging 
is de werking van inosine echter tegengesteld aan die van adenosine. 
In vivo zijn de effecten van adenosine duidelijk anders dan in bet geisoleerde 
hart. Adenosine beinvloedt zowel bet sympathische als bet parasympathische 
systeem. Er is een werking op sympathische zenuwcellen. op adenylaat cyclase, en 
mogelijk ook op intracellulaire effecten van cyclisch AMP. Verder beinvloedt 
adenosine bet renine systeem en bet glucose metabolisme. 
Ondanks bet vaatverwijdend effect van adenosine veroorzaakt toediening ervan 
bij gezonde vrijwilligers een verhoging van de hartfrequentie en de bloeddruk. 
Verder kunnen zij een pijnlijk drukkend gevoel op de borst krijgen. lijkend op 
angina pectoris. Bij patienten onder narcose kan adenosine gebruikt worden om de 
bloeddruk tijdelijk laag te houden. wat bij bepaalde ingrepen belangrijk kan zijn. 
De coronaire vaatverwijding, die hierbij optreedt, kan echter een 'steal fenomeen' 
veroorzaken. Het toevoegen van adenosine aan een oplossing met hoog kalium 
gehalte versnelt bet stilleggen van een hart door deze oplossing. Een diagnostische 
toepassing is toediening van adenosine tijdens ritmestoornissen om op veilige wijze 
achter de aard van deze stoornissen te kunnen komen. 
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UITLEG VOOR DE LEEK 
ATP is een stof die zorgt voor de overdraeht van de energie. Deze energie 
komt vrij bij de verbranding van suikers en vetten en wordt overgedragen aan 
energie-verbruikende proeessen, zoals het samentrekken van een spier. 
Afbraakprodueten van ATP zijn onder andere adenosine, inosine en hypoxanthine. 
Deze afbraakprodueten, purines, komen in het bloed voor in eoneentraties die 
versehillen per soort en die afhankelijk zijn van omstandigheden. 
In het hart treedt bij zuurstoftekort afbraak van ATP op. De eoneentraties van 
purines in het uit het hart afkomstige bloed worden dan hoger. De produetie van 
purines kan als maat worden gebruikt voor de ernst van het zuurstoftekort. In een 
aantal zoogdiersoorten kan hypoxanthine in het hart verder afgebroken worden tot 
xanthine en vervolgens tot uraat. Het enzym dat voor deze omzetting zorg draagt, 
xanthine dehydrogenase, kan tijdens zuurstoftekort omgezet worden tot xanthine 
oxydase. Dit laatste enzym is in staat zuurstofradiealen te produeeren, die de 
oorzaak kunnen zijn van eelbesehadiging. Bij doorstroming van geisoleerde harten 
van enkele knaagdiersoorten kon hoge activiteit van xanthine dehydrogenase 
worden aangetoond; dit in tegenstelling tot het bij hart-transplantatie vrijgekomen 
mensehart. Xanthine oxydase is daarom hoogst waarsehijnlijk niet verantwoordelijk 
voor besehadiging in het menselijk hart. 
Na een periode van zuurstoftekort is het ATP gehalte van een eel gedaald. 
Zonder behandeling duurt het dagen voordat een tekort, ontstaan door een 
kwartier zonder doorstroming van het hart, is hersteld. In principe kan het A TP 
gehalte versneld worden genormaliseerd door het aanbieden van een aantal 
purines. In een geisoleerd rattehartmodel bleek het eehter niet mogelijk het ATP 
gehalte te verhogen door gedurende 45 minuten inosine of adenine aan te bieden. 
Het transport van adenosine en inosine door de eelmembraan vindt plaats door 
middel van het nucleoside-transport eiwit. Adenosine en inosine remmen elkaars 
transport over de eelmembraan, omdat zij een eompetitie aangaan voor het 
gemeensehappelijke transporteiwit. Inosine toediening aan een geisoleerd rattehart 
veroorzaakt een stijging van de hoeveelheid adenosine die uit het hart weglekt. Dit 
is waarsehijnlijk het gevolg van een eompetitie tussen adenosine, wat normaal na 
vrijkomen opnieuw in de eel wordt opgenomen, en inosine. De eellen die de wand 
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van de (haar)vaten vormen, de endotheel cellen, vormen een metabool actieve 
barriere tussen de hartspiercellen en het bloed. 
In een geYsoleerd hart geeft adenosine in een lage concentratie vaatverwijding. 
Hogere concentraties veroorzak:en een vermindering van de hartfrequentie en de 
contractiekracht. Adenosine samen met kalium legt het hart sneller stil dan kalium 
aileen. Inosine veroorzaakt een kortdurende vaatvemauwing, gevolgd door een 
blijvende vaatverwijding. De oorzaak van de vaatverwijding is een verhoogde 
adenosine concentratie. 
Toediening van adenosine aan gezonde vrijwilligers geeft, in tegenstelling tot 
het effect in een geYsoleerd hart, een verhoging van de hartfrequentie. Bovendien 
wordt de bloeddruk door adenosine verhoogd en treedt een op angina pectoris 
lijkende pijn op de borst op. Ben belangrijke oorzaak voor de verschillen tussen de 
effecten van adenosine in een geYsoleerd orgaan en een intact organisme is het 
effect van adenosine op het autonome ( onwillekeurige) zenuwstelsel. Mogelijke 
toepassingen van adenosine zijn bloeddruk-verlaging tijdens operaties, toediening 
voor diagnostiek van hartritmestoornissen en verbeterde bescherming van het voor 
een operatie stilgelegde hart. 
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Appendix 1 
Regeneration of Adenine Nucleotides in the Heart 
P. van der Meer and J.W. de Jong 
ABS1RACT 
The fast adenine nucleotide degradation, which takes place in the ischemic heart, 
contrasts with the slow regeneration after ischemia. There are 4 pathways for adenine 
nucleotide regeneration: 
1. De novo synthesis. This is a slow process. IMP is built from small molecules in a 
number of steps. The process can be accelerated to some extent by administering 
ribose. Ribose is incorporated in 5-phosphoribosyl-1-pyrophosphate (PRPP) and the 
amount of PRPP is rate-limiting. Administration of 5-aminoimidazol-4-carboxamide 
ribose (AICAribose), which can be converted to an intermediate of this pathway, has 
also been tried for a faster regeneration, but this compound produced a deterioration 
of heart function. The conversion of IMP, end product of both de novo synthesis and 
salvage pathway, to AMP is very slow. 
2. Salvage of hypoxanthine or inosine. Inosine has to be catabolyzed to hypoxanthine 
before it can be incorporated. IMP is formed from hypoxanthine in one step, with 
subsequent conversion to AMP. PRPP is rate-limiting, so adding ribose enhances the 
incorporation rate. Inosine has some hemodynamic effects. · 
3. Adenine ribophosphorylation. Adenine is incorporated in AMP in one step. PRPP 
is again rate-limiting. No nucleotide conversion is necessary. Toxic effects of long-term 
adenine administration have been described. 
4. Adenosine phosphorylation. This is the fastest pathway for adenine nucleotide 
regeneration. Adenosine causes a renal vasoconstriction together with a systemic 
vasodilation (hypotension). These adverse reactions limit the practical value of ade-
nosine. 
Even though there is limited clinical experience with some of these compounds that 
enhance postischemic ATP pool repletion, none have been examined for this purpose 
in humans. 
INTRODUCTION 
Ischemia leads to a rapid fall in the adenine nucleotide content of the heart. The 
rate of ATP decrease depends on factors like tissue perfusion (collaterals), heart 
function, temperature, species. The dephosphorylated breakdown products of ATP, 
the purine nucleosides and oxypurines, leak out of the myocardial cell. A simple 
scheme of ATP breakdown is shown in Fig. 1. The amount of adenine nucleotides 
will be roughly halved within the first hour of ischemia. A return of flow will cause 
a restoration of the adenine nucleotide levels (if the cells are not irreversibly 
damaged), but this takes days to accomplish. 
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ATP-ADP-AMP -adenosine 
l l 
IMP - inosine --+ hypoxanthine -----. xanthine -----. urate 
Fig. 1. Adenine nucleotide catabolism: ATP loses its phosphate groups. AMP can be converted to 
either adenosine or IMP. They are both broken down to inosine. This is catabolyzed to hypoxanthine, 
xanthine and urate. 
PRPP l AfP 
CD l ADP 
PPi PRPP 
l ~S-AMP~ l 
GMP,...__.,...__ IMP AMP+---"'-""""--- adenine 
PPi 
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PRPP ~_,_:/ R7 
hypoxanthine 
r® 
adenosine 
Fig. 2. Pathways for adenine nucleotide regeneration: 1. De novo synthesis; 2. Salvage of hypoxanthine 
and inosine; 3. Adenine ribophosphorylation; 4. Adenosine phosphorylation. The pathways 1 to 3 utilize 
5-phosphoribosyl-1-pyrophosphate (PRPP). Pi= inorganic phosphate, PPi = inorganic pyrophosphate, 
R-1-P = ribose-1-phosphate, S-AMP = adenylosuccinate. 
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The effects of ischemia on a cardiac myocyte are complex and their mechanisms 
have not fully been unravelled. There is a good correlation between the effect of 
myocardial protection during ischemia and the postischemic content of adenine 
nucleotides. Thus it is plausible that a fast restoration of ATP levels will promote 
the recovery ofthe postischemic heart. To regenerate ATP in the heart, four path-
ways are available, as was pointed out by Goldthwaie• 30 years ago: 
1. De novo synthesis; 
2. Salvage of hypoxanthine or inosine; 
3. Adenine ribophosphorylation; 
4. Adenosine phosphorylation. 
A scheme of these pathways is shown in Fig. 2. 
1. De novo Synthesis 
This pathway involves the production of the purine skeleton from small molecules 
in 10 steps (see Fig. 3). The first step is the formation of 5-phosphoribosylarnine 
(PRA) from 5-phosphoribosyl-1-pyrophosphate (PRPP) and an amino group donor 
like glutamine. The last step is the formation of IMP. There are no branching 
points between PRA and IMP. The conversion of IMP, endproduct of both de novo 
synthesis and salvage pathway, to AMP or GMP is slow. 
Little is known about the value of enhanced guanine nucleotide regeneration. Ade-
nylosuccinate synthetase catalyzes the reaction: IMP + aspartate + GTP -> 
adenylosuccinate + GDP + P,. The activity of this enzyme is very low. 
Adenylosuccinate lyase catalyzes the reaction: Adenylosuccinate - > AMP + 
fumarate, but the same enzyme is also involved in one of the last steps of the de 
novo synthesis. 
Zimmer et al.39 estimated that 0.04% of the nucleotide pool can be regenerated 
per hour this way. The rate of ATP synthesis is enhanced after ischemia26, and 
limited by the concentration of PRPP11• 
Ribose induces a considerable enhancement of the PRPP-concentration and of 
the rate of adenine nucleotide synthesis in heart"', although the ribokinase activity 
in most tissues is low>. There is some clinical experience with ribose. Zollner et al.40 
described the successful symptomatic treatment of a patient suffering from an 
AMP-deaminase deficiency with high oral doses of ribose (maximum 60 g per day). 
Segal et al.29 described a hypoglycemic effect of ribose. Human lymphocytes, 
exposed to extremely high ribose concentrations (25-50 mM), showed inhibition of 
their DNA repair synthesis41• 
Another possibility is to give 5-amino-4-imidazolcarboxamide riboside 
(AICAriboside), which can be phosphorylated to its ribotide (AICAR). This 
intermediate in the pathway becomes IMP in two steps. Swain et al.31 showed that 
a 24-hour infusion of AICAriboside caused an accelerated repletion of ATP and 
GTP pools in postischemic canine myocardium. In an isolated cat heart Mitsos et 
al.27 described an increase in postischemic left ventricular developed pressure, but 
this was accompanied by a considerable increase in left ventricular compliance. 
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Fig. 3. De novo synthesis: Formation of IMP from small molecules in 10 steps. IMP is converted to 
AMP. AICAR = 5-aminoimidazol-4-carboxamide riboside, FH4 = tetrafolate, PRA 
phospheribosylamine, PRPP = 5-phosphoribosyl-1-pyrophosphate, S-AMP = adenylosuccinate 
l 
IS IMC AMP f PRPP PPi j 
hx 1~ m ____::::,."-.../~ T _ GMP 
CL EC 
Pi R-1-P 
ino ----fif--+ ino \..... /~ hx 
Fig. 4. Inosine has to be broken down to hypoxanthine within the endothelium before incorporation 
in adenine nucleotides of the myocytes. ( cl = capillary lumen, ec = endothelial cell, hx = 
hypoxanthine,ino= inosine, is = interstitial space, me = myocyte, Pi = inorganic phosphate, PRPP 
= 5-phosporibosyl-1-pyrophosphate.) 
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In an open-chest dog model, Hoffmeister et al.'8 observed a marked impairment 
of regional function by postischemic AICAriboside. This deterioration progressed 
in time. We conclude that the value of accelerating de novo synthesis is limited. 
2. Salvage of Hypoxanthine or Inosine 
Hypoxanthine can be utilized to restore the ATP content of the heart. The enzyme 
hypoxanthine guanine phosphoribosyl transferase catalyzes the reaction 
hypoxanthine + PRPP -> IMP + PP1• PRPP is rate-limitings. Harmsen et al.16 
found that adding ribose stimulates the hypoxanthine incorporation rate. (For a 
discussion about the conversion of IMP to the other nucleotides, we refer to the 
part on de novo synthesis.) Although the rate of adenine nucleotide production 
from this pathway is faster than the de novo synthesis, it is limited by the 
availability of PRPP and the activity of adenylosuccinate synthetase. Hypoxanthine 
enters the cell by simple diffusion. As a substrate for xanthine oxidase (XO), 
hypoxanthine may cause generation of free oxygen radicals in species showing XO 
activity in the heart. Its presence in the human heart has to be clearly 
demonstrated. Addition of a xanthine oxidase inhibitor could be important. 
Inosine has been described as a cardioprotective agent'·13,32• Mammalian cells lack 
inosine kinase35• Therefore inosine has to be broken down by nucleoside 
phosphorylase: Inosine + P1 -> hypoxanthine + R-1-P before it can be 
incorporated in the adenine nucleotides. As nucleoside phosphorylase is not located 
in the cardiomyocyte28, the ribose-1-phosphate can be utilized for PRPP production, 
but presumably not in the myocyte. It is possible that inosine incorporation in the 
myocyte can be enhanced by ribose addition, but as far as we know this has never 
been tried. 
In contrast to hypoxanthine, inosine does effect contractility, heart rate and blood 
flow. Juhasz-Nagy and Aviado22 found an increase in myocardial contractility in dog 
heart, while Hoffmeister et al.17 observed a decrease in rat heart. There is 
conflicting evidence about the effect on heart rate21.u. Coronary vasodilation has 
been reported by many authors21-'2• Inosine inhibits the uptake of adenosine in the 
heart25, both nucleosides use the same carrier to enter the cell36• Although inosine 
is used in Mediterranean countries as a cardiotonic, the effects of this nucleoside 
on humans have not extensively been investigated. Recently de Jong et al.7 
described the apparent inosine uptake by the human heart together with an 
increase in dP j dt. We conclude that inosine and hypoxanthine are possibly valuable 
to the postischemic heart, but more research on this subject is necessary. 
3. Adenine Ribophosphorylation 
Little research has been devoted to this pathway. The enzyme adenine phospho-
ribosyl transferse catalyzes the reaction: Adenine + PRPP -> AMP + PP1• The 
adenine concentration in blood is very loW'. If adenine is administered, the amount 
of PRPP becomes rate-limiting. Addition of ribose can enhance the incorporation 
rate. Ward et al.33 gave adenine + ribose to a dog heart, in which the ATP levels 
had been halved. They repleted ATP in 24 hours, while it took 5 days without 
treatment. In isolated ventricular cells Dow et al." compared the incorporation rate 
of adenosine, of adenine + ribose, and of hypoxanthine + ribose. They showed that 
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adenosine incorporation is twice as fast as adenine + ribose, and twenty times as 
fast as hypoxanthine + ribose. Adenine lacks hemodynamic effects; it has no effect 
on adenosine transpod5• Clifford and Story• described growth disturbances in young 
animals fed a high adenine diet. Recently Yokozawa et al. 37showed that metabolic 
abnormalities resembling chronic renal failure could be produced by long-term 
feeding of adenine to rats. Human experience with adenine is available from its use 
as an erythrocyte preservative in blood banks. We conclude that adenine could be 
a valuable compound, provided its safety for postischemic A TP regeneration can 
be proved. 
4. Adenosine Phosphorylation 
This pathway provides the fastest possibility to regenerate adenine nucleotides. 
The enzyme adenosine kinase catalyzes the reaction: Adenosine + A TP -> AMP 
+ ADP. Adenosine has been used for cardioprotection with varying 
success9'15'1 .. 19,20,23,30. Gerlach et al. showed that adenosine incorporation is very fast in 
endothelial cells12• Breakdown of adenosine in blood is very fast: a half life of 10 
seconds has been estimated. It is possible that most of the infused adenosine will 
be either catabolyzed or incorporated in the endothelial cells, with little adenosine 
incorporated in the myocardial cells. Infused adenosine is also taken up very rapidly 
by other cells (especially in the lungs). Adenosine transport is mediated by a 
carrier. Dow et al." reported that in isolated cardiac myocytes adenosine transport 
is rate-limiting for adenosine incorporation. 
Adenosine exerts other effects mediated by purinergic receptors. It is a potent 
vasodilator and plays presumably an important role in coronary vasoregulation•. 
Some groups described the slowing of atrioventricular impulse conductance and a 
decrease in heart rate3,34. Foker et al.10 reported that adenosine caused a 
vasoconstriction of the renal vessels. In humans, adenosine is used against arrhyth-
mias (superventricular tachycardias). We conclude that adenosine is potentially 
useful although it has many side effects. 
CONCLUSION 
There is no clinical experience with enhanced ATP regeneration in the post 
ischemic heart. For this purpose inosine or adenine in combination with ribose 
seem the most promising compounds. 
ACKNOWLEGMENTS 
The authors wish to thank Ms. M.J. Kanters-Stam and Ms. C.E. Zandbergen-Visser 
for their secretarial assistance. 
REFERENCES 
1. Aussedat J, Verdys M, Rossi A: Adenine nucleotide synthesis from inosine during normoxia and after ischaemia in 
the isolated perfused rat heart. Can J Physiol Pharmacol 63:1159-1164, 1985 
2. Becker MA, Raivio KO, Seegmiller JE: Synthesis of phosphoribosylpyrophosphate in mammalian cells. Adv Enzymol 
49:281-306, 1979 
3. Belardinelli L, Shryock J, West A, Clemo HF, DiMarco JP, Berne RM: Effects of adenosine and adenine nucleotides 
on the atrioventricular node of isolated guinea pig hearts. Circulation 70:1083-1091, 1984 
4. Berne RM: Cardiac nucleotides in hypoxia: Possible role in regulation of coronary blood flow. Am J Physiol 204:317-
322, 1963 
53 
5. Brown AK, Raeside DL, Bowditch J, Dow JW: Metabolism and salvage of adenine and hypoxanthine by myocytes 
isolated from mature rat heart. Biochim Biophys Acta 845:469-476, 1985 
6. Clifford AJ, Story' DL: Levels of purines in foods and their metabolic effects in rats. J Nutr 106:435-442, 1976 
7. De Jong JW, Czarnecki W, Ruzyllo W, Huizer T, Herbaczynska-Cedro K: Apparent inosine uptake by the human 
heart. J Mol Cell Cardia! 19, Suppl ill: S 16, 1987 (Abstr) 
8. Dow JW, Bowditch J, Nigdikar SV, Brown AK: Salvage mechanisms for generation of adenosine triphosphate in rat 
cardiac myocytes. Cardiovasc Res 21:188-196, 1987 
9. Ely SW, Mentzer RM Jr, Lasley RD, Lee BK, Berne RM: Functional and metabolic evidence of enhanced myocardial 
tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg 90:549-556, 1985 
10. Faker JE, Einzig S, Wang T: Adenosine metabolism and myocardial preservation. Consequences of adenosine 
catabolism on myocardial high-energy compounds and tissue blood flow. J Thorac Cardiovasc Surg 80:506-516, 1980 
11. Fox IH, Kelly WN: Phosphoribosylpyrophosphate in man: Biochemical and clinical significance. Ann Intern Med 
74:424-433, 1971 
12. Gerlach E, Nees S, Becker BF: The vascular endothelium: A survey of some newly evolving biochemical and 
physiological features. Basic Res Cardia! 80:459-474, 1985 
13. Goldhaber SZ, Pohost GM, Kloner RA, Andrews E, Newell JB, Ingwall JS: Inosine: A protective agent in an organ 
culture model of myocardial ischemia. Circ Res 51:181-188, 1982 
14. Goldthwait DA: Mechanisms of synthesis of purine nucleotides in heart muscle extracts. J Clin Invest 36:1572-1578, 
1957 
15. Haas GS, DeBoer LWV, O'Keefe DD, Bodenhamer RM, Geffin GA, Drop U, Teplick RS, Daggett WM: Reduction 
of postischemic myocardial dysfunction by substrate repletion during reperfusion. Circulation 70, Suppl 1:165-I74, 1984 
16. Harmsen E, De Tombe PP, De Jong JW, Achterberg PW: Enhanced ATP and GTP synthesis from hypoxanthine or 
inosine after myocardial ischemia. Am J Physiol 246:H37-H43, 1984 
17. Hoffmeister HM, Betz R, Fiechtner H, Seipel L: Myocardial and circulato'Y effects of inosine. Cardiovasc Res 21:65-
71, 1987 
18. Hoffmeister HM, Mauser M, Schaper W: Effect of adenosine and AICAR on ATP content and regional contractile 
function in reperfused canine myocardium. Basic Res Cardia! 80:455-458, 1985 
19. Humphrey SM, Seelye RN: fmproved functional recovery' of ischemic myocardium by suppression of adenosine 
catabolism. J Thorac Cardiovasc Surg 84:16-22, 1982 
20. Humphrey SM, Seelye RN, Gravin JB: The influence of adenosine on the no-flow phenomenon in anoxic and ischemic 
hearts. Pathology 14:129-133, 1982 
21. Jones CE, Mayer LR: Nonmetabolically coupled coron3I)" vasodilatation during inosine infusion in dogs. Am J Physiol 
238:H569-H574, 1980 
22. JuMsz-Nagy A, Aviado DM: Inosine as a cardiotonic agent that reverses adrenergic beta blockade. J Pharmacal Exp 
Ther 202:683-695, 1m 
23. Kao RL, Magovern GJ: Prevention of reperfusional damage from ischemic myocardium. J Thorac Cardiovasc Surg 
91:106-114, 1986 
24. Kelley WN, Levy RI, Rosenbloom FM, Henderson JF, Seegmiller JE: Adenine phosphoribosyltransferase deficiency: 
A previously undescribed genetic defect in man. J C1in Invest 47:2281-2289, 1968 
25. Kolassa N, Pfleger K, Rummel W: Specificity of adenosine uptake into the heart and inhibition by dipyridamole. Eur 
J Pharmacal 9:265-268, 1970 
26. Mauser M, Hoffmeister HM, Nienhaber C, Schaper W: Influence of ribose, adenosine and "AICAR" on the rate of 
myocardial adenosine triphosphate synthesis during reperfusion after corona'Y artery' occlusion in the dog. Circ Res 
56:220-230, 1985 
27. Mitsos SE, Jolly SR, Lucchesi BR: Protective effects of AICAn"boside in the globally ischemic isolated cat heart. 
Pharmacology 31:121-131, 1985 
28. Rubio R, Wiedmeier T, Berne RM: Nucleoside phosphorylase: Localization and role in the myocardial distribution 
of purines. Am J Physiol 222:550-555, 1972 
29. Segal S, Foley J, Wyngaarden JB: Hypoglycemic effect of D-ribose in man. Proc Soc Exp Bioi Med 95:551-555, 1957 
30. Silverman NA, Kohler J, Feinberg H, Levitsky S: Beneficial metabolic effect of nucleoside augmentation on reperfusion 
inju'Y following cardioplegic arrest. Chest 83:787-792, 1983 
31. Swain JL, Hines JJ, Sabina RL, Holmes EW: Accelerated repletion of ATP and GTP pools in postischemic canine 
myocardium using a precursor of purine de novo synthesis. Circ Res 51:102-105, 1982 
32. Thomas JX Jr, Jones CE: Effect of inosine on contractile force and high-energy phosphates in ischemic hearts. Proc 
Soc Exp Bioi Med 161:468-472, 1979 
33. Ward HB, StCyr JA, Cogordan JA, Alynno D, Bianco RW, Kriett JM, Faker JE: Recove'Y of adenine nucleotide 
levels after global myocardial ischemia in dogs. Surge')" 96:248-253, 1984 
34. Watt AH, Routledge PA: Transient bradycardia and subsequent sinus tachycardia produced by intravenous adenosine 
in healthy subjects. Br J Oin Pharmacal 21:533-536, 1986 
35. Wiedmeier T, Rubio R, Berne RM: Inosine incorporation into myocardial nucleotides. J Mol Cell Cardia! 4:445-452, 
1972 
36. Woo YT, Mane')" JF, Riordan JR, Dryden EE: Uptake and metabolism of purine nucleosides and nucleotides in 
isolated frog skeletal muscle. Life Sci 21:861-876, 1977 
37. Yokozawa T, Zheng PD, Oura H, Koizumi F: Animal model of adenine-induced chronic renal failure in rats. Nephron 
44:230-234, 1986 
38. Zimmer HG, Gerlach E: Stimulation of myocardial adenine nucleotide biosynthesis by pentoses and pentitols. Pfliigers 
Arch 376:223-227, 1978 
39. Zimmer HG, Trendelenburg C, Kammermeier H, Gerlach E: De novo synthesis of myocardial adenine nucleotides 
in rat. Acceleration during recove'Y from oxygen deficiency. Circ Res 32:635-M2, 1973 
40. ZOllner N, Reiter S, Gross M, Pongratz D, Reitners CD, Gerbitz K, Paetzke I, Deufel T, Hubner G: Myoadenylote 
deaminase deficiency: Successful symptomatic therapy by high dose oral administration of ribose. Klin W ochenschr 64: 
1281-1290, 1986 
41. Zunica G, Marini M, Brunelli MA, Chiricolo M, Franceschi C: D-ribose inhibits DNA repair synthesis in human 
lymphocytes. Biochem Biophys Res Commun 138:673-678, 1986 
54 
Appendix 2 
Inosine transiently decreases coronary flow, but potentiates 
vasodilation by adenosine 
Peter van der Meer, and Jan Willem de Jong 
ABSTRACT 
To test whether inosine interferes with the action of adenosine, we investigated the 
effects of inosine, adenosine, 8-phenyltheophylline and adenosine deaminase on 
isolated rat heart. Inosine did not change heart rate or function, but increased the 
effluent adenosine concentration. It also decreased exogenous adenosine uptake and 
breakdown. After the start of the inosine infusion (20 JJ.M), a transient 30% decrease 
of coronary flow took place within a half minute. It caused sustained vasodilation, 
dependent on the concentration (30 to 400 JJ.M). After the infusion we obseNed a 
transient vasodilation. A non-vasoactive inosine concentration (1 0 JJ.M) combined with 
an adenosine concentration that increased flow by 60% (0.1 J.£M) raised vasodilation 
by another 60%. Infusion of adenosine, adenosine deaminase or 8-phenyltheophylline 
did not influence the inosine-induced transient decrease in flow, indicating that this 
decrease is independent of adenosine and its receptor. We conclude that inosine 
1) potentiates the vasodilation induced by adenosine, 2) is a coronary vasodilator, but 
probably also a vasoconstrictor. 
INTRODUCTION 
The blood concentration of inosine, a purine nucleoside, is below 1 J.£M in humans, 
rats and dogs, and about 10 J.£M in pigs4'7'12,13. It increases when adenine nucleotide 
breakdown occurs. In heart the nucleoside is incorporated in both adenine and 
guanine nucleotides, or catabolized to hypoxanthine, xanthine and urate14• Inosine 
inhibits myocardial adenosine uptake20.23.24. 
Inosine has a number of hemodynamic effects, including coronary vasodilation. 
However, it is far less potent than adenosine, its precursor18• In humans and dogs 
it has a positive inotropic effect6'8'19, but it decreases contractility in rat heart15• 
Inosine also increases heart rate in dogs19• Adenosine has negative inotropic, 
dromotropic and chronotropic properties2,9.29. 
Little attention has been paid to the interference of inosine with the action 
of adenosine. We hypothesized that inosine potentiates exogenous and endogenous 
adenosine vasodilation through its inhibition of adenosine uptake. Because we 
noted transient flow reduction by inosine, we designed experiments to document 
this effect. Thus we investigated the biochemical and functional effects of 
adenosine/inosine on isolated rat heart, using adenosine deaminase to destroy 
endogenous adenosine and 8-phenyltheophylline to block adenosine receptors. 
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MATERIALS AND METHODS 
Chemicals 
All chemicals were of the highest grade available. Water was purified with the 
Millipore-R04/Milli-Q System (Millipore, Bedford, MA, USA). Inosine and 
adenosine were purchased from Merck, Darmstadt, FRG. The purity of the inosine 
and adenosine was 98%. The inosine contained some adenosine (about 0.001%). 
Adenosine deaminase from calf intestine was purchased from Boehringer, 
Mannheim, FRG; it was desalted with a PD-10 column (Pharmacia, Uppsala, 
Sweden). 8-Phenyltheophylline was supplied by Sigma, St. Louis, MO, USA. 
Heart perfusion 
Male Wistar rats (249 ± 26 g, n=29), with free access to food and water, were 
anesthetized intraperitoneally with 0.5 ml (30 mg) sodium pentobarbital. Hearts 
were rapidly removed and cooled in ice-cold 0.9% wjv NaCl solution until they 
stopped beating. Retrograde perfusion of the aorta according to Langendorf£ was 
performed with a modified Tyrode's buffer, pH 7.4. The buffer consisted (in mM) 
of NaCl 128, KCl 4.7, CaC12 1.4, NaHC03 20, NaH,PO. 0.42, MgC12 1.0 and D-
glucose 10. Depending on the protocol inosine, adenosine, 8-phenyltheophylline or 
adenosine deaminase was added (see Protocols). Mixtures were passed through a 
0.45-J,Lm filter and equilibrated with 95% 0 2/5% C02• The perfusion temperature 
was adjusted to 37oC with a thermocouple-regulated electric heater just prior to the 
perfusion canula. The canula was fitted with an A-F6 temperature probe, connected 
to a DU-3 monitor (Ellab, Copenhagen, Denmark). The perfusion pressure, 
measured with a Statham P23Db transducer (Hato Rey, PR, USA), was held 
constant at 70 mmHg. The perfusion apparatus had a valve for rapid switching 
between two perfusion buffers. All hearts were stabilized for 15-20 min before the 
protocols were carried out. 
Purine assay 
Adenosine, inosine, hypoxanthine, xanthine and urate in perfusion buffer and 
myocardial effluent were determined in 200-J,Ll samples by our high performance 
liquid chromatographic method17• The samples from the first protocol were frozen 
and kept below -20°C until determination. The samples from the second protocol 
were kept at 4°C and determined as soon as possible, but always within 48 hours. 
Myocardial function 
Function was monitored with a Konigsberg FS-2 pseudoisometric force transducer 
(Hugo Sachs, March/Freiburg, FRG) connected to the apex of the heart. 
Developed tension was calculated as the difference between peak systolic tension 
and resting tension. The applied resting tension was five gram at the start of the 
experiment. 
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Coronary flow 
An electromagnetic flow transducer (Skalar Transflow 601, Delft, The Netherlands) 
was used to measure the flow in the perfusion line. 
Statistical analysis 
Results are expressed as means ± SD. Statistical analysis was performed with two-
way analysis of variance or Student's t-test; p>O.OS (two-tailed) was considered 
nonsignificant. 
Protocols: 
Protocol 1. A fixed volume of inosine solution was infused into a mixing chamber 
in the perfusion apparatus with a rate-adjustable roller pump (Ismatec MV-MS3, 
Ziirich, Switzerland). In this chamber the inosine solution was diluted with standard 
perfusion buffer. The amount of test-compound, infused per minute, was held 
constant, while its concentration depended on the flow through the heart. The 
mixture was warmed and gassed with 95% Oi5% C02• After a 7.5-min control 
period, every 7.5 min the inosine infusion rate was doubled (see Figure 1). The 
initial infusion rate was 0.31 tLmol/min, the final one 10 tLmol/min. At the end of 
every 7.5-min period, function, heart rate and coronary flow were assessed and both 
effluent and perfusion buffer samples were collected. A 7.5-min period was chosen 
because this was the time necessary to reach a steady state. 
For comparison a group of control perfusions was performed in which 
hemodynamics were assessed and samples were collected at 7.5 and 52.5 min. 
These equal the time before inosine infusion and that of the highest inosine 
infusion rate, respectively. 
Protocol 2. A concentrated inosine solution was added with the pump to the 
perfusion buffer just prior to the canula. After a 5-min control period, inosine was 
infused for 10 min at a rate of 0.2 t.£moljmin. After a 10-min washout period, the 
perfusion buffer was switched to one containing 0.1 tLM adenosine. When a test-
compound was given by switching the valve, the buffer concentration was fixed, 
while the amount per minute varied. This adenosine infusion lasted 20 min. During 
the second half, inosine was again infused at a rate of 0.2 tLmoljmin (see Figure 
1). Samples for purine assay were collected at the times indicated in Figure 1. 
Function, heart rate and coronary flow were assessed every minute. 
Protocol 3. After a 5-min control period, the heart was perfused for 10 min 
with buffer containing inosine (20 t.£M). Following a 10-min washout period, 
adenosine deaminase (ADA, 4.8 U /min) was added with a roller pump to the 
buffer for 10 min. During the last 5 min, ADA was infused into inosine-containing 
buffer. After a second 10-min washout period, the heart was again perfused for 10 
min with inosine-containing buffer alone to exclude time effects on the preparation. 
Hemodynamics were monitored continuously. 
Essentially the same protocol was used for the experiments with 5 tLM 8-
phenyltheophylline (8-PT). In those studies the receptor blocker replaced ADA 
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RESULTS 
Protocol] 
Figure 2 shows the inosine concentration in the effluent represented as a function 
of the amount infused. The inosine concentration in the buffer, measured in 
samples drawn from the perfusion apparatus just prior to the heart, compared well 
with the values calculated from the pump speed and the flow through the heart. At 
the highest infusion rate, the effluent inosine concentration was 409 ± 97 J.'M. The 
differences between the inosine concentration in effluent and perfusion buffer were 
very small, except for the lowest inosine infusion rates. We calculated the 
production of catabolites by multiplying the concentration in the effluent by the 
flow. At all inosine infusion rates, the production of hypoxanthine, xanthine and 
urate exceeded that of the pre-infusion values (Figure 3). Concomitant with the 
increasing inosine concentrations, we found a rise in the production of 
hypoxanthine (p<0.001) and xanthine (p<0.001), but a decrease of the urate 
production (p < 0.05). Figure 4 depicts the dose-dependent increase of the coronary 
flow by inosine. The flow at the beginning of the experiment is within the ranges 
reported by other authors. At all inosine infusion rates, the flow increased 
compared to the pre-infusion values. When the inosine infusion started, a transient 
vasoconstriction took place, but we did not quantify this phenomenon using 
protocol 1. The coronary flow did not change in the control group. In the course 
of the experiment, developed tension went down to 76 ± 8% (inosine group) and 
88 ± 12% (control group). Resting tension and heart rate showed no differences 
between the two groups. 
Protocol2 
Figure 5 shows the effluent concentration of adenosine and inosine. Within one 
minute of inosine infusion (about 18 I-'M), the adenosine concentration increased 
from 14 ± 7 to 30 ± 15 nM (p<O.OOS), to remain 26 ± 13 nM (p<O.OOS vs. the 
value before inosine infusion) till the end of the first inosine infusion. The switch 
to 0.1 JLM adenosine increased the effluent adenosine concentration from 7 ± 5 to 
17 ± 5 nM (p<0.001). The combined infusion of inosine and adenosine increased 
the perfusate adenosine concentration to 44 ± 13 nM (p<0.001) within the first 
minute and to 52 ± 16 nM (p < 0.001 vs. the value before inosine infusion) after 10 
min. Figure 6 shows the effects on the coronary flow. Within the first minute of 
inosine infusion, flow decreased transiently from 9.1 ± 1.8 to 6.3 ± 1.5 ml/min 
(p<0.001), followed by a return to the pre-infusion value. After the inosine 
infusion, a transient vasodilation was seen from 9.6 ± 1.3 to 10.7 ± 1.4 ml/min 
(p<0.001). While adenosine was infused, the coronary flow slowly increased from 
8.6 ± 1.3 to 14 ± 2 ml/min (p<0.001). Within a minute after inosine infusion 
started, coronary flow decreased to 11 ± 3 ml/min (p<0.001), followed by a rapid 
increase to 18.8 ± 1.3 ml/min (p < 0.001 vs. the value before inosine infusion). 
During the experiment there was some decrease in developed tension, but resting 
tension (and heart rate) did not change. 
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FIG. 6. Protocol 2: Potentiation of adenosine's vasodilator effect by inosine. Start of inosine infusion 
(0.2 JLmoljmin) without adenosine caused a transient vasoconstriction, followed by a return to the pre-
infusion values (inset: actual flow record; arrow indicates start inosine infusion). The flow increased 
slowly during infusion of 0.1 JLM adenosine. When inosine and adenosine were infused together, the 
vasoconstriction was followed by a rapid vasodilation. Means ± SD, n=8. 
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Protocol3 
We used this protocol to compare three conditions: inosine perfusion without 
adenosine deaminase or 8-phenyltheophylline, inosine perfusion during the second 
half of an ADA or 8-PT infusion, and inosine perfusion starting 10 min after the 
washout of enzyme or blocker. Within the first minute of inosine infusion, flow 
decreased about 30% in all three conditions (Figure 7). ADA had no effect on flow 
during perfusion without inosine or on the transient decrease of flow due to inosine 
infusion. After 5 min of inosine infusion, coronary flow changed from 10 ml/min 
to 12 ± 2, 10 ± 3 and 12 ± 3 ml/min before, during and after ADA infusion, 
respectively. The flow during the combined ADA and inosine infusion was 
significantly lower then before (p<0.01) and after (p<0.05). 
With 8-PT in stead of ADA, essentially the same results were obtained: in 
four experiments coronary flow was 8.3 ± 1.9, 6.9 ± 1.6 and 7.6 ± 1.2 ml/min 
before, during and after drug infusion, respectively. The values during the combined 
8-PT and inosine infusion were significantly lower than before (p<0.02) and after 
(p<0.001) combined infusion. 
DISCUSSION 
In vivo nucleoside concentrations 
In human blood the inosine concentration is 0.2 JLM13• Pacing-induced angina 
increases the plasma concentration in the coronary sinus from 0.6 to 1.5 JLM (22). 
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In infarcted heart tissue, inosine amounts to 2.9 J.!.moljg dry weight, which suggests 
extremely high interstitial concentrations11• In pigs the coronary venous inosine 
concentration increases from 15 to more than 100 J..f.M due to local ischemia (7). 
In rat blood the concentration varies between 0.2 and 1.6 J..1.M4 • Thus, the inosine 
concentrations used in our experiments are supra normal, but likely to occur under 
pathological conditions. · 
In humans the normal values for adenosine are in the range from 0.06 to 0.14 
J..f.~. It follows that the adenosine concentration used is within the normal range. 
Xanthine oxidase/dehydrogenase activity 
We were able to recover most of the inosine infused in the effluent. Uptake and 
incorporation or catabolism were relatively small. Hypoxanthine production 
increased with increasing inosine concentrations. Augmentation of the inosine 
concentration infused increased xanthine production and decreased that of urate, 
but the sum of xanthine and urate production remained constant (Figure 3). Our 
values for xanthine and urate production during inosine infusion compare well 
with the activity of xanthine oxidase/dehydrogenase found in rat-heart homogenate 
after removal of low molecular weight inhibitors26• This finding suggests that in the 
intact heart these inhibitors do not affect enzyme activity. 
We considered the possibility that vasoconstriction may result from conversion 
of xanthine dehydrogenase to xanthine oxidase: Diversion of urate production 
through the oxidase pathway would generate superoxide and other noxious humors 
that can destroy endothelial derived relaxing factor. However, the ischemic 
conditions needed for this conversion26 were presumably not met during isolation 
and perfusion of the rat hearts. 
Increased adenosine concentration by inosine 
In protocol 2 inosine doubled the adenosine concentration within a minute (Figure 
5). The inosine-containing buffer was contaminated with some adenosine, but this 
amounted to less than 10% of the adenosine found in the effluent. The major fate 
of adenosine infused was uptake, followed by catabolism or incorporation. Infusion 
of both adenosine (0.1 J.!.M) and inosine (18 J..f.M) increased the adenosine 
concentration in the effluent to about 50% of the infused concentration. Using dog 
heart Olsson et al.23 described the inhibition of adenosine uptake by inosine. 
Aussedat et al.1 demonstrated a decrease in e•qinosine incorporation in isolated 
rat heart when adenosine was added. The findings of inosine interference with 
adenosine metabolism could be explained by a competition with the adenosine 
carrier. Dipyridamole fails to inhibit the carrier in rat heart, in contrast to its effect 
in other species16• Alternative explanations for the increased adenosine 
concentration are inhibition of adenosine deaminase or increased adenosine 
production. Dow et al.10 state that inosine (1-200 J..I.M) does not alter the activity of 
adenosine deaminase, adenosine kinase, 5'-nucleotidase or AMP deaminase. We 
conclude that increased adenosine production is unlikely because in that case the 
increase in adenosine concentration would have been smaller with exogenous 
adenosine. 
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Effects of inosine on contractility and heart rate 
Inosine did not change heart rate or function. Thus we failed to find the negative 
inotropy described in an open-chest rat-heart model15• Its effect on heart rate is 
controversial6,8,19.21. In dog and human heart6,.'19, inosine has a positive inotropic 
effect. We ascribe these discrepancies to differences in model and function 
assessment. 
As discussed above, inosine induced a rise in effluent adenosine. The 
concentration of the latter, however, was too low to affect function2• 
Inosine as vasodilator 
In the isolated rat-heart preparation, vasodilation by inosine occurs at high 
concentrations, i.e., between 30 and 400 J.£M (cf. Figure 4). In the second protocol, 
we showed that 0.2 J,£moljmin inosine (18 J.£M) did not cause significant 
vasodilation (Figure 6). Adenosine, 0.1 J,£M, increased flow by 60%. This 
vasodilation developed slowly in about 10 min. The combination of adenosine and 
inosine had a rapid effect (total increase of 120%, Figure 6). Decreased adenosine 
uptake may have caused this effect. ADA or 8-PT infusion together with inosine 
gave lower coronary flows than inosine infusion alone ( cf. Figure 7). The infusion 
of ADA or 8-PT without inosine had no effect. These findings suggest that part of 
inosine's vasodilation is mediated through endogenous adenosine. However, the 
effect of ADA or 8-PT was rather small ( <20% ). Possibly higher concentrations of 
ADA would have had more effect. On the other hand, a similar infusion in isolated 
guinea-pig heart, markedly attenuated coronary vasodilator responses to global 
hypoxia28• In addition, a number of adenosine analogues5 or pharmacological doses 
of inosine21 potentiate the coronary dilator action of adenosine, given intravenously 
to the dog. This could be due to decreased uptake and breakdown outside the 
heart. Olsson et al.23 showed, however, the correlation between apparent adenosine 
transport inhibition and vasodilation in canine heart to be weak. We conclude 
from the above that inosine-induced vasodilation is mediated by adenosine. 
Inosine, a vasoconstrictor? 
To the best of our knowledge, a decrease in coronary flow by inosine (Figures 6, 
7) has not been described before. Trachtenberg and Sullivan27 found that inosine 
increased blood pressure in the rat. Cessation of the inosine infusion caused a 
transient vasodilation (Figure 6). This suggests that inosine causes sustained 
vasoconstriction that is over-shadowed by adenosine vasodilation. Sakai et al.25 
reported vasoconstriction in hindlimb by inosine and adenosine, presumably 
mediated by a tryptaminergic mechanism. As the adenosine concentration has 
already increased at the time of vasoconstriction (Figures 5, 6), a decrease of 
adenosine concentration cannot be responsible. A possible mechanism for coronary 
vasoconstriction would be a competition between adenosine and inosine for a 
receptor, if inosine had a lower intrinsic activity. However, our experiments with 
8-phenyltheophylline strongly suggest that the inosine-induced vasoconstriction is 
not mediated by an adenosine receptor. 
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Appendix 3 
Cardiac effects of inosine in the pig are not mediated by c-AMP. 
Peter van der Meer, Wlodzimierz Czarnecki, Jan Willem de Jong 
ABSTRACT 
In order to evaluate the mechanism of inosine's positive inotropy, we examined the 
haemodynamic and biochemical effects of intravenous infusion of inosine (5 mgjmin 
per kg) in nine anaesthetized open-chest pigs. After 6 minutes of infusion, we saw a 
12 (SEM 4) %decrease in left-ventricular peak-systolic pressure (p<0.05), a 15 (5) 
% decrease in mean aortic pressure (p < 0.05) and a 24 (6) % increase in dP /dt(max) 
(p<0.005). Heart rate and left-ventricular end-diastolic pressure were not affected. 
During the infusion the concentration of inosine increased from 15 (4) to 554 (40) 
J.Lmollitre-1 in the aorta, and from 11 (1) to 380 (17) J.Lmol-litre·1 in the coronary sinus. 
The difference between the aorta and coronary sinus concentration was statistically 
significant after 4 and 6 minutes of infusion (p<O.OOJ). The hypoxanthine and 
xanthine concentration increased too, but no significant arterial-venous differences 
were present. Inosine infusion did not change the cardiac levels of c-AMP or high-
energy phosphates, except for a higher ADP leveL 
We conclude that inosine administration led to an increase in heart function, 
concomitant with a decrease in the mean aortic pressure and left-ventricular peak-
systolic pressure. In the heart no breakdown in the heart of inosine and hypoxanthine 
could be detected. During the infusion there was uptake of inosine. Cyclic-AMP did 
not change, indicating that the inosine-induced increase in heart perfonnance is not 
mediated by this compound. 
INTRODUCTION 
In an earlier study, we evaluated the effect of inosine on the human heare. The 
results prompted a further investigation in the mechanism of the inotropic action 
of inosine using the open-chest pig model. We chose the pig because its cardiac 
microcirculation resembles that of man. Inosine increases myocardial performance, 
both during normoxia and ischemia, in many species2-6. 
Inosine is a breakdown product of adenosine, which in tum is a catabolite of 
adenine nucleotides. Adenosine and inosine are also precursors for adenine 
nucleotide generation (for a review, see ref. 7). Both compounds use the nucleoside 
carrier to pass the cell membrane. In contrast to inosine, adenosine is rapidly 
catabolised, never reaching high intracellular concentrations". Inosine potentiates 
the effects of adenosine, by increasing the adenosine concentration, as it inhibits 
the (re-)uptake and breakdown of adenosine•. Both adenosine and inosine cause 
coronary vasodilation, but adenosine is 300 times more potent. It is possible that 
the inosine-induced vasodilation is partially mediated by adenosine. Aminophylline, 
an adenosine receptor inhibitor, decreases vasodilation by inosine10• 
Heart function depends on the interaction of calcium with the contractile 
proteins. The calcium concentration is regulated by Ca2+ -channels and Ca2+ -pumps. 
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Furthermore the calcium concentration is modified by Na+, K+ and H+ through 
effects on the action potential and Na+ /Ca2+ exchange. The sensitivity of the 
contractile proteins to Ca2+ may be modified through effects on troponin. c-AMP 
affects heart function by an increased influx through the slow Ca2+ -channels, 
modulation of the Ca2+ -handling of the sarcoplasmatic reticulum and a reduced 
sensitivity of the contractile proteins for calcium by phosphorylation of troponin-
1. 
c-AMP levels may be increased by direct or indirect activation of adenylate 
cyclase or an inhibition of phosphodiesterase. Blockade of the J3-adrenoceptor 
reduces the effect of inosine on heart function5 6• Adenosine inhibits adenylate 
cyclase, mediated both through a membrane receptor (A1-site) and directly (P-
site)11. Methylxanthines, with a structure similar to inosine, inhibit 
phosphodiesterase. We hypothesized, that inosine might increase the cardiac levels 
of c-AMP and thereby increase heart function. Thus the purpose of this study was 
to evaluate c-AMP as a possible mediator of inosine's positive inotropy. 
METHODS 
Chemicals 
All chemicals were analytical grade. Water (used for liquid chromatography buffers) 
was purified with the Milli-Ro4/Milli-Q system (Millipore, Bedford, MA). Inosine 
was purchased from Boehringer (Mannheim, FRG). 
Pig experiments 
Nine domestic pigs of either sex, weighing 22-26 kg, were fasted overnight. They 
were anaesthetized initially with ketamine hydrochloride (20 mgjkg i.m.) followed 
by chloralose (100 mgfkg i.v.). Artificial ventilation with room air was maintained 
through an endotracheal tube with end-expiratory pressure of 0.5 kPa of water. 
Adequacy of ventilation was monitored by arterial pH, pC02 and p02 
measurements. The temperature of the animals was kept within the range of 35 to 
37°C with a heating pad. 
A midline sternotomy was performed and the heart was suspended in a 
pericardia! cradle. The coronary sinus catheter was placed under manual control 
via the right atrial appendage and secured with a purse string silk suture. A 6F 
catheter was positioned in the aortic arch via the carotid artery for collection of 
blood samples. Aortic blood pressure was measured from the catheter (filled with 
0.9% NaCl) inserted into the femoral artery, advanced to the aorta and attached 
to a Statham P23Db pressure transducer (Hato Rey, PR, USA). A Gaeltec pressure 
transducer (type 16 CT) which had been mounted on the tip of a double lumen No 
8 USCI catheter was introduced retrogradely via the right carotid artery into the 
left ventricle to obtain left-ventricular pressure (LVP) recordings. 
The maximum rate of rise of LVP (LVdP/dtmax) was obtained by differentiation 
of pressure using a low-pass filter set at a frequency of 50 Hz. The haemodynamic 
parameters were recorded on a Watanabe WA 294 recorder (Watanabe 
Instruments, Tokyo, Japan) at a paper speed of 50 mmfs. 
Inosine dissolved in 0.9% NaCl was infused in a dose of 5 mgjkg per min 
into the jugular vein. The compound was administered for 6 minutes to analyse 
the steady-state response. Pressure variables were recorded before and at the 6th 
minute of infusion to assess the function of the heart. Blood was collected from the 
67 
aorta and from the coronary sinus for purine analysis at the 4th and 6th minute of 
infusion. At the same time myocardial biopsies were taken for adenine nucleotide 
determinations. 
Purine assay 
Two ml of blood were immediately mixed with 2.0 ml of cold 8% HCIO., present 
in pre-weighed tubes. The exact amount of each blood sample was determined by 
weighing. Denatured proteins were removed by centrifugation in the cold. The 
supernatant fluid was collected and stored below -l5°C. An aliquot of this fluid was 
neutralized with 6 mollitre·1 KOH plus 2 moUitre-1 K2C03• Potassium chlorate was 
removed by centrifugation in the cold. Nucleotides in the deproteinized, neutralized 
blood (1.5 ml) were absorbed on pre-washed Al20 3 (0.6 g) in a plastic column 
(internal diameter 8 mm), and purines eluted with 5 ml 10 mmollitre-1 Tris-HCl 
pH 7.4. The column did not absorb considerable amounts of the purine compounds 
except for urate. The eluate was stored at -l5°C. Purines were determined by high 
pressure liquid chromatography (HPLC), as descnbed by Huizer et al'2• 
High-energy phosphates 
Transluminal myocardial biopsies were taken with a Tru-cut biopsy needle 
(Travenol, Deerfield, IL, USA), quickly washed in ice-cold 0.9% NaCl, frozen in 
liquid nitrogen and kept in liquid nitrogen until determination. The biopsies were 
homogenized by a micro-dismembrator (Braun, Melsungen, FRG) at liquid nitrogen 
temperature together with 0.5 ml of 4% perchloric acid. After centrifugation in the 
cold, 350 JLl of the supernatant fluid was used for the nucleotide determination; the 
pellet was used for the protein determination. The high-energy phosphates were 
measured by a method described by Huizer et al12• The protein content was 
estimated according to Bradford13 using a commercial protein assay (Bio-Rad, 
Munich, FRG) and bovine serum albumin as the standard. 
c-AMP 
The measurement of c-AMP was carried out using a commercial assay kit 
(Amersharn, Amersharn, UK). 
Statistical methods 
Statistical significance was evaluated by Student's t-test for paired observations. 
For multiple comparisons we applied a Bonferroni correction. P<0.05 was 
considered significant. All results are expressed as means ± SEM. 
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Fig. 1. Haemodynamic effects after six minutes of inosine infusion. There was an increase in left-
ventricular dP /dt(max), while the mean aortic pressure and the left-ventricular peak-systolic pressures 
were decreased. The heart rate and left-ventricular end-diastolic pressure were unchanged. Means + 
SEM, n=7. HR = heart rate, MAP = mean aortic pressure, LVPSP = left-ventricular peak-systolic 
pressure, L VEDP = left -ventricular end-diastolic pressure, dP / dt( max) = maximum rate of rise ofleft-
ventricular pressure, * p<0.05 and** p<0.005 vs. before infusion . 
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Fig. 2. Inosine infusion caused an increase in the arterial concentration of inosine, hypoxanthine and 
xanthine. Meaus + SEM, n=9. 
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RESULTS 
Haemodynamic data 
After six minutes of inosine infusion the mean aortic pressure (MAP) and left-
ventricular peak-systolic pressure (L VPSP) decreased from 87 ± 6 to 73 ± 5 mmHg 
(p<0.05, n=7) and 10:2 ± 10 to 89 ± 8 mmHg (p<0.05, n=7), respectively (see 
figure 1). There were no significant changes in heart rate (HR) and left-ventricular 
end-diastolic pressure (LVEDP). The dP/dt(max) showed a 24% increase from 
1400 ± 200 to 1700 ± 200 mmHgjs (p<0.005, n=7). 
Biochemical values 
The arterial and coronary sinus concentration of inosine increased from 15 ± 4 to 
554 ± 41 J,£mol"litre-1 (p<0.001, n=9, figure 2) and 10.4 ± 1.2 to 375 ± 47 J,£mol"litre-
1 (p < 0.001, n = 9), respectively. After four and six minutes of infusion, the difference 
between the arterial and coronary sinus concentration was also statistically 
significant (p<0.001, figure 3A). Both the arterial (figure 2) and coronary sinus 
hypoxanthine levels increased, but no significant differences appeared between the 
arterial and coronary sinus concentration (figure 3B). The same was true for the 
xanthine concentrations (figures 2 and 3C). The ATP, AMP, creatine phosphate 
and c-AMP levels in the ventricular muscle biopsies taken during inosine infusion 
were not statistically different from the levels before infusion (see table 1 and 
figure 4). After four min inosine infusion, the ADP level was increased (p<0.01). 
However after six minutes this increase was no longer significant. 
DISCUSSION 
Purine metabolism 
Inosine infusion into the jugular vein increased the inosine concentration in both 
the aorta and the coronary sinus. During the infusion there is a large, statistically 
significant, concentration difference between the arterial and the venous side of the 
heart: the aortic value exceeded that in the coronary sinus by 150 J,£mollitre-1• We 
also found increases in the concentration of hypoxanthine and xanthine, the 
breakdown products of inosine. However, hypoxanthine and xanthine levels in the 
aorta and coronary sinus were not significantly different. The activity of xanthine 
oxidase/reductase, the enzyme which catabolizes the breakdown of hypoxanthine 
and xanthine, is very low in the pig•. Therefore, there is hardly any urate 
production. The difference between aortic and coronary sinus inosine concentration 
represents uptake in the heart. 
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Nucleotide metabolism 
Inosine is a precursor in the adenine nucleotide salvage pathway. It is broken 
down to hypoxanthine, followed by incorporation into IMP. Subsequently IMP is 
converted to AMP. In our experiments some of the inosine may have been 
incorporated into IMP and subsequently into the adenine nucleotides. We did not 
find a significant rise of ATP. The incorporation of inosine is slow. In isolated rat 
heart incorporation rates between 0.4 to 20 nmolmin-1 per g dry weight have been 
described15 16• If the highest rate would apply to the pig heart, the increase would 
have been about 0.1 J,Lmol per g protein, i.e., less then 0.5% of the normal value. 
We therefore assume that during the infusion inosine is present within the cell in 
a high concentration and most of it is not metabolized. 
We did find a significant increase in the level of ADP after four min. After 
six min there was no significant increase. Kypson and Hait found reduced ATP 
and increased ADP levels, along with increased function in isolated rabbit heart'. 
Other authors report that inosine does not affect the nucleotide levels in the in situ 
dog heart•. More research is necessary to evaluate these effects. 
Glucose metabolism 
In the dog inosine increases the release of insulin, and shifts myocardial metabolism 
towards increased uptake of carbohydrates relative to free fatty acids17• Compared 
to other species, pigs have a high blood inosine concentration. (The concentration 
is even so high that inosine may serve as energetic substrate for erythrocytes in 
pigs•••;. 
Haemodynamics 
The mean arterial pressure decreased during inosine infusion (figure 1). Although 
we were unable to measure adenosine levels (detection limit 0.2 J,Lmollitre·1), the 
effect of inosine on arterial pressure may have been secondary to adenosine. The 
latter is a very potent vasodilator. Adenosine causes hypotension, when 
administered during anaesthesia, but in awake healthy human volunteers, adenosine 
even increased blood pressure20• This difference is ascribed to the influence of 
anaesthesia on the autonomic nerve system. The breakdown products of inosine 
have no haemodynamic effects. 
Inosine showed no effects on heart rate (figure 1). Maximum rate of rise of 
ventricular pressure was used to estimate directional changes in contractility 
induced by inosine, since it was shown to be useful to assess acute changes in 
inotropic state of the heare• 22• Studies in humans as well as in animals have 
demonstrated that peak dP I dt is largely independent of changes in afterload23-25• 
The enhanced dP ldt(max) during inosine administration despite of lowered aortic 
pressure, shown in this study, strongly suggests a positive inotropic action of this 
nucleoside. If inosine would improve heart function via a vasodilating action, a 
decrease in dP I dt( max) would be more likely to occur"'. Since inosine did not 
affect heart rate and left-ventricular end-diastolic pressure we conclude that 
increased dPidt(max) reflects increase in myocardial contractility. In a similar 
open-chest pig model, Woollard et aL examined the effects of 0.3-1.2 mmoHitre·• 
inosine2• 
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Table 1. 
Variable 
Inosine infusion did not significantly change the ATP and AMP levels, the energy charge (EC) nor the 
level of creatine phosphate (CrP). After 4 minutes the ADP level was, however, increased. Means :!: SEM, 
n=5. 
before infusion during infusion 
4 min 6min 
ATP (ILmol·g protein"1) 263 :!: 1.2 30.2 :!: 1.7 28.3 :!: 2.2 
ADP (JLmol·g protein"1) 5.4 :!: 0.4 6.0 :!: 0.4. 5.8 :!: 0.4 
AMP (ILmol·g protein"1) 0.47 :!: 0.09 050 :!: 0.13 056 :!: 0.13 
EC 0.900:!: 0.008 0.908:!: 0.011 0.897 :!: 0.008 
CrP (ILmol·g protein"1) 42 :!: 7 50 :!: 9 58 :!: 7 
• p < 0.01 vs. before infusion 
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They showed that the increase in dP/dt(max) by inosine was not secondary to 
effects on the mean aortic pressure. At the end of the infusion, the dP/dt(max) 
was still increasing, while blood pressure returned to normal2• 
Wetzel and Hanel described seven mechanisms for cardiotonic agents: B-
adrenergic stimulation, phosphodiesterase inhibition, a-adrenergic stimulation, 
Na+ jK+ ATPase inhibition, enhanced sensitivity of contractile elements for Ca2+, 
Ca2+ -channel agonism, and slowed closing of N a+ -channels26• The effects of 
adenosine on function are complex. In isolated rabbit heart adenosine inhibits 
noradrenaline release by an effect on presynaptic purine receptorsv. However, in 
dog heart this mechanism is not found28• Adenosine attenuates the effects of 
isoproterenol on c-AMP levels, but reduces vagal tone29 30• The mechanism for 
inosine's effects are unknown. In rabbit heart the inotropic effects of inosine are 
abolished by propranolol5• In the in situ dog heart, Jones et al. found no alteration 
of the effects of inosine on the contractile force by propranolol'. Czarnecki and 
Noble reported that in the same species another B-blocker, sotalol, partially 
reduced the increase in dP/dt(max) by inosine, but that the nucleoside caused a 
supersensitivity to the positive inotropic effect of adrenaline6• In the same series 
verapamil had no reproducible effect. c-AMP levels were not affected in our 
experiments (figure 4). This makes the B-adrenergic mechanism, the 
phosphodiesterase inhibition or a direct effect on adenylate cyclase unlikely, as they 
are mediated through increased c-AMP levels. An alternative mode of action may 
involve increased intracellular calcium, either by a direct effect on the Ca2+ -channel, 
or secondary through effects on K+, Na+, H+, or by a-adrenergic stimulation. A 
completely different explanation is the sensitization of contractile proteins. A c-
AMP dependent protein kinase phosphorylates troponin-1, resulting in a reduced 
myofibrillar ATP-ase activity. The dephosphorylation of troponin-I involves a c-
GMP dependent phosphoprotein phosphatase. This dephosphorylation therefore 
enhances the sensitivity of the contractile proteins for Ca2+. As we found no 
increase in c-AMP, we speculate that the inosine-induced increase in performance 
involves either of these two mechanisms. 
Comparison to other species 
The effects of inosine in pigs are quite similar to our previous study in humans1• 
Both pig and human hearts take up inosine. In both species mean aortic pressure 
decreases, heart rate remains unchanged and dP /dt(max) increases. Similar effects 
have also been described for rabbits and dogs3-6. In rats inosine decreases 
myocardial performance31• 
We conclude that inosine, a naturally occurring substance, enhances heart 
performance in the pig. The mechanism of its effects remains unclear. We 
demonstrated that inosine does not increase function by increasing c-AMP levels. 
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Appendix 4 
Adenosine as adjunct to potassium cardioplegia: effect on function, 
energy metabolism and electrophysiology 
Jan Willem de Jong, PhD, Peter van der Meer, MD, Heleen van Loon, BSc, 
*Patricia Owen, PhD, and *Lionel H. Opie, MD, PhD, 
Rotterdam, The Netherlands, and *Cape Town, South Africa 
ABSTRACT 
Adenosine is known to induce rapid cardioplegic arrest and to improve post-ischemic 
arrest in the isolated rat heart. However, long exposures to high doses of adenosine 
impair post-ischemic recovery. In this paper we test the combination of low-dose 
adenosine (1 mM) with potassium 26 mM, with the aim of achieving rapid a"est (as 
with high-dose adenosine), but eliminating the need for post-arrest washout of 
adenosine. Cardioplegic solutions tested were: (1) Krebs-Henseleit potassium 26 mM 
(K); (2) K plus adenosine 1 mM (KA); (3) K plus an adenosine deaminase inhibitor 
[erythro-9-(2-hydroxy-3-nonyl)adenine EHNA)} 0.1 mM (KE); and as control 
(4) Krebs-Henseleit potassium 6 mM (C). We induced cardiac arrest in Langendorff-
perfused rat hearts by infusing the cardioplegic solution for 3 min at 3 mljmin. Total 
ischemia lasted 20 min at 3JOC, followed by reperfusion for 30 min. High-potassium 
decreased the arrest time from 260 ± 16 (group C) to 22 ± 4 s (group K, mean values 
± SEM). A further decrease to 10 ± 2 s was observed with KA (12. = 0.016 vs. K). KE, 
which increased endogenous adenosine, gave intermediate effects. All hearts recovered 
during reperfusion: the product of developed tension and heart rate (gjmin) was 
superior in KA hearts (6,250 ± 740 vs. K hearts 4,380 ± 390,12 = 0.021). KE gave an 
intermediate result (5,290 ± 900), while C showed the worst recovery (3,180 ± 830). 
Our electrophysiological studies with sinus node and atrial tissue suggest that 
adenosine-induced hyperpolarization and an increase in potassium permeability, 
thereby arresting the sinus node prior to depolarization of the membrane by potassium 
26 mM We conclude that low-dose adenosine as an adjunct to potassium shortens the 
arrest time in this model and improves post-ischemic recovery. 
INTRODUCTION 
Adenosine has several theoretical qualities which make it attractive as a component 
of a cardioplegic solution. Adenosine, by its activation of the potassium channel, 
inhibits the sinus and atrioventricular nodes.1.2 Adenosine also indirectly inhibits 
myocardial contractility,3 enhances the tolerance of the myocardium to ischemic 
arrest: and may improve recovery of cardiac contractile force after hypoxia.' 
Despite the rapid cardiac arrest induced by high concentrations of adenosine 
(10 mM) and improved post-ischemic recovery,6 a distinct disadvantage is that the 
adenosine had to be washed out after induction of cardiac arrest. 
We theorized that a lower dose of adenosine (1 mM) could still rapidly cause 
mechanical arrest of the heart in combination with potassium (26 mM) without 
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requiring washout.6 Secondly, we wished to assess whether low-dose adenosine 
when combined with potassium could improve recovery from cardiac arrest, in 
contrast to high-dose adenosine plus potassium which gave results no better than 
with potassium alone.6 Thirdly, we wished to distinguish between the 
electrophysiological mechanisms of action of potassium, adenosine and their 
combination. Fourthly, we examined whether an inhibitor of the breakdown of 
endogenous adenosine could achieve the same benefits as added adenosine. Part 
of this study has been reported in abstract form.7 
MATERIALS AND METHODS 
Chemicals 
All chemicals were of the highest grade available. Adenosine was supplied by 
Merck or Boehringer, and erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride 
(EHNA) by Burroughs Wellcome. 
Animals 
Fed male rats weighing 200- 250 g were used. All animals received humane care 
in compliance with the "Principles of Laboratory Animal Care" (National Society 
for Medical Research) and the "Guide for the Care and Use of Laboratory 
Animals" (National Academy of Sciences). For perfusion studies they were 
anesthetized intraperitoneallywith 30 mg sodium pentobarbital. Hearts were rapidly 
removed and cooled in ice-cold NaC1154 mM. For electrophysiological studies rats 
were anesthetized with diethyl ether and heparinized. Hearts were rapidly removed 
and cooled in ice-cold Krebs-Henseleit buffer (see below). 
Peifusion of hearts 
Retrograde perfusion of the aorta according to the method of Langendorf£ was 
immediately started with a modified Krebs-Henseleit buffer, pH 7.4, at an aortic 
pressure of 9.2 kPa. The buffer consisted of (mM): NaCl 118, KCl 4.7, CaC12 2.5, 
KH,PO. 1.2, MgS04 1.2, NaHC03 25, D-glucose 11. The mixture was passed 
through a 0.45-um filter, pre-warmed and equilibrated with 95% 0 2/5% C02• The 
heart was kept in a double-walled chamber. The perfusion temperature was 
adjusted to 37° C with a thermocouple-regulated electric heater just prior to the 
perfusion canula. The latter was fitted with an A-F6 temperature probe, connected 
to an Ellab DU-3 monitor. After 15 min equilibration at 9.2 kPa, cardioplegic 
solution was given for 3 min with a roller pump, which delivered 3 rnl/rnin. The 
following cardioplegic solutions were used at random: Krebs-Henseleit buffer 
K+ 26 mM (K), K+ 26 mM + adenosine 1 mM (KA), or K+ 26 mM + 
EHNA 0.1 mM (KE); or control group Krebs-Henseleit buffer K+ 5,9 mM (C). The 
ischemic control group C served to show (partial) protection by potassium 
cardioplegia. The study also included a normoxic control group N, to estimate the 
maximally obtainable benefit. Stop-flow ischemia was induced for 20 min, followed 
by 30 min of reperfusion. The perfusion pressure was measured with a Hewlett 
Packard model 1280 transducer. This variable, and the hemodynamic parameters 
mentioned below, were monitored on a Graphtec Linearcorder FWR3701. 
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Myocardial function 
Resting and peak systolic tension were measured continuously with a Konigsberg 
F5-2 pseudoisometric force transducer (Hugo Sachs), connected to the apex of the 
heart with a ligature".9. A resting tension ("preload") of 5 g was applied. During the 
first 15 min of perfusion, resting tension was readjusted if necessary. Developed 
tension was calculated as the difference of peak systolic and resting tension. 
Heart rate was measured from the tension tracing. The product of developed 
tension and heart rate was subsequently calculated. The heart was considered in 
arrest if the tension-rate product was smaller than 5% of the 15-min equilibration 
value. 
Coronary flow 
Flow was monitored with a Skalar electromagnetic flow probe, mounted in the 
perfusion line. During reperfusion, effluent from the heart was collected (for purine 
assay) in a graduated cylinder over periods indicated in Fig. 1. The two methods 
to measure flow correlated well. 
Assay of purines 
Samples were kept on ice until analysis, within one day.· Purine concentrations 
were determined by automated high-performance liquid chromatography (HPLC), 
essentially as described before.10'11 The uBondapak C,8 column (Millipore-Waters) 
was equipped with a 5-um Supelguard LC-18 guard column (Supelco ). Flow rate 
of the buffer, 1% KH2P04 - 10% CH30H (pH 4.7), was 0.6 ml/min. Urate was 
detected at 295 nm, hypoxanthine, xanthine, inosine and adenosine at 254 nm 
(Waters Model 490 absorbance detector). The retention times were 9, 10, 12, 16 
and 40 min, respectively. 
Analysis of cardiac high-energy phosphates 
At the end of the reperfusion period, hearts were freeze-clamped at liquid nitrogen 
temperature. The extraction and automated HPLC-analysis of high-energy 
phosphates was essentially done as described before.'2.13 The Partisil-10-SAX column 
(Whatman) was equipped with a 5-JJ.m Supelguard LC-SAX guard column 
(Supelco). The gradient of H3P04 16 mM (pH 2.85) and NH4H2PO. 750 mM 
(pH 4.5) started 10 min after sample injection; the second buffer increased 4% per 
min until 100%. Flow rate was 2.0 ml/min. The nucleotides were detected at 
254 nm, the creatine compounds at 214 nm (Model490 absorbance detector). The 
retention times of creatine, AMP, creatine phosphate, ADP and ATP were 2, 3, 18, 
27 and 37 min, respectively. The adenylate energy charge, (ATP + 0.5 ADP)/(ATP 
+ ADP + AMP), was calculated from the adenine nucleotides. 
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Table I. Tension-rate product during the first 30 seconds of cardioplegia 
Function Percentage of hearts 
o· 10" 20" 30" 
c K KA KE c K KA KE c K KA KE c K KA KE 
>90% 100 100 100 100 14 9 14 
>20-90% 100 86 18 57 100 29 9 100 14 
arrhythmic 9 29 14 
5-20% 9 14 9 
<5% 54 57 82 100 71 100 100 
After 15 min of equilibration, hearts were perfused at 3 mljmin wtth Krebs·Henselett buffer (C, n = 6); buffer containing 
K+ 26 mM (K. n= 7); K+ 26 mM + adenosine 1 mM (KA, n = 11); or K+ 26 mM + EHNA 0.1 mM (KE, n= 6). The 
percentage of hearts belonging to each function class is listed. Function, calculated as developed tension times heart 
rate, at t = 15 min was taken as 100%. 
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Fig. 1. Average coronary flow data in ml/min per gram dry weight of all groups (n = 23). After an 
equilibration period of 15 min (perfusion pressure 9.2 kPa), the cardioplegic solution (CP) containing 
high K+, high K+ /adenosine, high K+ /EHNA, or standard K+, was infused with a roller pump at a 
rate of 3 mljmin (18 mljmin per g dry weight) for 3 min. Total ischemia was subsequently induced 
for 20 min, followed by 30 min of reperfusion at 9.2 kPa with standard buffer. Means ± SEM are given. 
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Electrophysiological studies 
The electrophysiological techniques used are described by Coetzee and Opie.14 
Briefly, sinus-node (SA) and atrial tissue was isolated at 37°C and mounted in an 
incubation bath (0.5 x 1.0 ern). The preparation ( <0.5 x 1.0 rnrn) was superfused 
at 3 rnl/rnin at 35-36°C with the oxygenated Krebs-Henseleit buffer described 
above. The preparation was impaled with a microelectrode, containing KCl 3 M. 
The reference electrode was positioned in the fluid close to the preparation; action 
potentials were monitored on an oscilloscope (Tektronix 5103 N) and recorded on 
video-tape after digitization (Sony PCM-501 ES, Unitrade). After a stabilization 
period of 15 min, the cardioplegic solutions described above were randomly 
superfused for 3 min in one preparation, followed by Krebs-Henseleit buffer until 
control values were reached again. 
Statistics 
Data are reported as means ± SEM. Anova analysis was not performed, as the 
large differences between the control and other groups could mask differences 
between the high-potassium and the high-potassium/adenosine groups. For contrast 
of the high-potassium/ adenosine group versus the high-potassium group, data were 
analyzed with Student's t-test (two-tailed). Differences with p-values < 0.05 were 
considered statistically significant. 
RESULTS 
A) Function in normoxic control hearts 
In the norm oxic control hearts (N perfused for one hour), resting and developed 
tension were 5.0 ± 0.0 and 30 ± 2 g (10-rnin value) and 3.1 ± 0.5 and 28 ± 3 g (60-
rnin value), respectively. The values for heart rate in that period were 321 ± 16 and 
261 ± 6 beats/min, respectively. Consequently, cardiac function, expressed as the 
tension-rate product, was 9,790 ± 880 g/rnin after ten minutes, and 7,340 ± 630 
gjmin after one hour. Coronary flow was 58 ± 5 rnl/min per gram dry weight, ten 
minutes after the start of the perfusion, and 37.4 ± 1.7 rnljmin per g after one 
hour. 
B) Function in cardioplegic hearts 
1. Cardiac arrest 
Table I shows that administration of either adenosine 1 rnM or EHNA 0.1 
rnM, in addition to K+ 26 rnM, accelerated the arrest of the hearts. After 30 
seconds of reduced flow, all hearts in groups KA or KE were arrested, while only 
five out of seven hearts in group K were arrested. Arrest time for group K was 
22 ± 4 s, KE decreased the time to 14 ± 1 s, while KA gave the shortest arrest 
time, 10 ± 2 s (p=0.016 vs. K). In group Call hearts were still beating, with arrest 
only occurring after 260 ± 16 s in addition during ischemia, they resumed some 
contractile activity. 
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Fig. 2. Effect of potassium cardioplegia, with and without adenosine or EHNA on resting tension and 
peak systolic tension during ischemia and reperfusion. With the normal K+ -concentration (group C) 
in the buffer, infused from 15 to 18 min, the hearts arrested slowly and resting tension rose steeply 
during ischemia and reperfusion. High-potassium (K), with adenosine (KA) or EHNA (KE), induced 
quick arrest and minimized the rise in resting tension. The arrow indicates the start of reperfusion. 
Means ± SEM are given (n=5-6). 
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Fig. 3. Effect of potassium cardioplegia, with and without adenosine or EHNA, on heart rate. After 
an equilibration period of 15 min, flow was reduced to 3 mljmin for 3 min. This decreased heart rate 
partly (panel C). If K+ -cardioplegia was employed, the hearts stopped completely (panel K). This also 
occurred with K+ -cardioplegia plus adenosine (panel KA) or plus EHNA (panel KE). After this 
infusion, ischemia was induced. Reperfusion started at the point indicated with an arrow. At the end 
of reperfusion, heart rate was highest in the group treated with potassium and adenosine (KA). Mean 
values with SEM (n=5-6). 
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2. Tension-rate product 
We used the product of developed tension times heart rate as an index of 
cardiac function. During equilibration the differences between the groups were 
small (Fig. 2). Just 
before cardioplegia, the average tension-rate product was 8,500 g/min. At the end 
of the cardioplegic infusion, function in the K, KA and KE groups was zero, while 
control hearts (C) had reduced function (1,670 ± 320 g/min). After five minutes of 
reperfusion, all hearts had regained function. The highest values were found in the 
KA group (6,550 ± 629 gjmin), intermediate values with the groups KE 
(6,050 ± 950 g/min) and K (5,490 ± 290 gjmin, p < 0.001 vs. KA), while the 
control group gave the lowest function (2,060 ± 659 gjmin). At the end of 
reperfusion, function in the KA group remained constant and significantly higher 
than the K group which had deteriorated slightly (6,250 ± 740 and 
4,380 ± 390 g/min, respectively, p = 0.05). 
3. Heart rate 
Figure 3 shows the effect of cardioplegia, ischemia and reperfusion on heart 
rate. At the end of the 3-min cardioplegic buffer infusion, all high-potassium hearts 
(K, KA and KE) had arrested, while the heart rate in group C only fell from 268 
± 16 to 168 ± 18 beats/min, with final arrest occurring three minutes later (Fig. 3). 
At the end of reperfusion, the heart rate was lowest in control hearts (191 ± 
43 beats/min), and group K (209 ± 27 beats/min). The addition of adenosine to 
the cardioplegic solution did not inhibit the recovery of the post-ischemic heart 
rate, and the group KA gave the highest recovery (259 ± 30 beats/min (p=0.2). 
Addition of EHNA gave an intermediate value (Fig. 3). 
4. Resting tension 
Pre-ischemic resting tension in all hearts was about 5 g. It remained unchanged 
during ischemia in all groups except the control group C, where it increased to 
9.1 ± 0.7 gin the end of ischemia (Fig. 4). After two minutes of reperfusion, the 
resting tension in all hearts increased; group C gave the largest increase (17 ± 3 g), 
whereas the values in the remaining groups were 7.2 ± 0.8 g (K), 6.6 ± 0.7 g (KA), 
and 6.4 ± 0.5 g (KE). At the end of the 30-min reperfusion period, the resting 
tension in all groups had returned to the pre-ischemic value (around 5 g), while it 
was still elevated to 8 ± 2 gin group C (Fig. 4). 
5. Coronary flow 
All groups of hearts undergoing cardioplegia, ischemia and reperfusion, showed 
comparable values throughout the experiment. Flow in the first five minutes of 
reperfusion was 76 ± 6 ml/min per gram dry weight (group C), 72 ± 2 ml/min per 
g (group K), and 82 ± 4 ml/min per g (group KA), and 80 ± 5 rnl/min per g 
(group KE). For illustrative purposes, the data were combined (Fig. 1). 
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Fig. 4. Improved recovery of function after ischemia with adenosine as adjunct to potassium 
cardioplegia The product of developed tension and heart rate is depicted during the last 5 min of 
the equilibration period, cardioplegia (CP), ischemia and reperfusion. Cardioplegia was carried out 
with high K+ (curve K), high K+ + adenosine (curve KA), or high K+ + EHNA (curve KE). As a 
control, standard medium was infused (curve C). Mean values with SEM are presented (n=S-6). 
"' KE K 
Fig. 5. Semilogarithmic plot of ATP-catabolite release versus time. Effluent adenosine, inosine, 
hypoxanthine, xanthine and urate were measured with HPLC during 30 min of reperfusion. Purine 
production in the three fractions collected is depicted. EHNA did not reduce the release of ATP-
catabolites. The initial high purine release in the K+ /adenosine group (KA) is presumably caused by 
washout of adenosine( catabolite), employed during cardioplegia. Mean values with SEM (n = 5-6). 
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C) Metabolism 
1. Purine release 
Figure 5 depicts the production of purine nucleosides and oxypurines after 
ischemia. The control hearts (C) released 183 ± 13 nmoljrnin in the first five 
minutes of reperfusion. In K and KE-treated hearts, purine release was lower: 116 
± 15 nmolfrnin and 119 ± 12 nmolfrnin, respectively, while release was in KA-
treated hearts was 290 ± 10 nmol/rnin. At the end of reperfusion the rate of purine 
release was 10 nmoljrnin in all groups. The adenosine dearninase inhibitor EHNA 
changed the adenosine/inosine ratio in the effluent drastically. During early 
reperfusion the ratio increased from 0.24 ± 0.02 (K group) to 3.3 ± 0.3 (KE group) 
(Fig. 6). This was due to a 5.8-fold rise in adenosine concentration and a 2.5-fold 
fall in inosine concentration. At the end of reperfusion, these differences had 
almost disappeared. 
2. High-energy phosphates 
At the end of reperfusion the A TP values were depressed when compared to 
normoxic hearts (N); ATP values fell from 25 ± 3 J,£molfg dry weight to 16.3 ± 1.2 
J,£molf g (group C) and about 20 J,£molf g for groups K, KA and KE. We found a 
comparable pattern for ADP (Table ll). 
The amount of creatine phosphate in normoxic control hearts was 22 ± 2 
umol/g (Table ll). Mter reperfusion, both treated and untreated hearts contained 
about 30 umolf g. 
3. Water content 
The water fraction was about 0.87 in all groups, indicating that ischemia 
followed by reperfusion did not cause swelling (Table ll). 
C) Electrophysiological studies 
Potassium 26 mM (K) initiated depolarization of the atrial SA-node membrane, 
20 seconds after being added (Fig. 7). It took a further 20 s for depolarization to 
be complete and for the action potential to be abolished. When adenosine 1 mM 
(KA) was added, there was initial hyperpolarization during the first few seconds 
prior to depolarization to similar values by the high-potassium in the cardioplegic 
solution. Cessation of the action potential occurred prior to depolarization of the 
membrane by the high-potassium concentration. In four preparations KA shortened 
the arrest time by 18 ± 4 s when compared to K alone (p = 0.004, n = 7 
impalements). KE gave similar results to K alone, showing no hyperpolarization 
and arrest alone when depolarization was near completion. 
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Fig. 6. EHNA, present during cardioplegia and stopped-flow ischemia, increased the adenosine/inosine 
ratio in the cardiac effluent during reperfusion. Effluent was collected from 38 to 43 min, from 43 to 
53 min, and from 53 to 68 min. The nucleoside concentrations were determined by HPLC and their 
ratios calculated. The following additions were made to the perfusion buffer during cardioplegia: None 
(C), 20 mM K+ (K), 20 mM K+ + 1 mM adenosine (KA), or 20 mM K+ + 0.1 mM EHNA (KE). 
Mean values are given with SEM (n = 5-6). 
Fig. 7. Accelerated arrest of the atrial-sinus-node preparation with adenosine as adjunct to potassium 
cardioplegia. A typical example is given of action potential measurements in one single cell, superfused 
with Krebs-Henseleit buffer (3 mljmin). Arrest was induced by addition of 20 mM K+ (K), 20 mM 
K+ + 1 mM adenosine (KA), or 20 mM K+ + 0.1 mM EHNA (KE). 
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Table II. The effect of potassium cardioplegia, with and without adenosine or EHNA, on myocardial ATP and related 
metabolites in reperfused hearts 
Variable N c K KA KE 
ATP 25 ± 3 16.3 ± 1.2 20.3 ± 0.6 20.1 ± 0.6 21.1 ± 1.1 
ADP 4.9 ± 0.4 3.05 ± 0.17 3.47 ± 0.09 3.60 ± 0.07 357 ± 0.20 
AMP 0.98 ± 0.18 0.65 ± 0.11 0.75 ± 0.04 0.61 ± 0.05 0.66 ± 0.05 
ATP/ADP5.1 ± 05 5.3 ± 0.4 5.8 ± 03 55 ± 0.2 5.9 ± 0.3 
SumAdl'al ± 3 20.0 ± 1.3 245 ± 05 24.3 ± 0.6 25.6 ± 0.9 
AEC 0.888 ± 0.005 0.887 ± 0.011 0.898 ± 0.005 0.900 ± 0.003 0.903 ± 0.003 
CrP 22 ± 2 30 ± 2 30.3 ± 0.8 27.8 ± 1.0 30.0 ±1.1 
Cr 48 ± 3 315 ± 1.3 36.3 ± 1.6 38.0 ± 1.4 36 ± 4 
CrP/Cr 0.45 ± 0.04 0.98 ± 0.13 0.81 ± 0.06 0.75 ± 0.05 0.90 ± 0.13 
CrP+Cr 70 ± 5 605 ± 15 66.0 ± 1.4 65.8 ± 1.2 67 ± 3 
HzO fr. 0.861 ± 0.005 0.876 ± 0.004 0.872 ± 0.006 0.867 ± 0.004 0.870 ± 0.002 
n 4 6 6 6 5 
Mter equilibration hearts underwent cardioplegia, ischemia and reperfusion as described under Materials and methods. The 
hearts were freeze-damped, extracted and analyzed by HPLC for metabolites. N = normoxic non-ischemic, C = control 
(normal K+ in 'cardioplegic solution'), K = high K+ in cardioplegic solution, KA = high K+ + adenosine, KE = high K+ 
+ EHNA, AdNu = adenine nucleotides, AEC = adenylate energy charge, CrP = creatine phosphate, Cr = creatine. H20 
fr= water fraction. Data are in umotjgram dry weight, except the ratios which are dimensionless. Means ± SEM 
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DISCUSSION 
Overall effects of adenosine 
In this study the addition of low-dose adenosine to potassium decreased the time 
to cardiac arrest, in confirmation of our earlier study.6 The new data here presented 
concern (i) improved speed of cardiac arrest achieved by low-dose (1 mM) 
adenosine, when added to potassium (26 mM) as judged by the rate tension 
product; (ii) the electrophysiological mechanism whereby cardiac arrest is achieved 
by adenosine; and (iii) the effects of endogenous adenosine raised by EHNA (vide 
infra); and (iii). However, high-potassium alone was also effective in preventing 
reperfusion damage, as judged by prevention of the further rise in diastolic tension 
upon reperfusion (Fig. 4). The addition of low-dose adenosine to potassium 
accelerated arrest without improving recovery of high-energy phosphates or patterns 
of release of purine when compared with potassium alone. The mechanism of the 
benefit of added low-dose adenosine on function in the reperfusion period is 
unclear; we cannot exclude an improved energy status at the end of the ischemic 
period as a consequence of the accelerated cardiac arrest, although the patterns of 
purine release during the reperfusion period were unaltered by the addition of 
adenosine. 
Metabolic and myocardial function effects of adenosine and EHNA 
Effects of adenosine 
Previous authors suggest metabolic benefits due to adenosine and EHNA 
which we did not find. Takeo et al.5 reported increases in A TP and creatine 
phosphate due to adenosine( catabolite) administration to hypoxic rabbit heart. 
Kao and Magovern15 showed that adenosine 1 mM in a hypothermic cardioplegic 
solution prevented ATP breakdown during and after ischemia of the isolated rat 
heart. Large aberrations in myocardial glucose-6-phosphate, creatine phosphate and 
lactate content, however, were still present. In the anesthetized dog, 16 a 3-h infusion 
of adenosine after myocardial ischemia, repleted nearly 50 percent of the ATP lost, 
but regional and global myocardial function was not improved. Recently Wyatt et 
al.17 found in the same preparation that adenosine (plus hypoxanthine and ribose) 
maintains myocardial ATP content during ischemia and reperfusion and enhances 
functional recovery during the post-ischemic period. Silverman et al.18 claimed that 
adenosine (with or without EHNA) during reperfusion of the dog heart, after a 
period of hypothermic K+ -cardioplegic arrest, improved the myocardial ATP 
content. However, they failed to compare the groups (which seem to be from an 
inhomogeneous population) and they did not supply data on myocardial function 
with the regimens studied. 
Effects of EHNA 
In our study we put emphasis on the effect of exogenous adenosine and less 
on endogenous adenosine. Increasing endogenous adenosine by means of the 
inhibitor of adenosine deaminase EHNA (Fig. 6), gave functional results similar 
in trend to those achieved by addition of exogenous adenosine to potassium. Thus 
the time to cardiac arrest was diminished and post-ischemic cardiac function was 
improved by EHNA. We speculate that adenosine formed in the ventricle 
accelerates the arrest of the sinus-node of EHNA-perfused hearts. 
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Dhasmana et al.'9 showed that a very high dose of EHNA, given before and 
after ischemia, improved functional recovery of the rat heart. However, this benefit 
was also not correlated with ATP recovery during reperfusion nor did it prevent 
ventricular fibrillation. In dogs on cardiopulmonary bypass, treatment with EHNA 
before ischemia, and with adenosine during and after ischemia, resulted in some 
improvement in myocardial ATP.20 It is not clear whether this improvement was 
statistically significant. However, mean aortic pressure remained low, and renal 
vasoconstriction took place. Hull-Ryde et al.21 reported that EHNA (plus 
dipyridamole) in a cardioplegic solution, administered to dogs on cardiopulmonary 
bypass, increased the myocardial ATP content during reperfusion from 4.0 to 5.0 
umolj g wet weight. In their paper, the emphasis is on nucleotide analysis, and they 
supplied only few details about their animal preparation and infusates. We failed 
to see an improvement of ATP by EHNA in our model (Table IT). Humphrey et 
al.22 treated rat hearts with EHNA before ischemia. They found some increase in 
adenine nucleotides after reperfusion, but ventricular function failed to recover. We 
failed to see an improvement of ATP by EHNA added to potassium arrest in our 
model (Table II). 
Electrophysiological actions of adenosine 
Adenosine produces a dose-dependent increase in potassium permeability which 
leads to hyperpolarization of the membrane thus active in a similar way to 
acetylcholine; relatively high doses of adenosine alone caused complete arrest 
associated with hyperpolarization of 12-15 mV,'.z as also confirmed by our 
unpublished data. In whole-cell voltage clamp experiments, adenosine activated a 
time-dependent potassium current which at -50 mV was approximately 30 pAin a 
normal Tyrode's solution and 50 pAin high-potassium Tyrode's solution;2 The rapid 
cardiac arrest produced by adenosine (1 mM) in the presence of high-potassium 
(26 mM) was probably due to increased potassium permeability causing early arrest 
of the sinus-node. EHNA may have been ineffective in this model due to the high 
superfusion rate of 3 ml/min which could have prevented any accumulation of 
adenosine. 
In our study we only added adenosine and EHNA to the cardioplegic solution 
which was administered for 3 min prior to 20 min of total ischemia. The 
reperfusion solution contained no adenosine or EHNA and the potassium 
concentration was 6 mM. Although we did not find an improvement in high-energy 
phosphates at the end of the reperfusion period, we cannot exclude an 
improvement during ischemia or early in reperfusion. The benefits of adenosine 
and EHNA as shown by improved myocardial function were not translated into 
higher levels of ATP at the end of reperfusion. 
Reservations 
We studied the rat heart, thought to be 'hypercontractile', and, therefore, the 
results may not be applicable to other species, let alone man. Also, we did not 
assess whether adenosine, when added to the standard cardioplegic combination 
of hypothermia plus hyperkalemia, would still give any added benefit. Therefore, 
further work is required before adenosine can be recommended as a standard 
adjunct to potassium cardioplegia. 
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Appendix 5 
Relationship between pre-ischemic heart function and onset of 
contracture 
Rutger J. Stroeve, Jan Willem de Jong, and Peter van der Meer 
ABSTRACf 
We expected an inverse relationship between pre-ischemic function and onset of 
myocardial contracture. To test this, we manipulated the pre-ischemic inotropic state 
of 45 perfused rat hearts by adapting the buffer concentration to: potassium (20 mM), 
magnesium (15 mM), calcium (4 mM), nifedipine (0.3 J,JM), DL-verapamil (0.9 JJ.M), 
or dopamine (6 J,JM). High-calcium had a positive inotropic effect, dopamine affected 
function transiently, the other substances were negative inotropic. Then, we stopped the 
flow until contracture started. Time until contracture was delayed or shortened with 
negative or positive inotropic treatment, respectively. Despite these differences in total 
ischemic time, we found no significant differences between the groups in developed or 
resting tension, coronary flow or purine release during reperfusion, apart from a lower 
resting tension in the calcium-treated group. Thus, in this model: 1) an inverse 
relationship exists between pre-ischemic heart function and onset of contracture; 2) Ca-
antagonists fail to show benefits above other negative inotropic treatments. 
INTRODUCTION 
Prolonged myocardial ischemia or hypoxia leads to a depletion of A TP, a loss of 
contractile function and a rise in resting tension (onset of contracture). Full-blown 
contracture or "stone heart"5' 21 is now a rare complication in heart surgery. 
However, mild degrees of contracture are common occurrence after heart surgery 
and after acute coronary occlusion. Two factors seem to be of major importance 
in the onset and development of contracture11' 12, 16' 19: 1) A critical ATP-depletion, 
which leads to rigor bond formation between actin and myosin; the contracture 
itself further accelerates the ATP-hydrolysis2; 2) ca:+ -accumulation near the active 
sites of actin. 
Several authors9' 10' 16 using different protocols could delay the ischemic rise in 
resting tension by pretreatment of the hearts with agents like high-potassium 
cardioplegia or Ca-antagonists. These substances influence heart function. Our 
earlier work .. 7 already showed the relation between pre-ischemic heart function and 
ATP-breakdown during ischemia. Now, our objective was to investigate in one 
model the relationship between pre-ischemic heart function and onset of 
contracture. We pretreated hearts with a positive or negative inotropic agent; then 
we made them ischemic until they had reached a fixed rise in resting tension. We 
analyzed the relation between the inotropic response and the time to onset of 
contracture. 
MATERW.$ AND ME1HODS 
Heart perfusion. Male Wistar rats (255 ± 34 g) with free access to food and water 
were anesthetized with 50 mg pentobarbitone intraperitoneally. The heart was 
90 
rapidly excised and cooled in ice-cold 0.9% w /v NaCl until beating ceased. Then 
retrograde perfusion of the aorta according to Langendorff was started with a 
modified Tyrode's buffer containing (mM): D-glucose: 10; NaCl: 128; KCl: 4.7; 
CaC12: 1.4; NaHC03: 20; NaH2P04: 0.4; MgC12: 1.0. Water was purified with the 
Millipore-Ro4/Milli-Q System (Millipore, Bedford, MA, USA). The buffer was 
gassed with 95% 0 2 plus 5% C02• The perfusion temperature was 37°C. The buffer 
was delivered to the aorta at a pressure of 9.3 kPa. Pressure and temperature were 
measured above and in the aortic canula, respectively. During the entire 
experiment, the heart was paced at a frequency of 300 beats/min (4 V, 2 ms). 
Myocardial resting tension (preload) and developed tension (peak systole minus 
resting tension) were measured with a force transducer (Hugo Sachs F5-2, 
March/Freiburg, FRG) connected to the apex of the heart. Perfusate from the 
heart was collected in a graduated cylinder for 5-min periods. The cylinder was 
placed in ice to diminish purine catabolism. An electromagnetic flow probe 
(Transflow 601, Skalar Medical, Delft, The Netherlands) was used to monitor flow. 
During the period of no-flow ischemia, a water-jacketed chamber, sealed with 
Parafilm, prevented the heart from cooling. A thermistor was inserted into the left 
ventricular cavity to measure the intra-cardial temperature. Upon reperfusion this 
probe was removed from the ventricle. 
Protocol. Five hearts were perfused for one hour to check the stability of the 
preparation. Another 40 hearts were randomized into seven groups receiving the 
treatments described below. Mter being mounted on the canula (t=O min), the 
hearts were equilibrated for fifteen minutes with standard buffer. During this 
period, preload was adjusted to 5 g by manipulating the force-transducer; then it 
was corrected no more. The developed tension at t= 15 min was taken as 100% 
function. Mter equilibration the hearts were perfused with a modified solution for 
ten minutes. (During this period the untreated control group was perfused with 
standard medium.) Function at t = 25 min was used to determine the effect of the 
modified solutions during normoxia. At t=25 min the hearts were made globally 
ischemic by stopping flow to the hearts completely. Reperfusion with standard 
medium was started when the resting tension had increased by 10% of the 
developed tension at t= 15 min above the nadir. The reperfusion period lasted 
twenty minutes (Fig. 1). 
Treatments. The modified solutions consisted of standard medium adjusted to 
or fortified with one of the following: KCl (20 mM), MgC12 (15 mM), CaC12 (4 
mM), dopamine (6 J.£M), nifedipine (300 nM), or DL-verapamil (880 nM). To 
correct for osmotic differences, the NaCl-content of the buffer was adapted. 
Nifedipine was obtained from Bayer (Leverkusen, FRG), verapamil from Knoll 
(Almere, The Netherlands), and dopamine from Brocacef (Rotterdam, The 
Netherlands). Nifedipine solutions were kept in dark brown reservoirs to avoid 
breakdown by light. 
Purine analyses. Perfusate samples were stored on ice and analyzed for purine 
nucleosides and oxypurines by high-performance liquid chromatographys·17, usually 
within hours. In some experiments the samples were kept at -20°C up to two days 
before they were assayed. 
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FIG. 1. Schematic representation of an experiment (taken from the high-magnesium group. a: 
equilibrium period, b: treatment period, c: ischemia, d: reperfusion. x: developed tension before 
treatment, y: required rise in resting tension (y= 10% of x), *: nadir. 
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FIG. 2 Effect of various agents on contractility during normoxia (A), after reperfusion for 5 min (B) 
and 20 min (C). During ischemia developed tension became virtually zero (not shown). The dotted 
lines depict the average pooled values just prior to drug or ion administration; resting tension was 
(adjusted to) 5 g, developed tension was 14 ± 4 g (n=45). Con = ischemic control group; K = 
potassium group; Mg = magnesium group; Ver = verapamil group; Nif = nifedipine group; Ca = 
calcium group; Dop = dopamine group. 
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Statistical analyses. For statistical comparisons the one-way ANOVA-test was 
used with six degrees of freedom. Differences were further identified within each 
group using Student's unpaired t-test with Bonferroni correction. Chi-square 
analysis revealed statistical differences in time needed to regain function. 
Differences with a probability > 0.05 were considered not statistically significant 
(NS). Unless otherwise stated, P values refer to comparisons with the untreated 
hearts (ischemic control group). Data are presented as means ± SD. 
RESULTS 
Normoxic controls. In the normoxic control group tension, flow and purine release 
did not change. Developed tension in the control group decreased from 14 ± 3 g 
at t = 15 min to 13 ± 2 g after 60 min. Resting tension increased from 5.0 ± 0.0 to 
5.7 ± 0.7 g. The release of AMP-catabolites (purines) decreased from 6 ± 2 to 3.9 
± 1.3 nmoljmin per g wet weight. Flow remained about 13 ml/min per g. 
The first 15 min of all experiments was an equilibration period. We measured 
at the end of this period, developed and resting tension, flow and purine release. 
There were no statistically significant differences between the various groups during 
the equilibration period. 
Myocardial function. We used developed and resting tension (preload) as a 
measure of cardiac function. Fig. 2 shows resting and peak systolic tension; we 
obtained the developed tension by subtracting resting tension from the peak systolic 
tension. At t=25 min, developed tension in the ischemic control group (14 ± 4 g) 
had not changed from t= 15 min. Due to high-potassium, developed tension 
dropped to zero (P<0.001 vs. untreated control, Fig. 2A). This figure also shows 
the negative inotropic effect of high magnesium, verapamil and nifedipine. 
Developed tension fell to 0. 7 ± 0.4 g (P < 0.001 ), 6.9 ± 1.0 g (P < O.ol ), and 2.5 ± 1.0 
g (P<0.001), respectively. High calcium gave a marked positive inotropic response: 
Developed tension increased to 22 ± 6 g (P<0.001). Developed tension in the 
dopamine-treated group increased transiently, but did not significantly differ from 
the untreated control group at t = 25 min. 
Preload increased from 5.0 ± 0.0 to 7.8 ± 1.3 g in the high-potassium group 
(P<O.OOl, Fig. 2A) and to 8.0 ± 1.1 gin the high-magnesium group (P<0.001). 
Due to increased calcium, the preload decreased to 2.8 ± 0.6 g (P < 0.002). The 
preload in the other groups did not differ significantly from the untreated control 
group. 
During ischemia developed tension in the high-potassium group remained zero. 
In all other groups developed tension decreased precipitously. In all ischemic 
hearts, resting tension decreased first and rose later. The nadir in the ischemic 
control group was 4.1 ± 1.0 g. There were no significant differences between the 
groups (F-value: 0.79 with 6 degrees offreedom (group) and 32 degrees of freedom 
(event). 
After reperfusion most hearts took some time to resume their rhythmic heart 
rate. After 30 s all hearts in the high-potassium group had a rhythmic function, 
while in the other groups only a few hearts resumed a normal contraction pattern 
(P < 0.01, potassium vs. other groups). 
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FIG. 3. Effect of various agents on the release of AMP-breakdown products. Purine release before 
treatment, depicted by the dotted line, was 33 ± 10 nmol/5 min per g wet weight (n=45). For other 
details, see legend to Fig. 1. 
FIG. 4. Effect of various agents on coronary flow. Flow before treatment, depicted by the dotted line 
was 11.4 ± 1.7 ml/min per g wet weight (n=45). For other details, see ~egend to Fig. 1. 
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FIG. 5. Relation between inotropic response (tension at t=25 min expressed as percentage of t=lS 
min) and time until the onset of contracture. For details, see Materials and Methods. o = ischemic 
control group; = potassium group; = magnesium group; = verapamil group; = nifedipine 
group; = calcium group; = dopamine group. 
Upon reperfusion the preload rose steeply and decreased subsequently. After 
5 min of reperfusion, none of the groups had a preload significantly different from 
the ischemic control group (6 ± 3 g). Developed tension was not different from the 
ischemic control group (5 ± 3 g) either (Fig. 2B). Likewise, after 20 min of 
reperfusion, there were no statistically significant differences in developed tension 
between the groups (Fig. 2C). However, the preload in the high-calcium group was 
lower than that in the ischemic control group (3.6 ± 0.7 vs. 5.8 ± 1.0 g, P < 0.05). 
Purine release. Fig. 3A shows the effect of the various agents on myocardial 
purine release. In the high-potassium group, purine release at 25 min, i.e., before 
ischemia, was 42 ± 10 nmol/5 min per gram wet weight. This is significantly higher 
than that in the untreated group (28 ± 6, P < 0.05). The other groups did not differ 
significantly from the latter. After ischemia there were no statistically significant 
differences in purine release between the groups (Figs. 3B and 3C). 
Flow. The effect of the various agents on the flow at t=25 min, i.e., before 
ischemia, can be seen in Fig. 4A Flow (in ml/min per g wet weight) in the 
untreated control group was 10.6 ± 1.0. It increased by high potassium (to 15.1 ± 
0.6, P<0.001), high magnesium (to 18 ± 1, P<0.001), verapamil (to 17 ± 3, 
P<0.001), nifedipine (to 22 ± 2, P<0.001) and high calcium (14 ± 3,P<0.01). Only 
minor increases in flow were seen with dopamine. 
Reperfusion resulted in a marked reactive hyperemia. During reperfusion 
there were no significant differences in flow between the groups (Figs. 4B and 
4C). 
Time until onset of contracture. The hearts were made ischemic until the 
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resting tension had increased above the nadir by 10% of the developed tension at 
t= 15 min. There were marked differences between the groups in the time elapsed 
before the preload had reached such an increase. The time until onset of 
contracture was prolonged by negative inotropic treatment and shortened by 
positive inotropic treatment 
In the untreated hearts, contracture started to develop at 9.7 ± 1.1 min. 
Treatment with high concentrations of potassium or magnesium delayed this to 
21 ± 5 min (P<0.001) and 13.9 ± 1.4 min (P<0.05), respectively. For the Ca-
antagonists these values were: nifedipine (14.5 ± 1.9 min, P<0.05); verapamil 
(13.4 ± 1.2 min, NS). In the dopamine group contracture started at 8 ± 3 min (NS), 
while in the calcium group it began at 5.5 ± 1.6 min (P < 0.05). If we expressed the 
function after the inotropic intervention as a percentage of the developed tension 
at t = 15 min and plotted this against the logarithm of the time to onset of 
contracture, an inverse linear relationship was apparent (r=-0.876, P<0.001; see 
Fig. 5). 
DISCUSSION 
Methodological aspects. We used developed tension as an indicator for heart 
function13' 24• We avoided an intraventricular balloon, because of the resulting 
subendocardial ischemia18• 
We used purine nucleoside and oxypurine release as an indicator of ATP-
breakdown. Although part of the ATP metabolized remains in the cell as ADP or 
AMP, purine release rises in accordance with ATP-breakdown1' 20• 
Myocardial function. The effect of the six different inotropic agents on heart 
function were in accordance with their known modes of action3' 9' 28• No statistically 
significant differences in heart function were found during reperfusion, except for 
the lower resting tension in the high-calcium group at the end of reperfusion. 
Although wash-out of Ca-antagonists is notoriously slow, the hearts pretreated with 
Ca-antagonists did not exhibit a lower function. We cannot exclude that drug 
residues, causing negative inotropy, masked improved function due to protection 
against ischemic injury. The high-potassium group resumed contractile activity 
significantly earlier than all other groups. Probably in the former, ionic homeostasis 
was restored faster. 
Purine release. The effects of the various agents on purine release were mostly 
non-significant. Only during perfusion with high potassium did the purine release 
rise significantly. This ion probably induces increased calcium-influx through the 
depolarized membrane'4, causing increased energy turnovers. 
During reperfusion there were no significant differences in purine release 
between the ischemic control group and the treated groups. Our earlier work 
showed the inverse relationship between pre-ischemic myocardial function and 
ischemic purine release6• 
The similarity of purine release after ischemia in the present experiments 
indicates that ATP breakdown was comparable in the treated groups, and remained 
unaltered by the variation in duration of ischemia. We assume that the ATP-sparing 
effect of the negative inotropic treatments was masked by the longer duration of 
the ischemic period. 
Coronary flow. All agents but dopamine increased coronary flow significantly. 
This effect is due to either a direct vasodilation (potassium, magnesium, nifedipine 
and veraparnil) or to increased demand (calcium). These results are in line with the 
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known effects of the agents or drugs. 
After reperfusion there was no difference in flow between the groups. The 
interplay between coronary flow regulation and myocardial metabolism remains 
complex and may involve various factors26• When compared for flow, all hearts 
exhibited a similar recovery. 
Time until the onset of contracture. The time until the onset of contracture 
in our ischemic control group (about 10 min) is in accordance with the reports by 
other authors'6,Z7. We were particularly interested in the relationship between pre-
ischemic heart function and the time until onset of contracture. The fairly strong 
inverse relation found stresses the influence of pre-ischemic heart function on the 
ensuing ischemic period. This relation was also found in an in vivo dog modef'. In 
that study infarct size was used instead of onset of contracture. We think the same 
mechanisms apply in both studies. We reported earlier that ischemic function and 
ischemic purine release did not correlate8• On the other hand, ischemic purine 
release seemed dependent on pre-ischemic heart function. A lower cardiac function 
at the onset of ischemia probably results in reduced ischemic ATP-catabolism6• This 
agrees with the observation that different, equi-active negative inotropic treatments 
result in equivalent ischemic ATP-content (and recovery of heart function)28• Slower 
ischemic ATP-breakdown probably underlies the delay in onset of ischemic 
contracture due to hypothyroidism4• 
Calcium-antagonists are thought to be beneficial through a variety of 
mechanisms: increasing collateral flow, decreasing preload and afterload, reducing 
calcium-influx and preserving mitochondrial function22• We expected an additional 
protective effect of the calcium-antagonists compared to potassium cardioplegia. 
We did not find such an effect. Collateral flow or reduced afterload have no role 
in an isolated, non-working heart model. The preload in an intact organism is 
different from the in vitro preload. Remains the reduced calcium-influx which 
probably causes the negative inotropic effect of calcium-antagonists. So calcium-
antagonists probably have a broader (and better) effect in an in vivo situation than 
in an isolated heart preparation. We think that in our model, their main mode of 
action is through negative inotropy. 
The exponential relation between the inotropic response and the time until 
contracture suggests that, at low levels of heart function, a further small reduction 
of heart function results in a markedly longer time until the onset of contracture. 
We cannot exclude that the higher pre-ischemic resting tension in the negative 
inotropic groups resulted in a longer time until contracture. Further research is 
necessary to evaluate this possibility. 
Clinical implications. This paper further stresses the importance of 
pretreatment in therapeutic interventions that are accompanied by transient 
ischemia (percutaneous transluminal coronary angioplasty, bypass surgery, heart 
transplantation). 
CONCLUSIONS 
In an isolated rat heart preparation: 1) an inverse relationship exists between pre-
ischemic function and onset of contracture; 2) Ca-antagonists fail to show benefits 
above other negative inotropic treatments. 
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Appendix 6 
Effect of inosine and adenine on nucleotide levels in post-
ischemic rat heart perfused with and without pyruvate 
P. van der Meer, T. Huizer, J.W. de Jong 
ABSTRACT 
Reports on enhanced nucleotide regeneration by purines during reperfusion are 
conflicting. Therefore we evaluated the effects of post-ischemic inosine or adenine 
administration on adenine nucleotide levels and function recovery in the isolated rat 
heart. Experiments were performed with glucose-containing modified Tyrode solution 
both with and without addition of 5 mM pyruvate. After 15-min stop-flow ischemia, 
hearts were reperfused for 45 min with 20 JJ.M purine and 0.5 mM ribose. 
Adenine nucleotide levels tended to recover better in the purine-treated groups. 
The purine-treated hearts with pyruvate exhibited a higher energy status, as expressed 
by an elevation of the ATP /ADP ratio. The level of IMP was twice higher in the 
inosine/glucose group than in all other groups. 
Purine treatment, with or without pyruvate, did not affect function recovery, heart 
rate or coronary flow. Inosine treatment increased the adenosine concentration in the 
effluent, the hypoxanthine concentration rose with adenine treatment. 
We conclude that after 45 min reperfusion, inosine or adenine do not improve 
heart function and hardly affect nucleotide levels. 
INTRODUCTION 
Ischemia reduces the myocardial adenine nucleotide content. De novo synthesis of 
nucleotides is very slow. Purines, like inosine and adenine, can enhance nucleotide 
regeneration via the salvage pathways (for a review, see ref. 30). 
Isolated heart cells rapidly incorporate adenine into adenine nucleotides3, but 
there are few reports on incorporation in isolated heart or in the heart in vivo. 
Some authors report enhanced ATP levels, if inosine is provided during 
reperfusion, even though the incorporation rate of 14C-labeled inosine is too low to 
explain the observed elevation11,26. The maximal activity of adenylosuccinate 
synthetase, one of the enzymes in this salvage pathway, does not permit a rapid 
regeneration6• In addition, the 14C-incorporation rate overestimates net nucleotide 
gain, because even the normoxic heart catabolizes its AMP to adenosine. 
Inosine may alter the metabolic and functional state of the heart, possibly with 
secondary effects on· the nucleotides. Inosine causes coronary vasodilation and 
increases myocardial contractility in the dog14, but it is negative inotropic in rat 
heart12• It shifts the use of free fatty acids to glucose25• Inosine also inhibits 
adenosine uptake15• 
Exogenous pyruvate increases glycolysis and improves function recovery in the 
(post-)ischemic heart17'18,2'.28. The reduction in free AMP content, caused by pyruvate 
in glucose-perfused hearts, lowers the efflux of adenosine and inosine•. Pyruvate 
also decreases the NADH/NAD+ -ratio, and may thereby deblock an inhibition in 
the salvage of hypoxanthine, and thus also of inosine20• 
We wanted to assess the contribution of adenine and inosine in the post-
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MATERIALS AND METHODS 
Chemicals 
All chemicals were of the highest grade available. Water was purified with the 
Millipore-R04/Milli-Q System (Millipore, Bedford, MA, USA). Inosine and D-
ribose were purchased from Merck, Darmstadt, FRG; adenine from Koch-Light, 
Haverhill, Suffolk, UK; and sodium pyruvate from Boehringer, Mannheim, FRG. 
Perfusion of the hearts 
Male Wistar rats (252 ± 27 g, n=40) with free access to food and water were 
anesthetized by an intraperitoneal dose of 30 mg pentobarbital. Hearts were rapidly 
removed and immediately cooled in ice-cold saline until they stopped beating. 
Retrograde perfusion according to Langendorff was performed with a modified 
Tyrode buffer. The buffer consisted (in mM) of NaCl 128, KCl 4.7, CaCl2 1.4, 
NaHC03 20, NaHJ'O. 0.42, MgC12 1.0 and D-glucose 10. Mixtures were passed 
through a 0.45 J,£m filter and equilibrated with 95% 0 2/5% C02• The perfusion 
temperature was adjusted to 37°C with a thermocouple-regulated electric heater 
just prior to the perfusion canula. The canula was fitted with an A-F6 temperature 
probe, connected to a DU-3 monitor (Ellab, Copenhagen, Denmark). Cooling of 
the heart was prevented by keeping it in a double-walled chamber. The perfusion 
pressure, measured with a Statham P23Db-transducer (Hato Rey, PR, USA) was 
stabilized at 72 mmHg. 
Protocol After a 15-min equilibration period, followed by a 15-min pre-
ischemic period, hearts were made globally ischemic for 15 min. When heart rate 
dropped below 300 beats per minute, the hearts were paced at that rate. They were 
reperfused for 45 min with standard medium with one of the six following 
additions: none (GN), inosine + ribose (GI), adenine + ribose (GA), pyruvate 
(PN), pyruvate + inosine + ribose (PI), pyruvate + adenine + ribose (P A). The 
concentrations of inosine and adenine were 20 JLM, those of ribose and pyruvate 
0.5 mM and 5 mM, respectively. Finally, standard perfusion buffer was given during 
one min before the hearts were freeze-clamped with a Wollenberger clamp cooled 
in liquid nitrogen. 
Function was monitored with a force transducer (Hugo Sachs F5-2, 
March/Freiburg, FRG). During the equilibration period, resting tension was 
adjusted to 5 g. Developed tension was calculated as peak systolic tension minus 
resting tension. Flow was measured with an electromagnetic flow probe 
(Transflow 601, Skalar Medical, Delft, The Netherlands) or by timed collection of 
effluent. Heart rate was assessed and the rate tension product (RTP) was calculated 
as the product of heart rate and developed tension. 
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GN GI GA PN PI PA 
AMP 0.69 :!: 0.15 059 :!: 0.21 0.71 :!: 0.16 0.46 :!: 0.10 0.46 :!: 0.12 0.48 :!: 0.20 
ADP 2.88 :!: 0.28 351 :!: 0.39··· 3.25 :!: 0.36 2.44 :!: 0.28 251 :!: 0.17 2.66 :!: 0.39 
ATP 18.0 :!: 1.2 18.9. :!: 1.6 185 :!: 2.1 16.6 :!: 1.4 16.6 :!: 1.2 18.2 :!: 1.6 
TAN 21.6 :!: 1.4 23.0 :!: 1.7 225 :!: 2.4 195 :!: 15 19.6 :!: 1.2 21.3 :!: 1.8 
IMP 0.022 :t O.D15 0.053 :!: 0.013 •••• 0.030 :!: 0.013 0.026 :!: 0.008 0.030 :!: 0.006 0.028:!: 0.026 
CrP 345 :!: 3.6 32.4 :!: 9.0 32.9 :!: 33 45.3 :!: 3.1 43.6 :!: 3.7 33.9 :!: 16.4 
ATP/ADP 63 :!: 05 5.4 :t o5"" 5.7 :!: 0.4" 6.8 :!: 0.7 6.7 :!: 0.7 6.9 :!: 1.0 
dwt 0.15 :!: 0.02 0.14 :!: 0.04 0.18 :!: 0.03 0.20 :!: 0.01 0.18 :!: 0.02 0.18 :!: 0.02 
Table 1. The concentration of high-energy phosphates (in JLmollg dwt), ATP IADP ratio and dry 
weight (in gram) measured in freeze-clamped heart. Inosine increases the ADP and IMP concentration 
and decreases the ATP I ADP ratio in the glucose groups. Adenine also decreases A TP I ADP ratio. In 
the pyruvate-treated groups, addition of purine compounds did not cause significant differences. 
*p<0.05, **p<O.Ol, ***p<0.005, ****p<O.OOl, for p values: GI and GA were compared with GN, PI 
and PA were compared with PN; G=glucose, P=pyruvate, N=no purine, !=inosine, A=adenine, 
TAN =total adenine nucleotides, CrP=creatine phosphate, dwt=dry weight, means ± SD, n=6-9. 
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Fig. 1. Purine efflux in the first five-minute period of reperfusion after subtraction of infused inosine 
was comparable in all groups (means ± SD, n=6-9; G: glucose, P: pyruvate + glucose, N: no purine, 
1: inosine, A: adenine). 
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Fig. 2. Adenosine concentration in the emuent before ischemia and during 45 min of reperfusion. 
The adenosine concentration was higher in the inosine- treated hearts (GI, PI) than in the control 
hearts (GN, PN) (For abbreviations, see legend to Fig. 1, *p<0.05, **p<0.005, means, n=6-9). 
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Fig. 3. Effluent hypoxanthine concentration before ischemia and during reperfusion. The hypoxanthine 
emux was higher in the adenine-treated hearts (GA, PA) than in the control hearts (GN, PN) after 
45 min of reperfusion (For abbreviations, see legend to Fig. 1, *p<0.05, **p<0.005, means, n=6-9). 
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Cardiac high-energy phosphates, AMP and IMP were measured by our HPLC-
method13. Samples were taken from the effluent for the purine assay just before 
ischemia, 15 and 45 min after ischemia, and also from the effluent collected during 
the first five min reperfusion. Adenosine, inosine, adenine, hypoxanthine, xanthine 
and urate were determined in 200-,u.l samples as described before13• The retention 
times (min) were: urate 7.5, hypoxanthine 8.6, xanthine 9.4, inosine 11.9, 
adenine 13.6, adenosine 27.7. Identification ofHPLC peaks was done by comparing 
retention times and wavelength ratios of 254 and 290 nm (purines in effluent) and 
254 and 214 nm (high-energy phosphates in tissue) with standards. Compounds 
were quantified from peak areas. 
Statistics 
All values are presented as average ± standard deviation. GI and GA were 
compared with GN, PI and PA were compared with PN. Student's t-test was used 
(two-sided) for statistical analysis. G groups were not compared to the P groups, 
as the effects of pyruvate have been described in the literature, and because the G 
and P groups were not randomized. 
RESULTS 
Function, flow and heart rate 
Before ischemia the values of the groups, which were to be treated with the purines 
and those that were not, were similar. Developed tension was 14 ± 3 g in the 
glucose-perfused groups (G) and 15 ± 2 gin the groups with pyruvate addition (P). 
Coronary flow was 8 ± 1 ml/min (G) and 9 ± 1 ml/min (P). Heart rate was 310 ± 
35 beats/min (G) and 300 ± 24 beats/min (P). 
Addition of adenine or inosine to the reperfusion buffer did not significantly 
alter the recovery of developed tension. (The values between brackets are 
percentages of pre-ischemic values.) The developed tension recovered to 9 ± 3 g 
(G, 65 ± 14%) and to 14 ± 2 g (P, 89 ± 14%). Coronary flow at the end of 
reperfusion was 6 ± 2 ml/min (G, 76 ± 20%) and 9 ± 2 ml/min (P, 103 ± 30%) 
The product of developed tension and heart rate was 2600 ± 800 gjmin ( 60 ± 
15%) and 3900 ± 500 gjmin (85 ± 14%) in the glucose- and pyruvate-perfused 
groups, respectively. Heart rate was equal in all groups. 
Adenylates and high-energy phosphates 
Hearts treated with inosine plus glucose (GI), had only a tendency towards higher 
total adenine nucleotides (TAN) (p=0.09 vs GN, see Table 1). Inosine addition 
increased ADP levels from 2.88 ± 0.28 (GN) to 3.51 ± 0.39 (GI) ,u.moljg dwt 
(p=0.004). This increased ADP was reflected in a decrease ofthe ATP/ADP ratio 
(p = 0.008). The IMP levels more than doubled when inosine was added (p = 0.0006 
GI). Addition of adenine to the glucose buffer caused smaller alterations in the 
nucleotide levels, but in the same direction. The ATP / ADP ratio decreased 
(p=0.03) and the ADP level slightly increased (p=0.06). Purine treatment did not 
improve nucleotide levels in the pyruvate-treated hearts; they exhibited a higher 
energy status, as expressed by an elevation of the ATP / ADP ratio. Addition of the 
purines did not alter the creatine phosphate (CrP) levels. 
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GN GI GA PN PI PA 
0.63 :!: 0.18 054:!: 0.09 0.52:!: 0.12 0.59:!: 0.17 0.62:!: 0.19 0.52:!: 0.23 
12.2 :!: 2.9 30.9 :!: 2.7 11.7 :!: 3.8 11.4 :!: 1.7 29.8 :!: 1.0 10.2 :!: 1.4 
0.95:!: 0.31 20.0 :!: 0.3 0.84:!: 0.24 0.74:!: 0.14 20.4 :!: 0.2 1.23:!: 0.30 
0.45:!: 0.19 19.8 :!: 0.3 054:!: 0.14 0.38 :!: O.Q7 19.6 :!: 0.2 058:!: 0.16 
Table 2. Sum of the concentration (11M) of urate, xanthine, hypoxanthine, inosine 
and adenosine in the effluent, before and after ischemia (means ± SD, 
n=6-9). 
30 
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Fig. 4. The uptake/breakdown of adenine decreased during reperfusion in both adenine-treated groups 
(GA = glucose-adenine, PA = pyruvate adenine; means± SD, n=6). 
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Nucleosides and oxypurines 
In Table 2 the sum of the concentrations of AMP catabolites (adenosine + inosine 
+ hypoxanthine + xanthine + urate) are shown before, 0-5, 15 and 45 min after 
ischemia. 
Before ischemia, . the average purine concentration in the effluent was 
0.57 ± 0.16 JLM. Per minute, the heart lost 25 nmol/g dwt of purine compounds, 
which was about 0.1% of the myocardial adenine nucleotide content. In samples, 
drawn from the effluent collected from 0-5 min after ischemia, the sum of AMP 
catabolites had increased to 12 ± 3 JLM in the GN group. The GA, PN and P A 
groups showed similar results. When inosine was added, the sum was much higher 
(Table 2). We corrected the sum of catabolite concentrations for the added inosine, 
and calculated the washout of nucleotide catabolites during the first 5 min of 
reperfusion. These values, presented in Figure 1, show that the nucleotide 
breakdown in the groups is comparable. 
Figure 2 shows that addition of inosine increased the effluent concentration 
of adenosine 3-4 times in the samples collected 15 and 45 min after ischemia. 
Inosine addition also increased the concentration of inosine, hypoxanthine, xanthine 
and urate (not shown). 
Addition of adenine increased the hypoxanthine concentration 2-3 times 
45 min after ischemia (see Fig. 3). There was also a nonsignificant rise in urate 
and xanthine, but inosine and adenine levels were unaltered (data not shown). 
The uptake/breakdown of adenine is highest shortly after ischemia and decreases 
in the following samples (Fig. 4). These values were calculated as difference of 
infused concentration and effluent concentration multiplied by the coronary flow. 
DISCUSSION 
Nucleotide loss 
When oxygen requirement exceeds oxygen consumption, ATP is broken down and 
dephosphorylated catabolites leak out of the cell. In isolated rat heart, 30 min stop-
flow ischemia decreases the ATP level by 50%22• Reperfusion causes a rapid 
phosphorylation of ADP and AMP, but ATP recovers only to 60% within 1 h. 
Without treatment it takes days until pre-ischemic values are reached33• In our 
untreated glucose group, the ATP concentration after 15 min stop-flow ischemia 
and 45 min reperfusion was 18 J,£mol/g dwt. In a previous study, we found a pre-
ischemic ATP level of 23 J,£moljg13• The decrease of total adenine nucleotides 
would therefore be about 6 J,£molj g, which fits very well with the purine loss during 
the first 5 min of reperfusion. 
To find a net increase in adenine nucleotide concentrations, the formation 
has to be higher than the loss. In our pre-ischemic hearts, the average loss was 
25 nmoljmin per g, while at the end of the reperfusion period this was 
15 nmoljmin per g. These losses compare well with values earlier described by 
us11• There are four pathways for adenine nucleotide regeneration: adenosine 
incorporation, salvage of hypoxanthine (inosine) or adenine and de novo synthesis. 
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Adenosine incorporation 
Adenosine incorporation is the fastest regeneration pathway. Dow et al.6 measure 
an incorporation rate of about 400 nmoljmin per g dwt. in adult rat-heart myocytes. 
Transport across the cell membrane is rate-limiting6. Other authors find maximal 
adenosine transport and incorporation rates which are 7 times lowee,23,3S. Adenosine 
metabolism in the endothelium is very high. Therefore, conclusions drawn from 
studies in isolated myocytes can not be extrapolated to whole heart 
Reibel and Rovetto22,23 found that 30 min of adenosine infusion did not increase 
post-ischemic nucleotide levels, but 5-h infusion restored ATP levels which had 
been halved by ischemia. 
The hemodynamic effects of adenosine and its very short half-life in blood 
may limit its use as substrate for enhanced nucleotide synthesis. Therefore other 
precursors are more promising as potential treatments. 
Hypoxanthine incorporation 
Hypoxanthine is incorporated into IMP by hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT). The conversion of IMP to AMP is catalyzed by 
adenylosuccinate synthetase and lyase. Hypoxanthine incorporation is a factor 10 
slower than adenosine incorporation in neonatal cardiomyocytes35• The activity of 
HGPRT is limited by the concentration of phosphoribosyl-pyrophosphate (PRPP). 
Ribose-phosphate formed through the hexose-monophosphate shunt is used for 
PRPP production. The rate of synthesis of phosphoribosylpyrophosphate of whole 
heart cells with ribose as substrate is 50 nmol/min per g dwt6. The adenylosuccinate 
synthetase activity is extremely low, i.e. 15 nmol/min per g, therefore this should 
theoretically be the highest incorporation rate of hypoxanthine and inosine 
possible6. 
Inosine incorporation 
Inosine is catabolized to hypoxanthine and ribose-1-phosphate before 
incorporation19• This reaction is catalyzed by nucleoside phosphorylase, mainly 
localized in the endothelium2.14. The ribose-1-phosphate will probably remain within 
the endothelial cell, unused for enhancing the PRPP concentration in the myocytes. 
Hypoxanthine and adenosine inhibit inosine incorporation, possibly by competition 
for HGPRT and the nucleoside carrier, respectiveli'19• Inosine does not inhibit the 
activities of adenosine deaminase, 5'-nucleotidase, adenosine kinase and AMP-
deaminase6. 
The incorporation rates of 20 JJ.M inosine measured by various authors differ 
widely. Aussedat et al.1 found a 14C-inosine incorporation rate of 10 nmol/min per 
g dwt in isolated rat heart, while Harmsen et al.11 reported 0.4 nmoljmin per g. 
The former found no increase in ATP in hearts after 30-min inosine treatment 
during reperfusion. The increase in adenine nucleotides of 3.7 JJ.moljg dwt by 20 
min reperfusion with inosine, described by the latter, is much higher than could be 
explained by the rate of inosine incorporation. The adenine nucleotides content in 
our series increased from 21.6 (GN) to 23.0 (GI) JJ.moljg (Table 1). (This would 
indicate an average increase of 35-40 nmoljmin per g dwt, but the increase was not 
statistically significant.) 
Reperfusion with 200 JJ.M inosine in guinea-pig heart resulted in an increase 
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of adenine nucleotides of 35-40 nmol/min per If". The increases in adenine 
nucleotides are higher than might be expected from the 14C-incorporation rates or 
the in vitro activity of adenylosuccinate synthetase minus the amount of purine 
bases leaking out of the heart. A potential explanation for this discrepancy is an 
inhibition by inosine of adenosine transport out of the cell. 
The increase in IMP from 22 to 53 nmol/ g may have resulted from 
incorporation (Table 1). However, IMP may also have been generated through 
AMP-deaminase. In cardiomyocytes Geisbuhler et al.9 measured ten times higher 
amounts than we do. 
Adenine incorporation 
In isolated heart cells the maximum adenine incorporation rate is 50% of 
adenosine incorporation6• Adenine uptake does not interfere with adenosine 
metabolism6• In theory adenine incorporation should not be faster than the rate 
of PRPP synthesis (maximum 50 nmoljmin per g dwt in rat cardiomyocytes). In 
our series ther were only trends towards higer ATP levels. In a dog-heart model, 
a decrease of adenine nucleotides took 10 days to recover without treatment, but 
was replenished with adenine/ribose treatment in one da?. With ca. 18 ,uM 
adenine, the ATP regeneration was ca. 20 nmol/min per g during the first 4 h after 
ischemia, but this rate decreased rapidly in the following hours. In an earlier, 
preliminary paper, however, the same authors found no effect on A TP levels after 
90 min adenine/ribose treatment'2• 
Pyruvate and high-energy phosphate 
Addition of pyruvate to a glucose-perfused isolated heart decreases the 
concentrations of inorganic phosphate, AMP and ADP, but increases the level of 
CrP".s·'". Bunger showed that pyruvate lowered adenosine and inosine production 
in guinea-pig heart, and speculated that reduced AMP levels would decrease purine 
production5• Our values do not show this result. This point rieeds further evaluation. 
Pyruvate could decrease the inhibition of hypoxanthine incorporation by 
NADH in an isolated cardiomyocyte preparationm. In our model, however, there 
was merely a tendency towards an increased nucleotide level in the glucose/inosine 
group (GI) compared to the glucose group (GN), and in the pyruvate/adenine 
group (PA) compared to the pyruvate group (PN). These differences were not 
significant. We were unable to find evidence that this mechanismm functions in our 
model. 
Purines and energy status 
In the glucose-perfused group, addition of purines decreased the energy status of 
the heart (Table 1). We found an increase in ADP and a decrease in the 
ATP / ADP ratio. A similar tendency in the inosine group has been reported 
earlier". Inosine reduced ATP and increased ADP in isolated rabbit heart and 
reduced CrP in rat heart''16• 
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Purine concentrations in the effluent 
Inosine infusion caused the expected increase in effluent inosine and its breakdown 
products during reperfusion. In the inosine group -both with and without pyruvate-
the adenosine concentration increased (Fig. 2). This phenomenon, which we earlier 
described in normoxic rat heare\ therefore also occurs after ischemia. 
The adenine uptake by the heart is highest soon after the start of the adenine 
infusion (Fig. 4). Because of the reactive hyperemia, the effluent concentration of 
adenine is lowest after 15 min reperfusion. 
In intact dogs Ward et al.33 measured an adenine uptake of 38% in one passage 
through the heart (arterial concentration 18 ,u.M). Our value in isolated rat heart 
was less than 10%. Adenine perfusion caused an increase in the levels of 
hypoxanthine, xanthine and urate. Adenine increased hypoxanthine production, 
confirming literature data3• The absence of increased inosine concentrations 
suggests that adenine deamination is not routed via AMP and adenosine, or via 
IMP. 
Purines and function 
Purine derivatives affect hemodynamics. Inosine causes vasodilation, it increases 
contractility in some species12• Our earlier work showed that inosine ( > 30 ,u.M) 
increases coronary flow in isolated rat heart29• 
Many authors describe protection of the heart during and after ischemia by 
inosine9 ,27.28,34. Yoshiyama et al.34 showed that in an isolated guinea-pig model, after 
2 h of post-ischemic inosine treatment, function was better than in a control group. 
Shortly after ischemia they found the highest function, but this deteriorated later. 
Inosine decelerated this rate of decline. In our model function improved the first 
half hour after reperfusion and than stabilized. We found no differences between 
hearts treated with or without purines. 
The hearts perfused with pyruvate had a very good function recovery. Coronary 
flow was high. In post-ischemic working rat heart, it caused an earlier start of 
function, enhanced function and increased flow, but no increase in A TP18• 
CONCLUSION 
In an isolated rat-heart model, we tried to create optimal conditions for purine 
incorporation by perfusing the heart with ribose and pyruvate supplemented with 
adenine or inosine. We raised adenine nucleotide levels only marginally, but failed 
to improve function. 
ACKNOWLEDGEMENTS 
The authors are grateful to Ms. M.J. Kanters-Stam for her secretarial help 
and to Ms. H. van Loon and Ms. AS. Nieukoop for their technical assistance. 
REFERENCES 
1. Aussedat J, Verdys M, Rossi A (1985) Adenine nucleotide synthesis from inosine during normoxia and after ischaemia 
in the isolated perfused rat heart. Can J Physiol Pharmacal 63:1159-1164 
2. Bowditch J, Brown AK, Dow JW (1985) Accumulation and salvage of adenosine and inosine by isolated mature 
cardiac myocytes. Biochim Biophys Acta 844:119-128 
3. Brown AK, Raeside DL, Bowditch J, Dow JW (1985) Metabolism and salvage of adenine and hypoxanthine by 
108 
myocytes isolated from mature rat heart. Biochim Biophys Acta 845:469-476 
4. Bunger R, Swindall B, Brodie D, Zdunek D, Stiegler H, Walter G (1986) Pyruvate attenuation of hypoxia damage 
in isolated working guinea-pig heart. J Mol Cell Cardiol 18:423-438 
5. Bunger R (1987) Thermodynamic state of cytosolic adeny!ates in guinea pig myocardium. Energy-linked adaptive 
changes in free adenylates and purine nucleoside release. In: Gerlach E and Becker BF (eds) Topics and perspectives 
in adenosine research. Springer-Verlag, Berlin/Heidelberg, pp 223-235 
6. Dow JW, Bowditch J, Nigdikar SV, Brown AK (1987) Salvage mechanisms for regeneration of adenosine triphosphate 
in rat cardiac myocytes. Cardiovasc Res 21:188-196 
7. Ford DA, Rovetto MJ (1987) Rat cardiac myocyte adenosine transport and metabolism. Am J Physiol 252:H54-H63 
8. From AHL, Petein MA, Michurski SP, Zimmer SD, Ugurbil K (1986) 31P-NMR studies of respiratory regulation in 
the intact myocardium. FEBS Lett 206:257-261 
9. Geisbuhler T, Altshuld RA, Trewyn RW, Ansel AZ, Lamka K, Brierley GP (1984) Adenine nucleotide metabolism 
and compartmentalization in isolated adult rat heart cells. Circ Res 54:536-546 
10. Goldhaber SZ, Pohost GM, Kloner RA, Andrews E, Newell JB, Ingwall JS (1982) Inosine: a protective agent in an 
organ culture model of myocardial ischemia. Circ Res 51:181-188 
11. Harmsen E, De Tombe PP, DeJong JW, Achterberg PW (1984) Enhanced ATP and GTP synthesis from hypoxanthine 
or inosine after myocardial ischemia. Am J Physiol 246:H37-H43 
12. Hoffmeister HM, Betz R, Fiechtner H, Seipel L (1987) Myocardial and circulatory effects of inosine. Cardiovasc Res 
21:65-71 
13. Huizer T, DeJong JW, Achterberg PW (1987) Protection by bepridil against myocardial ATP-<:atabolism is probably 
due to negative inotropy. J Cardiovasc Pharmacol 10:55-<i1 
14. Jones CE, Mayer LR (1980) Nonmetabolically coupled coronary vasodilation during inosine infusion in dogs. Am J 
Physiol 238:H569-H574 
15. Kolassa N, Pfleger K, Rummel W (1970) Specificity of adenosine uptake into the heart and inhibition of dipyridamole. 
Eur J Pharmacol 9:265-268 
16. Kypson J, Hait G (1978) Effects of inosine on the metabolism and the performance of isolated oxygenated and 
hypoxic rabbit hearts. J Pharmacol Exp Ther 204:149-158 
17. Liedtke AJ, Nellis SH (1978) Effects of buffered pyruvate on regional cardiac function in moderate, short-term 
ischemia in swine heart. Circ Res 43:189-199 
18. Mochizuki S, Neely JR (1980) Energy metabolism during reperfusion following ischemia. J Physiol (Paris) 76:805-812 
19. Namm DH (1973) Myocardial nucleotide synthesis from purine bases and nucleosides. Circ Res 33:686-<;95 
20. Ravid K, Diamant P, Avi-Dor Y (1984) Regulation of the salvage pathway of purine nucleotide synthesis by the 
oxidation state of NAD + in rat heart cells. Arch Biochem Biophys 229:632-<i39 
21. Regitz V, Azumi T, Stephan H, Naujocks S, Schaper W (1981) Biochemical mechanism of infarct size reduction by 
pyruvate. Cardiovasc Res 15:652-<iSS 
22. Reibel DK, Rovetto MJ (1978) Myocardial ATP synthesis and mechanical function following oxygen deficiency. Am 
J Physiol 234:H620-H624 
23. Reibel DK, Rovetto MJ (1979) Myocardial adenosine salvage rates and restoration of ATP content following ischemia. 
Am J Physiol 237:H247-H252 
24. Rubio R, Berne RM (1980) Localization of purine and pyrimidine nucleoside phosphorylases in heart, kidney, and 
liver. Am J Physiol 239:H721-H730 
25. Smiseth OA (1983) Inosine infusion in dogs with acute ischaemic left ventricular failure: favourable effects on 
myocardial performance and metabolism. Cardiovasc Res 17:192-199 
26. Takeo S, Tanonaka K, Miyake K, Imago M (1988) Adenine nucleotide metabolites are beneficial for recovery of 
cardiac contractile force after hypoxia. J Mol Cell Cardiol 20:187-199 
27. Thomas JX, Jones CE (1979) Effect of inosine on contractile force and high-energy phosphates in ischemic hearts. 
Proc Soc Exp Bioi Med 161:468-472 
28. Van Bilsen M, Vander Vusse GJ, Snoeckx LHEH, Arts T, Coumans WA, Willemsen PHM, Reneman RS (1988) 
Effects of pyruvate on post-ischemic myocardial recovery at various workloads. Pflugers Arch 413:167-173 
29. Van der Meer P, DeJong JW (1987) Inosine infusion in isolated rat heart: effect on flow, function and catabolism. 
J Mol Cell Cardiol 19:S99 ( abstr) 
30. Van der Meer P, De Jong JW (1988) Regeneration of adenine nucleotides in the heart. In: De Jong JW (ed) 
Myocardial energy metabolism. Martinus Nijhoff Publishers, Dordrecht/BostonjLancester, pp 283-289 
31. Van der Meer P, De Jong JW (1988) Inosine causes vasoconstriction, but potentiates vasodilation by adenosine. 1 
Mol Cell Cardiol 20:S75 (abstr) 
32. Ward HB, Wang T, Einzig S, Bianco RW, Poker JE (1983) Prevention of ATP catabolism during myocardial ischemia: 
a preliminary report. J Surg Res 34:292-297 
33. Ward HB, St. Cyr JA, Cogordan JA, Alyono D, Bianco RW, Kriett JM, Poker JE (1984) Recovery of adenine 
nucleotide levels after global myocardial ischemia in dogs. Surgery 96:248-255 
34. Yoshiyama M, Sakai H, Teragaki M, Takeuchi K, Takeda T, lkata M, Ishikawa M, Miura I (1988) The effect of 
inosine on the post ischemic heart as bio-energy recovering factor in 31P-MRS. Biochem Biophys Res Commun 
151:1408-1415 
35. Zoref-Shani E, Kessler-Icekson G, Wasserman L, Sperling 0 (1984) Characterization of purine nucleotide metabolism 
in primary rat cardiomyocyte cultures. Biochim Biophys Acta 804:161-168 
109 
Appenclix 7 
Xanthine Oxidoreductase Activity in Perfused Heart of 
Various Species, Including Man 
Jan Willem de Jong, Peter van der Meer, A Selma Nieukoop, 
Tom Huizer, Rutger J. Stroeve, and Egbert Bos 
ABSTRACT 
Oxygen free radicals generated by xanthine oxidase have been implicated in cardiac 
damage. The activity of xanthine oxidase/reductase in (adult) rat heart is considerable. 
Its assay gives controversial results in other species, e.g., rabbit and man. Therefore, we 
perfused isolated hearts of various species, including explanted human hearts, to 
measure the conversion of exogenous hypoxanthine to xanthine and urate. We assayed 
these purines with high-performance liquid chromatography. The apparent xanthine 
oxidoreductase activities, calculated as release of xanthine plus 2x urate, were (mUjg 
wet weight, mean ± SE): mouse, 33 ± 3 (n =5); rat, 28.5 ± 1.4 (n = 9); guinea pig, 
14.4 ± 1.0 (n=5); rabbit, 0.59 ± 0.09 (n=5); pig, <0.1 (n=6); man, 0.31 ± 0.04 
(n = 7); and cow, 3.7 ± 0.8 (n =4). In rabbit heart the conversion of hypoxanthine to 
xanthine was slow, that of xanthine to urate even slower. On the other hand, guinea-
pig and human heart released little xanthine, indicating that xanthine breakdown 
exceeds its formation. We conclude that isolated perfused mouse, rat, guinea-pig, and 
also bovine hearts show considerable xanthine oxidoreductase activity, contrasting 
rabbit, porcine and human hearts. 
INTRODUCTION 
In heart adenine nucleotides are broken down to adenosine, inosine and 
hypoxanthine. These can be found in the cardiac effluent, and be used as markers 
for ischemia.1 In rat heart, xanthine oxidoreductase catabolizes hypoxanthine to 
xanthine and urate.2,3 Adult rat heart shows considerable activity of the enzyme;'.s 
in contrast to neonatal heart.3,9 The oxidase form, which generates free oxygen 
radicals, • could potentially damage cardiac tissue. Whether the enzyme expresses 
itself in the heart of man6.s.to.n-14 and several other species, including rabbit,s.7,9'10 is 
controversial. The classical assay of the enzyme in homogenates may lead to 
erroneous results, e.g., due to endogenous inhibitors.4'14 We decided to use the 
isolated, perfused heart of various species, measuring the conversion of added 
hypoxanthine to xanthine and urate. This enabled us to estimate the cardiac 
xanthine oxidoreductase activity in a physiological environment 
MATERIALS AND METHODS 
Perfusion of rodent hearts 
Fed adult animals (Balb-c and hybrid C57 black/CBA mice, Wistar rats, Dunkin-
Hartley guinea pigs and New-Zealand white rabbits) were anesthetized 
intraperitoneally with pentobarbital in accordance with institutional guidelines. 
Hearts were removed, arrested, and perfused retrogradely with Tyrode buffer at 
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9.6 kPa and 37°C as described before.' Heart weight was 0.15-0.20 g (mouse), 0.9-
1.6 g (rat), 1.6-2.2 g (guinea pig) and 8-12 g (rabbit). Canulation of mouse aorta 
proved difficult and time-consuming: about 25 min were needed. For the other 
species one minute sufficed. In all hearts, except those from mice, apex 
displacement was used to monitor function and heart rate. Coronary flow was 
measured electromagiletically (Skalar) or by timed collection of perfusate. Unless 
otherwise indicated, a control period of 15 min was used; then the perfusion 
medium was supplemented with hypoxanthine (Merck), infused just above the 
aortic canula, to give an optimal substrate concentration, usually 30-50 JLM. In the 
coronary effluent, purines were assayed by high-performance liquid 
chromatography,' with detection at 295 nm (urate) and 254 nm (hypoxanthine, 
xanthine). For each species, also perfusions with [8-14C]-hypoxanthine (5-40 Ci/mol, 
Amersham) were carried out. Radioactive chromatographic peaks were detected 
on line with a 171 Radioisotope detector (Beckman). 
Perfusion of human, porcine and bovine heart 
Hearts of transplant patients in end-stage heart failure due to ischemic heart 
disease or dilated cardiomyopathy were arrested in situ with St. Thomas' Hospital 
cardioplegic solution 4oC (ref. 15). Hearts from anesthetized, young adult pigs 
(hybrid Yorkshire/Danish Landrace, fasted overnight) underwent cardioplegic 
arrest just before or after excision at the conclusion of experiments performed for 
other purposes. Bovine hearts were flushed with the cardioplegic solution [with 
5000 IU/liter heparin (Organon Teknika)] within 15-20 min after slaughter in a 
local abattoir. 
Hearts were transported in ice-cold saline; canulation time was 30-50 min. 
Then retrograde perfusion of the aorta started. The perfusion fluid (37°C) 
consisted of Tyrode buffer', supplemented with 5 mM Na-pyruvate, 10 IU /liter 
insulin (Novo), 5000 IU/liter heparin and 25 g/liter dextran (40,000 dalton; 
Pharmacia). After ca. 20 min perfusion, 50 JLM hypoxanthine was added. The 
perfusion fluid was oxygenated with 95%02/5% C021 using an S-070/S oxygenator 
(Shiley), with heat exchanger and defoaming membrane. The perfusion apparatus 
was also equipped with a roller-pump, a manometer, an LPE-1440 filter (Pall), a 
bubble trap and a fluid reservoir. Blood was washed from the hearts for 10 min at 
a rate of 200 ml/min. Then recirculation started with 800-2200 ml; perfusion 
pressure was 6.4-8.3 kPa. In human and porcine hearts, flow necessary to maintain 
perfusion pressure was 200-600 ml/min. Bovine hearts required 900-1200 ml/min. 
Heart weight after the experiment was 300-800 g (man), 200-300 g (pig) and 1.9-
3.2 kg (cow). 
RESULTS 
Rodent hearts 
Due to their small size, we were unable to monitor function in mouse heart. In the 
other hearts, changes in heart rate and apex displacement were minimal during the 
experiment. Control coronary flow (ml/min per g wet weight) was 7.6 ± 1.0 (mouse, 
mean ± SE), 7.3 ± 0.5 (rat), 11.4 ± 1.1 (guinea-pig) and 5.0 ± 0.6 (rabbit). In the 
course of the experiment, flow decreased somewhat. 
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Table 1. Apparent xanthine oxidoreductase activity in isolated, perfused heart 
Hypoxanthine was infused into isolated hearts. From the xanthine and urate production rates, the 
xanthine oxidoreductase (XOD) activity was calculated as xanthine + 2x urate. Data are expressed as 
means ± SE and per gram wet weight. n = Number of experiments. 
Species n Xanthine 
(nmol/min/g) 
Mouse 5 18 ± 2 
Rat 9 14.1 ± 1.1 
Guinea-pig 5 1.2 ± 0.3 
Rabbit 5 0.51 ± 0.08 
Pig 6 <0.05 
Man 7 0.023 ± 0.003 
Cow 4 1.1 ± 0.3 
40 
10 
20 40 
Urate 
(nmol/min/g) 
8.3 
7.8 
72 
O.Q75 
<0.07 
0.14 
1.4 
60 
Time (min) 
± 1.4 
± 0.4 
± 0.5 
± 0.015 
± 0.02 
± 0.3 
80 
XOD 
(mU/g) 
33 ± 3 
28.5 ± 1.4 
14.4 ± 1.0 
0.59 ± 0.09 
<0.1 
0.31 ± 0.04 
3.7 ± 0.8 
100 
FIG. 1. Effect of cold potassium cardioplegia on apparent xanthine oxidoreductase activity. After an 
equilibration period of 20 min, rat hearts were infused for 10 min with 50 JLM hypoxanthine (horizontal 
bar). From the effluent xanthine and urate concentration, the enzymatic activity was calculated. Ten 
minutes post -infusion, cold St. Thomas' Hospital cardioplegic solution was administered (3.0 mlfmin ), 
followed by an ischemic, hypothermic period of 30 min. After 15 min reperfusion, hypoxanthine was 
again infused; the xanthine oxidoreductase activity measured was similar to that before 
cardioplegia/ischemia (Student's paired t-test, P>0.05). Data are given as means + SE (n=4). XOD 
= xanthine oxidoreductase. wwt = wet weight. 
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Contrasting its precursors/6 infused hypoxanthine had no obvious inotropic or 
chronotropic effects; it was not vasoactive. We measured the catabolites xanthine 
and urate in the coronary effluent. Xanthine concentrations (J..£M) amounted to 2.9 
± 0.4 (mouse), 2.4 ± 0.2 (rat), 0.23 ± 0.08 (guinea-pig) and 0.106 ± 0.014 (rabbit); 
urate concentrations (J..£M) were 1.3 ± 0.3, 1.19 ± 0.09, 0.74 ± 0.09 and 0.018 ± 
0.004, respectively. The studies with radioactive hypoxanthine excluded a major 
contribution of xanthine from guanine. We found no evidence of urate breakdown 
to allantoin. · 
The apparent xanthine oxidoreductase activity, calculated from the 
concentrations mentioned above, was high in mouse heart (33 mU/g). The activity 
was comparable in rat heart, twice lower in guinea-pig heart, and very low in rabbit 
heart (Table 1). In the latter the conversion of hypoxanthine to xanthine was very 
slow, that of xanthine to urate even slower (Table 1). Exogenous hypoxanthine 
affected only the first reaction step in rabbit heart. The guinea-pig heart released 
relatively little xanthine. 
Pig, cow and human hearts 
Human and porcine hearts beat regularly, whereas bovine hearts showed only atrial 
activity. Coronary flow (ml/min per gram wet weight) was: 0.82 ± 0.12 (man), 
1.8 ± 0.2 (pig) and 0.43 ± 0.07 (cow). Xanthine and urate concentration increased 
per minute by 0.012 ± 0.001 and 0.08 ± 0.02 J,.£M, respectively, in human-heart 
perfusate, and by 0.72 ± 0.10 and 1.2 ± 0.4 J,.£M, respectively, in bovine-heart 
perfusate. We observed only marginal changes in the perfusate of porcine heart. 
From Table 1 it is clear that relatively little activity was present in explanted 
human heart, i.e., 0.31 mU /g. Only porcine heart showed a lower value: the activity 
was below the detection limit (0.1 mU/g). Bovine heart had a tenfold higher 
activity and fivefold lower urate/xanthine ratio than human heart. 
Upon collection of hearts of the larger species, we administered a cardioplegic 
solution. To check whether this affected the xanthine oxidoreductase activity, we 
subjected rat hearts (which display a relatively high activity) to cold 
cardioplegia/ischemia. Figure 1 shows that this procedure hardly affected the 
enzymatic activity. We also tested in rat hearts whether the perfusion fluid used 
for the large hearts influenced the enzyme. Again a similar activity was found with 
both perfusion fluids. These control experiments make it unlikely that the low 
activity found in human, porcine and bovine hearts is due to differences in 
experimental set-up. 
DISCUSSION 
Species differences 
Ronca-Testoni and Borghini2 were the first to show urate production by the 
isolated, perfused rat heart. We confirmed their observation that urate comprises 
the major purine released from rat heart under basal conditions.:!4 Gerlach et al.17 
did similar observations in guinea-pig heart. We reported blockade of hypoxanthine 
breakdown during anoxia by allopurinol.4 These observations strongly suggested that 
rat and guinea-pig heart contain xanthine oxidoreductase. Enzymatic measurements 
confirmed this hypothesis.4'6,18 Reported discrepancies on the activity of cardiac 
xanthine oxidoreductase in various other species initiated the present study. The 
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apparent xanthine oxidoreductase activity in mouse heart (33 mU/g), measured 
with hypoxanthine, was of the same order of magnitude as that in rat and guinea-
pig heart (Table 1). It exceeds the only reported value for mouse heart by a factor 
ten.19 Our estimate for rat and guinea-pig heart is in reasonable agreement with 
values found in extracts.4-8,18 The conversion of xanthine to urate seems to be faster 
in guinea-pig than in mouse and rat heart. This should be checked with xanthine 
as substrate. 
The activity found in isolated pig hearts was <0.1 mU/g. Several authors 
reported minimal activity of the enzyme in pig-heart homogenates.6,20 Our value 
for cow heart agrees with data given in refs. 13 and 21, but is > 30x higher than 
that reported in ref. 22. In guinea-pig and human hearts, xanthine breakdown 
seems to be faster than xanthine formation. Rabbit heart had little xanthine 
oxidoreductase activity, as calculated from the xanthine and urate production. 
Several authors reported minimal xanthine oxidoreductase activity in rabbit-heart 
homogenate,s-7,9 which is in line with our ex vivo observation. The high activity in 
homogenate found by Wajner and Harkness10 is puzzling, as is the high activity 
reported for human-heart autopsies.10 
Xanthine oxidoreductase in heart explants 
We suggested recently that xanthine oxidoreductase is present in the heart of 
patients, suffering from ischemic heart disease. 23 This was based on the 
demonstration of cardiac urate production during transient myocardial ischemia. 
Autopsy material revealed high. activity of the enzyme.10.t• Limited histochemical 
work has shown substantial amounts of xanthine oxidoreductase in human-heart 
endothelium.11 On the other hand, several authors have reported very low to 
undetectable activity of the enzyme in human heart 6,8,t2,2A Based on our isolated 
heart perfusions, we conclude that hearts from patients with cardiomyopathy or 
end-stage ischemic heart disease are almost devoid of xanthine oxidoreductase. 
We cannot exclude the possibility that the (diseased) human heart contains inactive 
xanthine oxidoreductase. Such enzyme has been described recently. Xanthine 
oxidase can destroy itself by self-generated 0 2 metabolites.25 At present we assume 
that extracardiac factors, such as neutrophils or other blood components, are 
responsible for the apparent xanthine oxidoreductase activity observed in 
catheterized patients23 or autopsies.10'14 
CONCLUSION 
Isolated, perfused mouse, rat, guinea-pig and also bovine hearts show considerable 
xanthine oxidoreductase activity, contrasting porcine, rabbit and human hearts. 
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